Medicinal Chemistry Approaches to Widen Therapeutic Potential for Melatonin and Temozolomide Derivatives by Furiassi, Lucia
 DIPARTIMENTO DI SCIENZE PURE E APPLICATE  
Corso di dottorato di ricerca in: SCIENZE DI BASE E APPLICAZIONI 
Curriculum: SCIENZE CHIMICHE E SCIENZE FARMACEUTICHE 
XXXI CICLO 
 
 
 
 
 
 
Medicinal Chemistry Approaches to Widen 
Therapeutic Potential for Melatonin and 
Temozolomide Derivatives 
 
 
 
 
 
SSD: CHIM/08 
 
RELATORE                                                                       DOTTORANDO 
Chiar.mo Prof. Gilberto Spadoni                                       Dott.ssa Lucia Furiassi 
 
Anno Accademico 2017/2018  
2 
 
Table of Contents 
 
Preface ................................................................................................................................................ 4 
 
Section I: Medicinal Chemistry Approaches to Widen Therapeutic Potential for Melatonin 
Derivatives ............................................................................................................................................. 5 
1.1 General Introduction .................................................................................................................. 6 
1.2 Design and Synthesis of New Tetrahydroquinoline Melatonin Receptor Ligands                   
 .............................................................................................................................................................. 12 
1.2.1 Introduction and Aim of the Work ...................................................................................... 13 
1.2.2 Results and Discussion ........................................................................................................... 17 
1.2.3 Conclusions ............................................................................................................................. 34 
1.2.4 Experimental Section ............................................................................................................. 35 
1.2.4.1 Materials and Methods ................................................................................................... 35 
1.2.4.2 Reagents ........................................................................................................................... 35 
1.2.4.3 Synthesis and Physicochemical Characterization of THQ MLT Receptor Ligands 36 
1.3 Dual-acting Melatoninergic Derivatives: Design, Synthesis and Pharmacological 
Investigations ....................................................................................................................................... 46 
1.3.1 Introduction and Aim of the Work ...................................................................................... 47 
1.3.2 Results and Discussion ........................................................................................................... 56 
1.3.2.1. Chemistry ....................................................................................................................... 56 
1.3.2.2. In vitro Pharmacological Studies and SARs ................................................................ 59 
1.3.2.3. In vivo Intraocular Pressure (IOP) Lowering Effects ................................................. 62 
1.3.3 Conclusions ............................................................................................................................. 64 
1.3.4 Experimental Section ............................................................................................................. 65 
1.3.4.1 Materials and Methods ................................................................................................... 65 
1.3.4.2 Reagents ........................................................................................................................... 65 
1.3.4.3 Synthesis and Physicochemical Characterization of Dual-acting Compounds ......... 66 
 
Section II: C8-Substituted Temozolomide Derivatives: SAR Studies and Effects on Stability     
 .............................................................................................................................................................. 83 
2.1 Introduction and Aim of the Work ......................................................................................... 84 
2.1.1 General Introduction ......................................................................................................... 84 
2.1.2 Summary of Known SAR on Imidazotetrazines Derivatives ......................................... 87 
3 
 
2.1.3 Aim of the Work ................................................................................................................ 89 
2.2 Result and Discussions .............................................................................................................. 91 
2.3 Conclusions .............................................................................................................................. 103 
2.4 Experimental Section .............................................................................................................. 104 
2.4.1 Materials and Methods .................................................................................................... 104 
2.4.2 Synthesis and Physicochemical Characterization of C8-Temozolomide Derivatives 104 
 
List of Abbreviations .................................................................................................................... 115 
Acknowledgements ....................................................................................................................... 118 
References ...................................................................................................................................... 119 
 
  
4 
 
Preface 
 
The work described in this thesis was primarily focused on the design, synthesis, 
physicochemical characterization and biological evaluation of small molecules of pharmaceutical 
interest.   
The thesis consists of two sections, one concerning the development of new melatonin derivatives and 
the other regarding the expansion of the structure-activity relationships of the anticancer agent 
temozolomide.   
 
Specifically, part of the melatoninergic work has been dedicated to the design and synthesis of 
different MLT receptor ligands structurally characterized by a tetrahydroquinoline scaffold.  The semi 
rigid THQ ring was found to be a good synthetically accessible template for the design of potent MLT 
ligands with different topology.   
 Rivara, S.; Scalvini, L.; Lodola, A.; Mor, M.; Caignard, D-H.; Delagrange, P.; Collina, S.; Lucini, V.; 
Scaglione, F.; Furiassi, L.; Mari, M.; Lucarini, S.; Bedini, A.; Spadoni, G. J. Med. Chem., 2018, 61, 3726. 
 
In the second part of this first section, new dual-acting compounds have been designed and 
synthesized by combining the interesting properties of melatonin derivatives with other, potentially 
synergistic, pharmacological activities.  The new dual-acting compounds have showed a promising 
antiglaucoma activity.   
 Spadoni, G.; Bedini, A.; Furiassi, L.; Mari, M.; Mor, M.; Scalvini, L.; Lodola, A.; Ghidini, A.; Lucini, 
V.; Dugnani, S.; Scaglione, F.; Piomelli, D.; Jung, K-M.; Supuran, C. T.; Lucarini, L.; Durante, M.; 
Sgambellone, S.; Masini, E.; Rivara, S. J. Med. Chem., 2018, 61, 7902. 
 
The second section of the thesis, conducted during my visiting period at University of Illinois 
at Urbana-Champaign, has been carried out in a different research field concerning the anticancer agent 
temozolomide.  To understand the relationship between its structure, hydrolytic stability and anticancer 
activity, new imidazotetrazines derivatives bearing previously unexplored functionalities at the C8 
position have been synthetized and tested against a panel of human GBM cell lines showing interesting 
anticancer activities. 
 Svec, L. R.; Furiassi, L.; Skibinski, C. G.; Fan, T. M.; Riggins, G. J.; Hergenrother, P. J. ACS Chem. 
Bio., 2018, 13, 3206. 
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Section I: Medicinal Chemistry Approaches to Widen 
Therapeutic Potential for Melatonin Derivatives 
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1.1 General Introduction 
 
Melatonin (N-acetyl-5-methoxytryptamine, MLT, 1 in Figure 1), first isolated from bovine 
pineal gland in 1958,1 is a tryptophan derivative widely distributed in nature ranging from the plant to 
animal kingdom.  In all vertebrates and humans, the biosynthesis of MLT takes place primarily in the 
pineal gland2 and occurs via rate limiting N-acetylation of serotonin and subsequent O-methylation.  
Characteristically, pineal MLT is synthesized and secreted in a circadian rhythmic fashion with the 
highest levels, in all species, during the night dark phase.  This rhythmicity is controlled by an 
endogenous circadian clock in the suprachiasmatic nucleus (SCN) of the hypothalamus, through a 
neuronal pathway linking the SCN and the pineal gland, and whose activity is synchronized to the 24 h 
period by the light/dark cycle.3  Evidence has accumulated that MLT is also produced in extrapineal 
organs and tissues, such as retina, skin, gastrointestinal tract, bone marrow, immune and hematopoietic 
cells, some reproductive organs and endocrine glands.  However, while pineal MLT diffuses out into 
the bloodstream and CSF, rapidly reaching all tissues, the extrapineal produced MLT is thought to act 
only locally.  Circulating MLT is preferentially metabolized by cytochrome P-450 to 6-OH-MLT and 
subsequent conjugated with sulfuric or glucuronic acid.  Especially in non-hepatic tissues and under the 
influence of reactive oxygen species, a substantial fraction of MLT can be metabolized to N1-acetyl-
N2-formyl-5-methoxykynuramine by oxidative pyrrole ring cleavage.   
Since MLT isolation,1 considerable progress has been made towards understanding the 
molecular biology, pharmacology and medicinal chemistry of the melatoninergic system.  The circadian 
pattern of MLT secretion, coupled with the localization of specific MLT binding sites in the brain region 
associated with the “biological clock” has led to considerable interest in its potential in treating 
disordered circadian rhythms that occur in jet-lag, shift work, some blind subjects and in 
delayed/advanced sleep phase syndromes,4 as well as a sleep-promoting agent.  Besides the above cited 
sleep-inducing and chronobiotic properties, many studies have also indicated the MLT involvement in 
most of the main physiological functions of the body, including the activity of the immune system, the 
homeostasis of the cardiovascular system, control of mood and behavior, hormone secretion and pain 
perception.5  Other effects of MLT described in the literature include its neuroprotective, anti-
inflammatory, retinal, antioxidant and anticancer properties.6  However, after four-five decades of 
investigation, the scientific evidence supporting the potential benefits of MLT assumption in humans 
remains controversial.  A major obstacle for the use of MLT for many possible treatment purposes, 
results from its low absolute bioavailability after exogenous administration (from 1% to 37%), due to 
first pass metabolism,7 and its short half-life (40-50 min).8   
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Figure 1 Metabolism of melatonin by human cytochromes p450 
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A feature that characterizes MLT is the variety of mechanisms it employs to modulate the cell 
physiology.  MLT displays antioxidant effects,9 and interacts with different intracellular mediators,10 
such as calmodulin or the transcription factor Nrf2, but the majority of its actions are due to the 
interaction with two G protein-coupled receptors (GPCR), named MT1 and MT2.11  In addition to these 
high affinity MLT receptors, another low-affinity MLT binding site, termed MT3, has been 
characterized as a melatonin-sensitive form of the human enzyme quinone reductase 2.12   
Human MT1 and MT2 receptors are 350 and 362 amino acids long respectively, with molecular 
weights of 39–40 kDa and 55% amino acid homology overall (70% within the transmembrane 
domains),13 they exhibit subnanomolar binding affinity for MLT and are negatively coupled to 
adenylate cyclase, even if they can also interact with other intracellular signaling pathways.  These 
receptors are mainly expressed in the central nervous system, particularly in the SCN, cerebellum, 
thalamus, hippocampus, but have also been detected in peripheral organs and tissues.14  Although great 
efforts have been devoted in the last few decades, assessing the pharmacology and function of each 
melatonin receptor subtype remains challenging.  This is primarily due to the fact that their native 
binding site densities in animal tissues are low or undetectable, the tissue-specificity expression might 
vary depending on the species, and different expression patterns were observed during development, 
aging and in some pathological conditions.15  The complexity of MLT receptor signaling and activity 
is further increased by their ability to homo- and heterodimerize with different G-proteins; receptor 
oligomerization can alter receptor function (i.e. increase or decrease function) depending on the 
oligomerization partner and which signal transduction processes are being affected.   
Efforts to define the physiological role of MLT through the activation of MT1 and MT2 
receptors have led, over the years, to the design and synthesis of several high affinity melatonin receptor 
ligands.  These derivatives, which activities span from full agonist, to partial agonist, antagonist and 
inverse agonist, belong to structurally different classes that range from simple indole derivatives and its 
bioisosteres to ring opened derivatives and conformationally restricted ligands.16   
Some of these MLT ligands are available on the market (Figure 2); in particular the nonselective 
MT1/MT2 agonists ramelteon (Rozerem, 2) and tasimelteon (Hetlioz, 3), have obtained marketing 
authorization for the treatment of insomnia and non-24-h sleep–wake disorder respectively.17,18  The 
naphthalene MLT bioisostere agomelatine (Valdoxan/Thymanax, 4), endowed with MT1/MT2 agonist 
and 5-HT2C antagonist activities, is prescribed for the treatment of major depression.19  These early 
studies also allowed to obtain information on the structural elements required for high binding affinity.  
The pharmacophore structure that can be found in almost all MLT receptor agonists is composed by an 
amide group connected, by a linker chain, to an aromatic nucleus carrying a methoxy group or one of 
its bioisosteres, such as bromine.   
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Figure 2 Melatonin and market approved melatoninergic drugs 
Unfortunately, none of the most clinically advanced MLT ligands discriminates between MT1 and MT2 
subtypes.  Therefore, in recent years, much work has been undertaken to identify or develop new 
candidates more metabolically stable than MLT, exhibiting higher affinity to the MT1 and MT2 
receptors, and most importantly, showing selectivity towards individual receptor subtype.  Subtype-
selective MLT receptor agonists and antagonists could be used as valuable experimental tools in 
understanding the role of this enigmatic neurohormone in health and disease, and opening new 
therapeutic perspectives by targeting a specific receptor.  In the last few decades, MLT receptor subtype 
selectivity has registered some important advances leading to the identification of a number of selective 
compounds.  The first encouraging results in this area refer to the development of MT2-antagonists or 
partial agonists.   
These compounds comprise benzofuran (7a-c) and tetrahydronaphtalenic derivatives (8a-b), 
6,7-dihydro-5H-benzo[c]azepino[2,1-a]indoles (11), 2-N-acylaminoalkylindoles (6), 
tetrahydroisoquinoline (9a-b), 10,11-dihydrodibenzocycloheptene (12) and anilinoethylamido 
derivatives (13a-c) (Figure 3), and display various degrees of binding affinity and selectivity.  The main 
feature identified in these MT2-selective antagonists or partial agonists is the presence of a flexible 
bulky hydrophobic substituent in a position topologically equivalent to C2 or N1 of melatonin. 
From a comparison of the results obtained from structure-activity relationship studies at the two 
receptor subtypes, it seems that the MT2 subtype is characterized by a higher steric tolerance in the 
region of space surrounding the N1-C2 binding region of MLT.  This hydrophobic pocket is positioned 
out-of-plane of the indole nucleus of MLT and its occupation has been proposed as a key feature to 
confer MT2-selectivity and reduction of intrinsic activity.  Docking experiments within three-
dimensional homology models of the MT1 and MT2 receptors provided a possible explanation for the 
observed MT2 selectivity and low intrinsic activity.16   
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Figure 3 Structures of representative MT2 selective ligands 
Research on new MLT ligands has expanded to also identify selective compounds for the MT1 
receptor subtype.  Unfortunately, these attempts have not yet borne good fruit, making it difficult to 
ascertain the physiological role of this receptor subtype.  The first approach used to develop MT1 
selective ligands was the preparation of symmetric dimers, by coupling two moieties deriving from 
known ligands through an appropriate spacer.  Binding affinity, intrinsic activity and subtype selectivity 
of these dimers depend on the position of the junction and on the length of the linker.  Among MT1-
selective dimers, two of the most interesting ligands are compounds 1420 and 15a21 (Figure 4), 
respectively obtained by linking two agomelatine units, or two molecules of the monomer ligand based 
on the 3-methoxyanilino skeleton, through their methoxy substituent by a three methylene linker.  
Another strategy used to design MT1 selective ligands involves the introduction of a bulky hydrophobic 
substituent in a position topologically equivalent to the 5-methoxy group of MLT.  For instance, 
compounds endowed with good binding affinity and MT1 moderate selectivity (approximately 20-40 
fold) were obtained by introducing a 4-phenylbutyl group at the C-2 position of a bicyclic scaffold 
benzofuran, benzoxazole or dihydrobenzofuran, mimicking the methoxyphenyl fragment of MLT, as 
exemplified by compounds 16, 17, 18 in Figure 4.  Using a similar approach the N-acetyltryptamine 
(19a) and the N-anilinoethylamide derivative (20),22,23 bearing a phenylbutoxy substituent, were 
11 
 
synthesized and they displayed about 10-70 fold preference toward MT1 receptors.  Taken together, all 
these results have led to the hypothesis that MT1-selectivity is favoured by replacement of the 5-
methoxy group by a larger substituent.  As proposed in a 3D homology model of the MT1 receptor, the 
phenylbutyloxy group, and in general a bulkier lipophilic substituent, could be accommodated in a 
lipophilic region, mainly defined by the transmembrane helices TM3 and TM4, characterized by the 
presence of some amino acids smaller than those present in the analogue MT2 binding site region.24   
 
Figure 4 Structures of representative MT1  selective melatonin ligands  
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1.2 Design and Synthesis of New 
Tetrahydroquinoline Melatonin Receptor 
Ligands 
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1.2.1 Introduction and Aim of the Work 
 
Despite the efforts already undertaken, the research for new melatonin selective ligands remains 
a scientific and medical challenge.  New candidates should be novel to be patented, must be 
characterized by high potency and selectivity, and must have good biopharmaceutical and PK 
properties.  Among the previously reported MLT receptor ligands, the class of anilinoethylamides (13a-
c in Figure 3) has proven to be one of the most interesting and versatile.  These compounds show a 
general good affinity for MLT receptors and, particularly, the possibility to be chemically modified, 
giving predictable modulations of selectivity and intrinsic activity.  A problem with anilinoethylamides 
SAR profile is the existence of a parallelism between MT2 selectivity and lowering of intrinsic activity, 
so it seemed hard to get MT2-selective full agonists within this class.  In an attempt to satisfy this need, 
the research team, where I spent most of my PhD course, has recently developed a new class of 
tetrahydroquinoline (THQ) derivatives carrying an acylaminomethyl side chain in position 2 (Figure 
5).25  Specifically, starting from the structure of N-anilinoethylamides ligands, the flexible ethylamide 
side chain was constrained in a six-membered ring to reproduce the putative bioactive conformation of 
the endogenous hormone, previously identified and validated by studying potent conformationally 
constrained ligands such as the tricyclic 1,3,4,5-tetrahydrobenzo[cd]indole agonist 21.  SAR 
optimization, based on superposition models with known melatoninergic ligands, resulted in N-1-
benzyl-5-methoxyquinolin-2-yl)methyl]propionamide (UCM1014, 22 in Figure 5), which is the most 
potent and selective MT2 full agonist reported to date (KiMT2 = 0.001 nM, more than 10000-fold 
selectivity over the MT1 receptor).25   
 
 
Figure 5  
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As highlighted in Figure 6 the tetrahydroquinoline ring, in which the heterocyclic nitrogen can replace 
the carbon 2a of the tricyclic derivative 21, could represent an excellent scaffold to favour the proper 
arrangement of pharmacophoric groups, providing potent and selective MLT ligands.   
 
 
Figure 6 (left): superposition of compound 21 (green carbons) to the putative bioactive conformation of MLT (yellow 
carbons); (right): superposition of the tetrahydroquinoline UCM1014 (orange carbons) to the putative bioactive 
conformation of MLT (yellow carbons) 
 
Indeed, the tetrahydroquinoline system is a very common structural motif found in several 
biologically active natural products and pharmacologically relevant therapeutic agents (Figure 7).26   
For example, the potent antiviral agent virantmycin and the antibiotic helquinoline isolated, respectively 
from a strain of Streptomyces or Janibacter limosus, belong to the wide variety of 1,2,3,4-
tetrahydroquinoline-based natural products.  Tetrahydroquinoline compounds with interesting 
biological activities also include quinfamide, a luminal amebicide used to treat chronic and subacute 
amebiasis, and nicainoprol, a calcium channel antagonist used as antiarrhythmic agent.  Some of other 
compounds containing tetrahydroquinoline scaffold interact with neurotransmitter receptors and other 
membrane receptor, such as the glycine site at NMDA receptor antagonist (23), the 5-HT3 receptor 
antagonist (24) or the β3- adrenergic agonist (25).  The tetrahydroquinoline system is also the key 
structural fragment of compounds acting on steroid hormone receptors (i.e. the ERβ estrogen receptor 
agonist (26) and the inhibitor of cholesteryl ester transfer protein torcetrapib, used in clinical trials as 
anti hypercholesterolemic drug), or of inhibitors of therapeutically relevant enzymes such as the 
commercial antithrombotic drug argatroban, acting as a thrombin inhibitor.  The above cited 
biologically active compounds, widely support the idea to consider the tetrahydroquinoline ring a 
“privileged structure”, a term first coined by Ben Evans27 and more recently refined by Klaus Mueller,28 
to define “small, non-planar structures with robust conformations that provide interesting 3D exit 
vectors for substitution, with drug-like properties and ideally readily accessible synthetically”.   
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Figure 7 Examples of Pharmacologically Relevant Tetrahydroquinolines   
The semi-rigid THQ scaffold seems to possess geometries suitable for decoration with different 
side chains, and can be considered a good template for chemical diversification to discovery novel MLT 
receptor ligands.  Given the peculiar geometries of the THQ ring and the previous excellent results 
obtained for 2-acylaminomethyl-THQs, one of the main purposes of my PhD work was to test the 
possibility to get new MLT receptor ligands with different patterns of substitution on the THQ scaffold.   
In particular, we i) designed two different classes of THQs with an amide side chain in position 
1 or 3 and different substituents on the THQ ring (Figure 8), and ii) compared the behavior of THQs 
with that of the corresponding tetralin analogues to evaluate if the THQ scaffold can be considered as 
a valuable bioisostere of the tetralin ring present in some of the best known and most characterized 
MT1/MT2 ligands (e.g., 4-P-PDOT, 8a in Figure 3).   
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Figure 8 Schematic representation of new designed tetrahydroquinoline melatonin receptor ligands  
The synthesis and pharmacological characterization of these new compounds could allow to 
expand the chemical space of MLT receptor ligands, and to obtain new interesting lead candidates with 
potential therapeutic perspectives in melatoninergic diseases.   
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1.2.2 Results and Discussion 
 
Taking into account previous structure-activity relationships for the melatoninergic ligands, and 
considering that previously developed pharmacophoric models seem to indicate that the 
tetrahydroquinoline ring is not involved in polar interactions with the amino acids present in the receptor 
binding site, we started our exploration by testing the possibility to shift the THQ nitrogen, in the 2-
acylaminomethyl-THQ series, to the opposite site of the heterocycle (Figure 9). 
  
 
Figure 9. Nitrogen shift to the opposite site of the heterocycle and superposition of a 2-acylaminomethylTHQs prototype 
(UCM934: R1=Me, R=Et: orange), MLT (green) and the 3-acetylaminomethyl-THQ 28a (blue) 
We therefore prepared the new 3-acetylaminomethyl-THQ 27, and its derivatives 28a-e in 
which we investigated the influence on receptor activity of the size and shape of the substituent on the 
THQ nitrogen atom.  The synthetic procedures used to synthesize these compounds are depicted in 
Scheme 1.  Briefly, hydrogenation (4 atm, 60 °C) of the commercially available 3-cyanoquinoline in 
the presence of Raney-Ni and ammonia (a simultaneous reduction of the nitrile and pyridine ring 
occurs), followed by N-acetylation of the intermediate primary methanamine, provided the desired 3-
methanamidotetrahydroquinoline 27.  N1-substituted 3-methanamido derivatives 28a−e were prepared 
by N1-alkylation of 27 with the suitable alkyl halide (28a-d) or by palladium-catalyzed N1-arylation 
(28e) using bromobenzene, palladium (II) acetate, and (±)-BINAP.   
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Scheme 1 Synthesis of 3-acetylaminomethyl-THQs. Reagents and conditions: (a) H2 (4 atm), Raney-Ni, 2 M NH3 in EtOH, 
THF, 60 °C, 16 h; (b) Ac2O, Et3N, THF, rt, 1 h, two steps (a, b) yield 70%; (c) R-X, Et3N, toluene, Δ,1−16 h, yield 46−85%; 
(d) bromobenzene, Pd(OAc)2, (±)-BINAP, t-BuOK, toluene, 100 °C, 24 h, yield 29%. 
 
The new synthesized tetrahydroquinoline derivatives were evaluated for their binding affinity 
and intrinsic activity at human MT1 and MT2 receptors stably transfected in Chinese hamster ovarian 
(CHO) cells using 2-[125I]iodomelatonin as radioligand.  The hMT1 and hMT2 binding affinity and 
intrinsic activity values of the new THQs derivatives 27 and 28a-e are reported in Table 1, together 
with those of the reference compounds melatonin and cis-4-P-PDOT.   
Compound 28e, having a phenyl group on the tetrahydroquinoline nitrogen, showed MT1 and MT2 
binding affinities in the same range as MLT and 4-P-PDOT and it behaved as an antagonist with slight 
MT2 selectivity (10 fold).  These data confirm THQ as a versatile and efficient scaffold to derive MLT 
receptor ligands and a valuable bioisostere of the tetraline ring.   
Binding affinities of these compounds are quite correlated with the size of the substituent on 
the nitrogen atom.  The N-unsubstituted compound (27) is the one with lower receptor binding affinity 
and increased potency is observed moving from N-methyl (28a) to N-ethyl (27b) and N-phenyl (28e).   
The N-benzyl derivative 28c showed the highest MT2-selectivity (59 fold), consistently with what 
previously observed for compounds with out-of-plane substituents.   
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Table 1 Binding affinity and intrinsic activity of 3-acylaminomethyl tetrahydroquinoline derivatives at human MT1 and MT2 
melatonin receptors 
 
 
 
Compounda 
 
R1 
MT1 MT2 
Ki  
(nM) 
EC50 
(nM) 
Emax  
(%) 
Ki  
(nM) 
EC50 
(nM) 
Emax 
(%) 
1 (MLT)b  0.23 1.7 123 ± 13 0.52 0.4 76 ± 6 
Cis-4-P-PDOTc  76  23 ± 6 0.69  46 ± 2 
27 H 430   110   
28a Me 83 ˃10000  15 10 32 ± 3 
28b Et 20 ˃10000  1 7 59 ± 8 
28c Bn 59   1 3 28 ± 4 
28d C6H5CH2CH2 246   47 80 47 ± 5 
(+/-)-28e Ph 2.4 ˃10000 27 ± 9 1.2 ˃10000 10 ± 1 
(-)-28e Ph 3.02  30 ± 8 1.38  29 ± 2 
(+)-28e Ph 1.58  25 ± 9 0.78  5 ± 3 
Ki and EC50 (nM) values are geometric mean values of at least two separate experiments performed in duplicate.  Emax values 
are arithmetic mean values ± SEM.  aChiral compounds were tested as racemates.  bTaken from ref 29.  cTaken from ref 30. 
 
NMR conformational studies of the most potent compound 28e (Table 2) revealed a high 
prevalence of half-chair conformation for the tetrahydroquinoline ring wherein the C3 
acetylaminomethyl side chain has an equatorial arrangement.   
In details, 1H-1H vicinal coupling constant analysis in DMSO-d6 showed J values = 10.0 and 
4.5 Hz for H3 with H2a and H2e respectively, indicative of an anti-arrangement of H3 with H2a, and with 
H3 gauche to H2e; this is consistent with an equatorial arrangement of the C3-side chain.  Additionally, 
the NOE contact between H2a and H4a is in line with the suggested equatorial arrangement of the side 
chain.  Similar NMR patterns, supporting equatorial conformations of the amide side chain, were 
recorded for the other 3-acylaminomethyl-THQs 27 and 28b−d.   
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Table 2. Chemical shifts, Geminal and Vicinal Coupling Constant Values Observed by NMR Spectroscopy (400 MHz) for 
compound 28e in DMSO-d6. 
 
N
Ph
NHCOMe
 
28e (S + R) 
N
H3
N
H3
H2e
H2a
Ph
H2a
H2e
H4a
H4e
Ph
H3COCHN H4e
H4a
H3COCHN
H11a H11b
H11a
H11b
NOE Contact
 
 
Proton  (ppm) Protons J (Hz) 
H2a 2.52 
3J2a-3 
2J2a-2e 
10.0 
16.0 
H2e 2.84 
4J2e-4e 
3J2e-3 
2J2e-2a 
1.5a (long range W coupling) 
4.5 
16.0 
H3 2.13 
3J3-4e 
3J3-2e 
3J3-2a 
3J3-11a 
3J3-11b 
3J3-4a 
3.5 
4.5 
10.0 
6.0 
6.0 
9.0 
H4a 3.25 
3J4a-3 
2J4a-4e 
9.0 
11.5 
H4e 3.63 
4J4-2e 
3J4e-3 
2J4e-4a 
1.5a (long range W coupling) 
3.5 
11.5 
H11a 3.06 
3J11a-3 
2J11a-11b 
6.0 
13.5 
H11b 3.13 
3J11b-3 
2J11b-11a 
6.0 
13.5 
a The H2e signal is a broad dd in the 400MHz 1H NMR spectrum, the long range coupling constant is clearly visible in the 
H4e signal and in the corresponding COSY cross peaks. 
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Figure 10 NOESY spectrum for compound 28e. The spectrum was recorded at 298 K on a 400 MHz using a 0,036 mM 
solution of 28e in CDCl3. Mixing time 300 ms. 
 
Interestingly, the equatorial arrangement of the C3-actylaminomethyl side chain allows a good 
superposition with the putative bioactive conformation of MLT as shown in Figure 11.   
 
 
Figure 11 Superposition of melatonin (green carbons) and the enantiomers of compound 28e 
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Separation of the two enantiomers of the compound 28e by semi preparative chiral HPLC 
allowed us to investigate the influence of chirality on their interaction with melatonin receptors.  The 
enantiomers displayed similar binding affinities and intrinsic activities at both receptors, likely due to 
the equatorial arrangement of the acetylaminomethyl side chain, which allows good superposition of 
each enantiomer to the putative bioactive conformation of MLT (see Figure 11).   
 
To further validate the CH/N isosterism in the field of MLT ligands we prepared and tested the 
two trans- and cis-1-phenyl-2-acylaminomethyl-tetralin diastereoisomers 31 and 32 (Scheme 2), in 
which the THQ nitrogen is replaced by a CH group.   
The synthetic route adopted for the preparation of tetralin derivatives 31−32 is depicted in 
Scheme 2.  The first step involved the reaction of 1-phenyl-3,4-dihydronaphthalen-2(1H)-one,31 with 
trimethylsilyl cyanide and ZnI2 followed by treatment with phosphorus oxychloride in pyridine to give 
the intermediate nitrile 29, which was converted into the dihydronaphthalene derivative 30 by reduction 
with LiAlH4/AlCl3 and subsequent N-acylation of the crude intermediate amine with propionic 
anhydride.  The trans-(31) and cis-(32) tetralin target compounds were respectively obtained by 
reduction of the unsaturated nitrile 29 with LiAlH4 followed by N-acylation with propionic anhydride 
or by Pd-catalyzed hydrogenation of 30.   
 
  
23 
 
 
Scheme 2 Synthesis of 3-acylaminomethyl tetralines. Reagents and conditions: (a) trimethylsilyl cyanide, ZnI2, toluene, rt, 18 
h; (b) POCl3, Py, reflux, 1 h, two steps (a, b) yield 65%; (c) LiAlH4/AlCl3, dry THF, rt, 1 h; (d) propionic anhydride, Et3N, 
THF, rt, 16 h, two steps (c, d) yield 37%; (e) LiAlH4, THF, reflux, 2 h, two steps (e, d) yield 30%; (f) H2 (4 atm), 10% Pd−C, 
MeOH, 60 °C, 6 h, yield 47%. 
To obtain information about their preferred conformational states, the tetraline derivatives 31 
and 32 were submitted to suitable NMR studies.  1H NMR spectrum of the trans-tetralin derivative (31) 
showed vicinal coupling constants between H2 and the two distinct H3 protons (J2-3e ≈ 3.0; J2-3a ≈ 9.0), 
which is consistent with an axial arrangement for the H2; these data together with a 3J1-2 value of ≈ 8 
Hz confirm the diequatorial arrangement of both amido side chain and phenyl substituent (Table 3).   
On the contrary, the NMR spectrum of the cis-tetralin derivative (32) revealed an equilibrium 
between the equatorial and the axial arrangement of its side chain.  In fact, the observed coupling 
constants values between H2 and the two H3 protons (J2−3a = 6.5 Hz and J2−3e = 3.5 Hz (Table 4)) derives 
respectively, from the combination of a gauche and an anti-arrangement of the two protons, and from 
two gauche arrangements.   
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Table 3 J coupling constant for compound 31 
   
Ph
NHCOEt
 
trans-31  
 
H3a
H3e
H3e
H3a
H2
H2
H4a
H4e
H4e
H4a
H1
Ph
NHCOEt Ph
H1
NHCOEt
H11a
H11b
 
Proton 
 (ppm) 
CD3OD 
J (Hz) 
CD3OD 
H1 3.84 3J1-2 = 8.0 
H2 2.14 
3J2-3e = 3.0  
3J2-11a = 5.5 
3J2-1 = 8.0 
3J2-11b = 8.0 
3J2-3a = 9.0 
H3a 1.57 
3J3a-4e = 6.5 
3J3a-4a = 8.5 
3J3a-2 = 9.0 
2J3a-3e = 13.5 
H3e 2.03 
3J3e-2 = 3.0  
3J3e-4a = 5.5 
3J3e-4e = 5.5 
2J3e-3a = 13.5 
H11a 3.14 
3J11a-2 = 5.5 
2J11a-11b = 13.5 
H11b 3.19 
3J11b-2 = 8.0 
2J11b-11a = 13.5 
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Table 4 J coupling constant for compound 32 
 
Ph
NHCOEt
 
cis-32 
H3e
H3a
H2H
4e
H4a
H1
Ph
NHCOEtH3a
H3e
H2
H4a
H4e
Ph
H1
NHCOEt
H11a
H11b
H11a
H11b
 
Proton 
 (ppm) 
DMSO-d6 
J (Hz) 
DMSO-d6 
H3a 1.51 
3J3a-4e = 6.0 
3J3a-2 = 6.5 
3J3a-4a = 11.5 
2J3a-3e = 13.5 
H3e 1.68 
3J3e-4e =1.5  
3J3e-2 = 3.5 
3J3e-4a = 6.5 
2J3e-3a = 13.5 
H4a 2.82 
3J4a-3e = 6.5 
3J4a-3a = 11.5 
2J4a-4e = 18.0 
H4e 3.00 
3J4e-3e = 1.5 
3J4e-3a = 6.0 
2J4e-4a = 18.0 
H11a 2.54 
3J11a-NH = 6.0 
3J11a-2 = 6.0 
2J11a-11b = 13.0 
H11b 2.93 
3J11b-NH = 5.5 
3J11b-2 = 5.5 
2J11b-11a = 13.0 
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Both compounds display good receptor binding affinity (Table 5); in particular the trans isomer 
31 in its diequatorial conformation is a potent and selective (300 times) MT2 partial agonist (MT1 Ki 
= 62 nM, Emax = 61%; MT2 Ki = 0.23 nM, Emax = 78%), in analogy to what observed for the 2-
acylaminomethyl-THQ bioisostere UCM949.   
 
Table 5 Binding affinity and intrinsic of tetraline derivatives at human MT1 and MT2 melatonin receptors 
 
 
Compounda 
MT1 MT2 
Ki (nM) Emax (%) Ki (nM) Emax (%) 
1 (MLT)b 0.23 123 ± 13 0.52 76 ± 6 
UCM949c 1.6 69 ± 12 0.06 90 ± 0.5 
30 28 16 ± 8 3.81 30 ± 6 
31 62 61 ± 4 0.23 78 ± 9 
32 3.5 56 ± 8 0.22 75 ±3 
Ki and EC50 (nM) values are geometric mean values of at least two separate experiments performed in duplicate.  Emax values 
are arithmetic mean values ± SEM. aChiral compounds were tested as racemates.  bTaken from ref 29.  cTaken from ref 25. 
Molecular superposition models provide an explanation of the observed high affinity and MT2 
selectivity for compound 31.  As shown in Figure 12a, the trans-isomer 31, in its diequatorial 
conformation, can be closely superposed to the bioactive conformation of melatonin, and placing the 
phenyl substituent in the out-of-plane region confering MT2 selectivity.   
 
 
Figure 12 (a) Superposition of the bioactive conformation of melatonin (green carbons) with compound 31 (yellow carbons) 
and compound 32 (orange carbons) with equatorial arrangement of its side chain. (b) Superposition of melatonin and 
compound 32 with axial arrangement of its side chain. 
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All these results clearly demonstrated that THQ derivatives can mimic the SARs observed for tetraline 
analogs and viceversa.   
The THQ scaffold could also be arranged in a different way to the alignment proposed in Figure 
9 and 13 (left), especially in the absence of bulky N-substituent.  An alternative arrangement is proposed 
in Figure 13 (right) in which the aromatic portion of the THQ ring is positioned in the same region as 
the benzene of the indole of MLT, and to point the amide groups in the same direction, the 
tetrahydropyridine ring is superposed to the fused six-membered ring of the tricyclic 1,3,4,5-
tetrahydrobenzo[cd]indole agonist 21, (Figure 13 on the right), in analogy to what previously proposed 
for the series of 2-acylaminomethylTHQs.25   
 
 
Figure 13 Classical superposition of 28a to the bioactive conformation of MLT (left) and alternative superposition (right) 
 
If this alternative orientation is possible, 3-acylaminomethyl-THQs should allow substitution 
at C4 with groups that in general can be accommodated in allowed regions of the MT1 and, particularly, 
MT2 binding sites.   
In order to confirm this “alternative spatial arrangement” we synthesized and tested the 
tetrahydroquinoline derivative (34, Scheme 3) having the propionylaminomethyl side chain in position 
3, a methyl group on the nitrogen and a phenyl ring in position 4.   
This compound 34 can be considered a new application of the design of melatonin ligands based 
on the THQ scaffold, in which the bulkier substituent, generally involved in the modulation of binding 
affinity and MT1/MT2 subtype selectivity, is linked at the C4 position instead of the THQ nitrogen.  34 
can be also considered a bioisostere of the 1-phenyl-2-acylaminomethyTHQ (UCM949) by applying 
the classical isosteric CH/N replacement at the atom opposite to the THQ nitrogen.   
Compound (+/-)-cis-34 was prepared following the steps outlined in Scheme 3.  Hydrogenation 
of 4-phenylquinoline-3-carbonitrile32 in the presence of Raney-Ni and ammonia, and subsequent N-
acylation of the intermediate primary methanamine with propionic anhydride provided the 4-phenyl-
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tetrahydroquinoline derivative 33, which was then converted to the desired N1-methyl derivative 34 by 
reductive amination using 37% HCHO and NaBH3CN.   
1H NMR analysis (J4-3 ≈ 5.0 Hz) confirmed that the applied synthetic procedure makes it 
possible to obtain only a racemic mixture of the cis-34 isomers.   
 
 
Scheme 3 Synthesis of 4-substituted 3-acylaminoethyTHQ. Reagents and conditions: (a) H2 (4 atm), Raney-Ni, 2 M NH3 in 
EtOH, THF, 40 °C, 12 h; (b) propionic anhydride, Et3N, THF, rt, 1 h, two steps (a, b) yield 46%; (c) 37% HCHO, 
NaBH3CN, MeOH/AcOH, 40 °C, 3 h, yield 72%. 
 
The THQ derivative cis-34 showed MT1 and MT2 binding affinities (MT1 Ki = 3.4 nM; MT2 Ki 
= 0.48 nM) in the same range as the N-phenyl derivative 28e with a partial agonist behaviour and only 
minimal selectivity (7 fold) for the MT2 subtype.  NMR conformational studies revealed that the amide 
side chain has equatorial arrangement as confirmed from the large coupling constant J2a‑3 (∼11.5 Hz) 
and the small one J2e‑3 (∼4.0 Hz), and the phenyl ring is in pseudo-axial position (J3‑4 ∼5 Hz and long-
range W coupling 4J2e‑4 ≈ 1.0 Hz) (Table 6).  The pseudo-axial arrangement of the phenyl substituent 
was further confirmed by 2D-NOESY experiments showing a cross peak between proton 2a and the 
hydrogens of the phenyl ring.   
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Table 6 J coupling constant for compound 34   
 
 
34 
 
 
Proton Chemical shift (ppm) Coupling constant (Hz) 
H2a 2.93 
3J2a-3 = 11.5 
2J2a-2e = 11.5 
H2e 3.10 
4J2e-4 = 1.0 (long range W 
coupling)a 
3J2e-3 = 4.0 
2J2a-2e = 11.5 
H3 2.28 
3J3-4 = 4.5 
3J3-11b = 5.0 
3J3-2e = 4.0 
3J3-11a = 9.0 
3J3-2a = 11.5 
H4 4.13 
4J4-2e = 1.0 (long range W 
coupling)a 
3J4-3 = 4.5 
H11a 2.52 
3J11a-3 = 9.0 
2J11a-11b = n.c.b 
H11b 2.96 
3J11b-3 = 5.5 
2J11b-11a = n.c.c 
aThe H4 signal is a broad doublet in the 400MHz 1H NMR spectra, the long range coupling constant is clearly visible in the 
H2e signal and corresponding COSY cross peaks.  b Not computable, the signal is partially covered by DMSO-d6 signal.  c 
Not computable, the signal is partially covered by NMe signal.   
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The axial arrangement of the phenyl substituent seems to indicate that the preferential 
accommodation of cis-34 within the MT1 binding site is that outlined in Figure 14b, since in the 14a 
orientation the phenyl substituent would be placed in a region considered forbidden at MT1 receptor.   
 
 
Figure 14 Alternative accommodations of cis-34 within the MT1 binding site 
To further explore the versatility of the THQ ring as a good template for the design of new 
MLT receptor ligands, we evaluated the possibility of eliminating the methylene spacer of the side 
chain, by directly linking the amide group to position 3, in agreement to what already reported for 
tetraline bioisosteres, such as 4-P-PDOT or its analogs.   
The new 3-propionylaminoTHQ derivatives 37a-b were prepared according to the synthetic 
steps illustrated in Scheme 4.   
A key intermediate for their synthesis was 3-propionamidotetrahydroquinoline (36)33 which 
was obtained by N-acylation of the commercially available 3-aminoquinoline with propionic anhydride 
and subsequent reduction of the pyridine ring with NaBH3CN/ AcOH.  The N-phenyl (37a) and N-
benzyl (37b) desired compounds were respectively prepared by palladium catalyzed N-arylation or N-
benzylation of 36.   
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Scheme 4 Synthesis of 3-propionylaminoTHQ derivatives 37a-b. Reagents and conditions: (a) propionic anhydride, Et3N, 
THF, reflux, 3 h, yield 81%; (b) NaBH3CN, AcOH, 50 °C to rt, 20 h, yield 40%; (c) bromobenzene, Pd(OAc)2, (±)-BINAP, t-
BuOK, toluene, 100 °C, 6 h, yield 46%; (d) benzyl bromide, Et3N, toluene, reflux, 1 h, yield 61%. 
The results of binding studies with the new THQ derivatives 37a-b are shown in Table 7.  37a 
showed nanomolar affinity and it behaved as a partial agonist (MT1 Ki = 22 nM, EC50 = 20 nM; MT2 Ki 
= 2 nM, EC50 =1 nM).  Compared to cis-4-P-PDOT, its formal CH/N isostere, the N-phenyl-THQ 37a 
displayed the same MT1 receptor affinity and a similar partial agonist, behavior but it resulted less 
potent at MT2 receptor and thus less MT2-selective (11 fold).  Replacing the N-phenyl substituent with 
a benzyl group restored MT2 selectivity and shifted intrinsic activity toward antagonism (MT1 Ki = 892 
nM; MT2 Ki = 6 nM, EC50 = >10000 nM).  This is consistent to the greater hindrance of the benzyl 
group, which can occupy the previously proposed accessory out of plane binding site region conferring 
MT2 selectivity. 34  The pharmacological results for the 3-propionamido THQs confirm, once again, the 
bioisosterism between the tetralin and THQ rings.   
 
Table 7 Binding affinity and intrinsic of 37a-b at human MT1 and MT2 melatonin receptors 
 
 
Compounda 
 
R1 
MT1 MT2 
Ki  
(nM) 
EC50 
(nM) 
Emax 
(%) 
Ki  
(nM) 
EC50 
(nM) 
Emax 
(%) 
1 (MLT)b  0.23 1.7 123 ± 13 0.52 0.4 76 ± 6 
Cis-4-P-PDOTc  76  23 ± 6 0.69  46 ± 2 
37a Ph 22 20 29 ± 3 2 1 41 ± 3 
37b Bn 892   6 ˃10000  
Ki and EC50 (nM) values are geometric mean values of at least two separate experiments performed in duplicate.  Emax 
values are arithmetic mean values ± SEM. aChiral compounds were tested as racemates. bTaken from ref 29  cTaken from ref 
30 
NMR conformational investigations of 37b pointed out that such compound does not assume 
a fixed arrangement of the THQ nucleus, as shown from the conflicting J values registered in CDCl3 
and DMSO-d6 (Table 8).    
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Table 8 J coupling constant for compound 37b 
 
N
Bn
NHCOEt
 
37b 
 
Proton 
 (ppm) 
CDCl3 
J (Hz) 
CDCl3 
 (ppm) 
DMSO-d6 
J (Hz) 
DMSO-d6 
H4e 2.77 
4J4e-2e = 2.5 (long 
range W coupling) 
3J4e-3 = 3.0 
2J4e-4a = 16.5 
2.69 
3J4e-3 = 9.0 
2J4e-4a = 15.5 
H4a 3.16 
3J4a-3 = 4.5 
2J4a-4e = 16.5 
2.93 
4J4a-2a = 1.5 (long range 
W coupling)a 
3J4a-3 = 4.5 
2J4a-4e = 15.5 
H2e 3.29 
4J2e-4e = 2.5 (long 
range W coupling) 
3J2e-3 = 4.0 
2J2e-2a = 11.5 
3.17 
3J2e-3 = 8.5 
2J2e-2a = 11.0 
H2a 3.54 
3J2a-3 = 2.5 
2J2a-2e = 11.5 
3.40 
4J2a-4a = 1.5 (long range 
W coupling) 
3J2a-3 = 4.0 
2J2a-2e = 11.0 
H3 4.54 
3J3-2a = 2.5 
3J3-4e = 3.0 
3J3-2e = 4.0 
3J3-4a = 4.5 
4.13 
3J3-2a = 4.0 
3J3-4a = 4.5 
3J3-2e = 8.5 
3J3-4e = 9.0 
a The H4a signal is a broad dd in the 400MHz 1H NMR spectra, the long range coupling constant is clearly visible in the H2a.   
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To further extend chemical space of THQ ligands for melatonin receptors, we finally consider 
the possibility to move the side chain to the N-1 THQ position.  A new series of THQ melatonin 
analogues, bearing the amido side chain attached at the N-1 position of the THQ nucleus, were 
synthesized and tested for their affinity for the melatonin receptors.  Optimization of the C-2, C-8 
substituent and of the side chain led to interesting compounds with different pharmacological profiles 
in term of affinity, subtype selectivity and functional selectivity.  Further details will be omitted, 
because the obtained results are being evaluated for a possible patent application.   
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1.2.3 Conclusions 
 
In conclusion, three new series of tetrahydroquinoline derivatives were synthetized and tested 
to extend the chemical space of melatonin receptor ligands.  Different ligand-based techniques, such as 
pharmacophore models, SAR studies and classical isosteric CH/N replacement, were applied to design 
these new compounds.  Thanks to alternative accommodations of the ligands within the binding site, 
all new synthesized THQs fulfill the pharmacophore requirements for proper receptor binding, with the 
possibility of modulating, at least partially, both MT2/MT1 selectivity and intrinsic activity, through 
appropriate substitutions on the tetrahydroquinoline ring.  The obtained results reinforce our initial 
hypothesis that the semi-rigid THQ ring possess geometries suitable for decoration with different side 
chains and it can be considered a good synthetically accessible template for the design of potent MLT 
receptor ligands with different topology.   
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1.2.4 Experimental Section  
 
1.2.4.1 Materials and Methods 
 
Melting points were determined on a Buchi B-540 capillary melting point apparatus and are 
uncorrected.  1H NMR and 13C NMR spectra were recorded on a Bruker AVANCE 200 or 400 
instrument. Chemical shifts (δ scale) are reported in parts per million (ppm) relative to the central peak 
of the solvent. Coupling constants (J) are given in hertz (Hz).  1H and 13C signals were unambiguously 
assigned by COSY, NOESY, DEPT135, HMQC, and HMBC experiments. EI MS spectra (70 eV) were 
taken on a Fisons Trio 1000 instrument; only molecular ions (M+) and base peaks are given.  ESI MS 
spectra were taken on a Waters Micromass ZQ instrument; only molecular ions (M+1)+ or (M-1)- are 
given.  High-resolution mass spectroscopy was performed on a Micro mass Q-ToF Micromass 
spectrometer (Micromass, Manchester, UK) using an ESI source.  The purity of tested compounds, 
determined by high performance liquid chromatography (HPLC), was greater than 95%.  These 
analyses were performed on a Waters HPLC/UV/MS system (separation module Alliance HT2795, 
Photo Diode Array Detector 2996, mass detector Micromass ZQ; software: MassLynx 4.1).  Column 
chromatography purifications were performed under “flash” conditions using Merck 230−400 mesh 
silica gel.  Analytical thin-layer chromatography (TLC) was carried out on Merck silica gel 60 F254 
plates.  Chiral HPLC runs were conducted on a Jasco (Cremella, LC, Italy) HPLC system equipped 
with a Jasco AS-2055 plus autosampler, a PU2089 plus quaternary gradient pump, and an MD-2010 
plus multiwavelength detector.  Experimental data were acquired and processed by Jasco Borwin PDA 
and Borwin Chromatograph Software.  Solvents used for chiral chromatography were HPLC grade and 
supplied by Carlo Erba (Milan, Italy).  Optical rotation values were measured on a Jasco (Cremella, 
LC, Italy) photoelectric polarimeter DIP 1000 with a 0.2 dm cell at the sodium D line (λ = 589 nm); 
sample concentration values (c) are given in 10−2 g mL −1.  
 
1.2.4.2 Reagents 
 
3-Quinolinecarbonitrile and 3-aminoquinoline were purchased from commercial suppliers and 
used without further purification.   
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1.2.4.3 Synthesis and Physicochemical Characterization of THQ MLT 
Receptor Ligands 
 
(±)-N-[(1,2,3,4-Tetrahydroquinolin-3-yl)methyl]acetamide (27)  
 
To prepare this compound, quinoline-3-carbonitrile (0.154 g, 1 mmol) was submitted to catalytic 
hydrogenation (Raney-Ni, H2 4 atm, 60 °C, 16 h).  The catalyst was filtered on Celite, the filtrate was 
concentrated in vacuo, and the residue was partitioned between EtOAc and water.  The organic phase 
was washed with brine, dried (Na2SO4), and evaporated under reduced pressure to give the 
corresponding crude oily amine, which was used without any further purification.  Et3N (0.14 mL, 1 
mmol) and propionic anhydride (0.13 mL, 1 mmol) were added to a cold solution of the above crude 
amine in THF (6 mL), and the resulting mixture was stirred at room temperature for 1 h.  The solvent 
was removed by distillation under reduced pressure, and the residue was taken up in EtOAc and washed 
with a saturated aqueous solution of NaHCO3 and then with brine.  After drying over Na2SO4, the 
solvent was removed by distillation in vacuo to give a crude product that was purified by silica gel flash 
chromatography (EtOAc−MeOH 95:5 as eluent) and crystallization.  White solid, mp 126−7 °C (diethyl 
ether−petroleum ether), 70% yield.   
1H NMR (200 MHz, CDCl3): δ 6.94−7.02 (m, 2H), 6.63 (dd, 1H, J
1 = 1.0, J2 = 7.5 Hz), 6.49 (d, 1H, J 
= 7.5 Hz), 5.68 (br s, 1H), 3.83 (br s, 1H), 3.17−3.43 (m, 3H), 3.05 (dd, 1H, J1 = 8.0, J2 = 11.0 Hz), 
2.86 (dd, 1H, J1 = 5.0, J2 = 11.0 Hz), 2.53 (dd, 1H, J1 = 8.0, J2 = 16.0 Hz), 2.18−2.23 (m, 1H), 1.98 (s, 
3H).  13C NMR (100 MHz, CDCl3): δ 170.4, 144.0, 129.7, 126.9, 120.0, 117.6, 114.3, 44.7, 42.3, 32.5, 
30.7, 23.3.  EI MS (m/z): 204 (M+), 130 (100).  HR MS (ESI): m/ z calculated for C12H16N2O, [M + 
H]+: 205.1341, found: 205.1341.   
 
General Procedure for N1-Alkylation of N-[(1,2,3,4-tetrahydroquinolin-3-yl)methyl]acetamide 
(27): Preparation of compounds 28a-d 
 
A solution of N-[(1,2,3,4-tetrahydroquinolin-3-yl)methyl]acetamide 27 (0.204 g, 1 mmol), Et3N (0.8 
mL, 5.7 mmol), and the suitable alkyl halide (5 mmol) in dry toluene (6 mL) was heated for 1−24 h.  
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After cooling to room temperature, the reaction mixture was poured into water and extracted with 
EtOAc (4×), and the combined organic phases were washed with brine and dried (Na2SO4).  The solvent 
was removed by distillation in vacuo, and the residue was purified by silica gel flash chromatography 
and/or crystallization.   
 
(±)-N-[(1-Methyl-1,2,3,4-tetrahydroquinolin-3-yl)methyl]acetamide (28a) 
Methyl iodide as alkylating reagent; 70 °C in a sealed vessel for 16 h.  Purification by silica gel flash 
chromatography (EtOAc−cyclohexane 8:2 as eluent) and crystallization.  Beige solid, mp 109−10 °C 
(diethyl ether−petroleum ether), 68% yield.   
1H NMR (200 MHz, CDCl3): δ 7.09 (dd, 1H, J
1 = 1.0, J2 = 7.5 Hz), 6.96 (d, 1H, J = 7.5 Hz), 6.58−6.66 
(m, 2H), 5.63 (br s, 1H), 3.16−3.49 (m, 3H), 2.98 (dd, 1H, J1 = 8.0, J2 = 11.0 Hz), 2.88 (s, 3H), 2.85 
(dd, 1H, J1 = 5.0, J2 = 11.0 Hz), 2.54 (dd, 1H, J1 = 8.5, J2 = 16.0 Hz), 2.18−2.34 (m, 1H), 1.99 (s, 3H).  
13C NMR (100 MHz, CDCl3): δ 170.3, 145.7, 129.2, 127.3, 121.6, 117.3, 111.6, 54.3, 42.5, 39.5, 32.7, 
31.4, 23.3.  ESI MS (m/z): 219 (M+H)+.  HR MS (ESI):m/z calculated for C13H18N2O, [M + H]+: 
219.1497, found: 219.1497.   
 
(±)-N-[(1-Ethyl-1,2,3,4-tetrahydroquinolin-3-yl)methyl]acetamide (28b) 
Ethyl iodide as alkylating reagent; 100 °C in a sealed vessel for 16 h. Purification by silica gel flash 
chromatography (EtOAc−cyclohexane 8:2 as eluent) and crystallization.  Beige solid, mp 84−5 °C 
(diethyl ether−petroleum ether), 81% yield.   
1H NMR (200 MHz, CDCl3): δ 7.06 (dd, 1H, J
1 = 1.5, J2 = 7.5 Hz), 6.96 (d, 1H, J = 7.5 Hz), 6.53−6.62 
(m, 2H), 5.65 (br s, 1H), 3.13−3.49 (m, 5H), 3.02 (dd, 1H, J1 = 8.0, J2 = 11.0 Hz), 2.83 (dd, 1H, J1 = 
5.0, J2 = 16.0 Hz), 2.52 (dd, 1H, J1 = 8.5, J2 = 16.0 Hz), 2.13− 2.32 (m, 1H), 1.99 (s, 3H), 1.12 (t, 3H, 
J = 7.0 Hz).  13C NMR (100 MHz, CDCl3): δ 170.4, 144.3, 129.6, 127.3, 120.9, 116.1, 110.8, 51.3, 45.5, 
42.5, 32.5, 31.8, 23.3, 10.6.  EI MS (m/z): 232 (M+), 130 (100).  HR MS (ESI): m/z calculated for 
C14H20N2O, [M + H]+: 233.1654, found: 233.1654.   
 
(±)-N-[(1-Benzyl-1,2,3,4-tetrahydroquinolin-3-yl)methyl]acetamide (28c) 
Benzyl bromide as alkylating reagent; 1 h under reflux. Purification by silica gel flash chromatography 
(EtOAc as eluent) and crystallization.  White solid, mp 97−8 °C (diethyl ether− petroleum ether); 85% 
yield.   
1H NMR (200 MHz, CDCl3): δ 7.22−7.37 (m, 5H), 6.97−7.05 (m, 2H), 6.54−6.65 (m, 2H), 5.41 (br s, 
1H), 4.56 (d, 1H, J = 16.5 Hz), 4.36 (d, 1H, J = 16.5 Hz), 3.34 (ddd, 1H, J1 = 1.5, J2 = 3.5, J3 = 11.5 
Hz), 3.22−3.30 (m, 2H), 3.12 (ddd, 1H, J1 = 1.0, J2 = 7.5, J3 = 11.0 Hz), 2.92 (dd, 1H, J1 = 5.0, J2 = 
15.0 Hz), 2.57 (dd, 1H, J1 = 8.5, J2 = 16.0 Hz), 2.21−2.34 (m, 1H), 1.91 (s, 3H).  13C NMR (100 MHz, 
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CDCl3): δ 170.3, 145.1, 138.7, 129.6, 128.7, 127.4, 127.1, 126.9, 120.5, 116.6, 111.2, 55.1, 51.9, 42.1, 
32.4, 31.7, 23.3.  EI MS (m/z): 294 (M+), 144 (100).  HR MS (ESI): m/z calculated for C19H22N2O, [M 
+ H]+: 295.1810, found: 295.1810.   
 
(±)-N-[(1-Phenylethyl-1,2,3,4-tetrahydroquinolin-3-yl)methyl]acetamide (28d) 
2-Phenylethyl bromide as alkylating reagent; 16 h under reflux.  Purification by silica gel flash 
chromatography (EtOAc as eluent) and crystallization.  White solid, mp 123−4 °C (CH2Cl2− petroleum 
ether); 46% yield.  1H NMR (200 MHz, CDCl3): δ 7.19−7.37 (m, 5H), 7.07−7.15 (m, 1H), 6.97 (dd, 
1H, J1 = 1.0, J2 = 7.5 Hz), 6.57−6.70 (m, 2H), 5.22 (br s, 1H), 3.46−3.56 (m, 2H), 3.08−3.18 (m, 3H), 
2.77− 2.96 (m, 4H),  2.49 (dd, 1H, J1 = 8.0, J2 = 16.0 Hz), 2.02−2.20 (m, 1H), 1.92 (s, 3H).  13C NMR 
(100 MHz, CDCl3): δ 170.2, 144.5, 140.0, 129.6, 129.0, 128.5, 127.3, 126.2, 120.6, 116.1, 110.4, 53.3, 
52.6, 42.2, 32.8, 32.3, 31.7, 23.3.  ESI MS (m/z): 309 (M + H)+.  HR MS (ESI): m/z calculated for 
C20H24N2O, [M + H]+: 309.1967, found: 309.2012.   
 
(±)-N-[(1-Phenyl-1,2,3,4-tetrahydroquinolin-3-yl)methyl]acetamide (28e) 
A Schlenk flask was charged with Pd(OAc)2 (22 mg, 0.1 mmol), (±)-BINAP (60 mg, 0.1 mmol), t-
BuOK (0.26 g, 2.32 mmol), and 27 (0.204 g, 1 mmol) in dry toluene (2 mL) under nitrogen atmosphere.  
Bromobenzene (0.2 mL, 2 mmol) was added dropwise via syringe, and the resulting mixture was stirred 
at 100 °C for 6 h.  After cooling to room temperature, the reaction mixture was quenched with water 
and then extracted twice with CH2Cl2.  The combined organic phases were dried over Na2SO4 and 
concentrated by distillation under reduced pressure to yield a crude residue that was purified by silica 
gel flash chromatography (cyclohexane−EtOAc 3:7 as eluent) and crystallization.  White solid, mp 
144−5 °C (diethyl ether−petroleum ether); 29% yield.   
1H NMR (400 MHz, DMSO-d6): δ 7.95 (br t, 1H), 7.01−7.40 (m, 6H), 6.88 (dddd, 1H, J
1 = J2 = 1.5, J3 
= J4 = 8.0 Hz), 6.65 (dddd, 1H, J1 = J2 = 1.0, J3 = J4 = 7.5 Hz), 6.56 (dd, 1H, J1 = 1.0, J2 = 8.0 Hz), 3.63 
(ddd, 1H, J1 = 1.5, J2 = 3.5, J3 = 11.5 Hz), 3.25 (dd, 1H, J1 = 9.0, J2 = 11.5 Hz), 3.13 (dd, 1H, J1 = 6.0, 
J2 = 13.5 Hz), 3.06 (dd, 1H, J1 = 6.0, J2 = 13.5 Hz), 2.84 (ddd, 1H, J1 = 1.5, J2 = 4.5, J3 = 16.0 Hz), 2.52 
(dd, 1H, J1 = 10.0, J2 = 16.0 Hz), 2.13 (dddddd, 1H, J1 = 3.5, J2 = 4.5, J3 = J4 = 6.0, J5 = 9.0, J6 = 10.0 
Hz), 1.81 (s, 3H).  13C NMR (100 MHz, CDCl3): δ 170.3 (CO), 147.9 (C9), 143.8 (C10), 129.8 (C5), 
129.5, 126.5 (C7), 124.7, 124.0, 122.4, 118.6 (C6), 115.4 (C8), 53.5 (C4), 42.2 (C11), 33.1 (C3), 31.5 
(C2), 23.3 (CH3). EI MS (m/ z): 280 (M+), 208 (100).  HR MS (ESI): m/z calculated for C18H20N2O, [M 
+ H]+: 281.1654, found: 281.1692.   
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1-Phenyl-3,4-dihydronaphthalene-2-carbonitrile (29) 
 
A solution of 1-phenyl-3,4-dihydronaphthalen-2(1H)-one17 (1 g, 4.5 mmol), trimethylsilyl cyanide (0.8 
mL, 6 mmol), and ZnI2 (0.038 g, 0.11 mmol) in dry toluene (3.5 mL) was stirred at room temperature 
for 18 h. Pyridine (6 mL) and afterward POCl3 (1.3 mL, 14 mmol) were added to the above solution, 
and the resulting mixture was refluxed for 1 h.  After cooling to room temperature, the reaction mixture 
was poured into 5% HCl/ ice, and the aqueous phase was extracted with EtOAc.  The combined organic 
extracts were washed with brine, dried (Na2SO4), and concentrated under reduced pressure to give a 
crude residue that was purified by flash chromatography (silica gel, cyclohexane−EtOAc 9:1 as eluent) 
and crystallization.  White solid, mp 81−2 °C (diethyl ether−petroleum ether); 65% yield.   
1H NMR (200 MHz, CDCl3): δ 6.86− 7.51 (m, 9H), 2.95−2.99 (m, 2H), 2.64−2.73 (m, 2H).  ESI MS 
(m/z): 232 (M + H)+.   
 
N-[(1-Phenyl-3,4-dihydronaphthalen-2-yl)methyl]propionamide (30) 
 
A suspension of aluminum trichloride (0.293 g, 2.2 mmol) in dry THF (2.8 mL) was added to a stirred 
ice-cooled suspension of LiAlH4 (0.041 g, 1.1 mmol) in dry THF (1.3 mL) under a nitrogen atmosphere.  
The mixture was stirred for 10 min, a solution of the nitrile 29 (232 mg, 1.0 mmol) in dry THF (0.9 mL) 
was then added dropwise, and the resulting mixture was stirred at room temperature for 2 h.  Water was 
carefully added at 0 °C, and the resulting mixture was filtered through a Celite pad.  The filtrate was 
concentrated in vacuo and partitioned between water and EtOAc.  The combined organic phases were 
washed with brine, dried (Na2SO4), and concentrated under reduced pressure to yield the crude desired 
amine, which was used without any further purification.  Et3N (0.15 mL, 1.07 mmol) and propionic 
anhydride (0.136 mL, 1.07 mmol) were added to a stirred solution of the above crude amine in dry THF 
(12 mL), and the mixture was stirred at room temperature for 16 h.  The solvent was evaporated in 
vacuo, and the residue was dissolved in EtOAc.  The solution was washed with 2 N NaOH and brine, 
dried (Na2SO4), and then concentrated under reduced pressure to give a crude residue that was purified 
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by flash chromatography (silica gel, cyclohexane−EtOAc 7:3 as eluent) and crystallization.  White solid, 
mp 154−5 °C (EtOAc−petroleum ether); 37% yield.   
1H NMR (200 MHz, CDCl3): δ 7.35−7.49 (m, 3H), 7.00−7.19 (m, 5H), 6.61 (dd, 1H, J
1 = 1.5, J2 = 7.0 
Hz), 5.29 (br t, 1H), 3.91 (d, 2H, J = 6.0 Hz), 2.85−2.93 (m, 2H), 2.41−2.49 (m, 2H), 2.19 (q, 2H, J = 
7.5 Hz), 1.14 (t, 3H, J = 7.5 Hz).  13C NMR (100 MHz, CDCl3): δ 173.7, 138.5, 136.8, 136.1, 135.3, 
133.7, 129.9, 128.6, 127.2, 126.9, 126.2, 126.0, 42.1, 29.8, 28.3, 25.9, 9.9.  ESI MS (m/z): 292 (M+H)+.  
HR MS (ESI): m/z calculated for C20H21NO, [M + H]+: 292.1701, found: 292.1715.   
 
(±)-trans-N-[(1-Phenyl-1,2,3,4-tetrahydronaphthalen-2-yl)methyl]propionamide (31) 
 
A solution of 29 (0.1 g, 0.43 mmol) in dry THF (1.5 mL) was added dropwise to a stirred ice-cooled 
suspension of LiAlH4 (0.035 g, 0.92 mmol) in dry THF (0.5 mL) under nitrogen atmosphere at 0 °C.  
The reaction mixture was refluxed for 2 h, quenched by water addition at 0 °C, and then filtered on 
Celite.  The filtrate was extracted with EtOAc (3×), and the combined organic phases were dried 
(Na2SO4) and concentrated under reduced pressure to give the desired crude corresponding amine.  Et3N 
(0.08 mL, 0.57 mmol) and propionic anhydride (0.07 mL, 0.54 mmol) were added to a solution of the 
above crude amine in THF (5 mL), and the resulting mixture was stirred at room temperature for 16 h.  
After distillation of the solvent under reduced pressure, the residue was partitioned between EtOAc and 
2 N NaOH.  The organic layer was washed with brine, dried (Na2SO4), and concentrated under reduced 
pressure to give a crude residue which was purified by flash chromatography (silica gel, 
CH2Cl2−acetone 95:5 as eluent) and crystallization.  White solid, mp 120−1 °C (EtOAc−petroleum 
ether); 30% yield.   
1H NMR (400 MHz, MeOD): δ 7.27−7.31 (m, 2H), 7.20 (dddd, 1H, J1 = J2 = 1.5, J3 = J4 = 7.5 Hz), 
7.06−7.14 (m, 4H), 6.98 (ddd, 1H, J1 = 1.5, J2 = J3 = 8.0 Hz), 6.71 (d, 1H, J = 8.0 Hz), 3.84 (d, 1H, J = 
8.0 Hz), 3.19 (dd, 1H, J1 = 8.0, J2 = 13.5 Hz), 3.14 (dd, 1H, J1 = 5.5, J2 = 13.5 Hz), 2.87−2.99 (m, 2H), 
2.17 (q, 2H, J = 7.5 Hz), 2.14 (ddddd, 1H, J1 = 3.0, J2 = 5.5, J3 = J4 = 8.0, J5 = 9.0 Hz), 2.03 (dddd, 1H, 
J1 = 3.0, J2 = J3 = 5.5, J4 = 13.5 Hz), 1.57 (dddd, 1H, J1 = 6.5, J2 = 8.5, J3 = 9.0, J4 = 13.5 Hz), 1.11 (t, 
3H, J = 7.5 Hz).  13C NMR (100 MHz, CDCl3): δ 173.8 (CO), 145.8, 139.0, 136.6, 130.2, 129.3, 128.6, 
126.5, 125.93, 125.89, 50.7 (C1), 43.7 (C2), 42.8 (C11), 29.6 (C4), 28.8 (CH2CH3), 26.2 (C3), 9.8 
(CH2CH3).  ESI MS (m/z): 294 (M + 1)+.  HR MS (ESI): m/ z calculated for C20H23NO, [M + H]+: 
294.1858, found: 294.1858.   
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(±)-cis-N-[(1-Phenyl-1,2,3,4-tetrahydronaphthalen-2-yl)methyl]propionamide (32) 
 
A solution of 30 (0.3 g, 1.3 mmol) in MeOH (6 mL) was hydrogenated (4 atm) in the presence of 10% 
Pd/C for 6 h at 60 °C.  The catalyst was removed by filtration on Celite, and the filtrate was evaporated 
under reduced pressure to afford a crude product that was purified by flash chromatography (silica gel, 
CH2Cl2-acetone 95:5 as eluent) and crystallization.  White solid, mp 129−30 °C (diethyl 
ether−petroleum ether); 47% yield.   
1H NMR (400 MHz, DMSO-d6): δ 7.72 (br t, 1H), 7.15−7.26 (m, 4H), 7.12 (dddd, 1H, J
1 = J2 = 1.5, J3 
= J4 = 7.5 Hz), 7.03 (dd, 1H, J1 = J2 = 7.0 Hz), 6.96−6.98 (m, 2H), 6.85 (d, 1H, J = 7.5 Hz), 4.25 (d, 
1H, J = 5.0 Hz), 3.00 (ddd, 1H, J1 = 1.5, J2= 6.0, J3 = 18.0 Hz), 2.93 (ddd, 1H, J1 = J2 = 5.5, J3 = 13.0 
Hz), 2.82 (ddd, 1H, J1 = 6.5, J2 = 11.5, J3 = 18.0 Hz), 2.54 (ddd, 1H, J1 = J2 = 6.0, J3 = 13.0 Hz), 
2.05−2.13 (m, 1H), 2.09 (q, 2H, J = 7.5 Hz), 1.68 (dddd, 1H, J1 = 1.5, J2 = 3.5, J3 = 6.5, J4 = 13.5 Hz), 
1.51 (dddd, 1H, J1 = 6.0, J2 = 6.5, J3 = 11.5, J4 = 13.5 Hz), 0.99 (t, 3H, J = 7.5 Hz).  13C NMR (100 
MHz, CDCl3): δ 173.8 (CO), 143.1, 138.8, 136.4, 130.6, 130.0, 128.9, 128.1, 126.5, 126.2, 125.9, 47.9 
(C1), 42.8 (C11), 38.8 (C2), 29.7 (CH2CH3), 28.8 (C4), 21.6 (C3), 9.9 (CH2CH3).  ESI MS (m/z): 294 
(M + 1)+.  HR MS (ESI): m/z calculated for C20H23NO, [M + H]+: 294.1858, found: 294.1858.   
 
(±)-N-[(4-Phenyl-1,2,3,4-tetrahydroquinolin-3-yl)methyl]propionamide (33) 
 
A solution of 4-phenylquinoline-3-carbonitrile (0.230 g, 1 mmol) in THF (5 mL) and 2 M NH3 in EtOH 
(0.6 mL) was hydrogenated (4 atm) over Raney-Ni for 16 h at 60 °C.  The catalyst was filtered on Celite, 
the filtrate was concentrated in vacuo, and the residue was partitioned between EtOAc and water.  The 
organic phase was washed with brine, dried (Na2SO4), and evaporated under reduced pressure to give 
the corresponding crude oily amine, which was used without any further purification. Et3N (0.14 mL, 1 
mmol) and propionic anhydride (0.13 mL, 1 mmol) were added to a cold solution of the above crude 
amine in THF (6 mL), and the resulting mixture was stirred at room temperature for 1 h.  The solvent 
was removed by distillation under reduced pressure, and the residue was taken up in EtOAc and washed 
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with a saturated aqueous solution of NaHCO3 and then with brine.  After drying over Na2SO4, the 
solvent was removed by distillation in vacuo to give a crude product that was purified by silica gel flash 
chromatography (EtOAc−MeOH 98:2 as eluent) and crystallization.  White solid (CHCl3−hexane); 46% 
yield.   
1H NMR (400 MHz, acetone-d6): δ 7.25−7.29 (m, 2H), 7.14−7.21 (m, 3H), 7.00 (br s, 1H), 6.93 (ddd, 
1H, J1 = 1.5, J2 = J3 = 8.0 Hz), 6.78 (dd, 1H, J1 = 1.0, J2 = 7.5 Hz), 6.63 (dd, 1H, J1 = 1.0, J2 = 8.0 Hz), 
5.27 (br s, 1H), 4.16 (d, 1H, J = 4.5), 3.29 (dddd, 1H, J1 = 1.0, J2 = J3 = 4.0, J4 = 11.5 Hz), 3.16 (ddd, 
1H, J1 = J2 = 5.5, J3 = 14.0 Hz), 3.05 (ddd, 1H, J1 = 3.0, J2 = J3 = 11.5 Hz), 2.71 (ddd, 1H, J1 = 6.0, J2 
= 9.0, J3 = 14.0 Hz), 2.28−2.36 (m, 1H), 2.15 (q, 2H, J = 7.5 Hz), 1.05 (t, 3H, J = 7.5 Hz).  ESI MS 
(m/z): 295 (M + H)+.   
 
(±)-cis-N-[(1-Methyl-4-phenyl-1,2,3,4-tetrahydroquinolin-3-yl)methyl]propionamide (34) 
 
Sodium cyanoborohydride (0.1 g, 1.20 mmol) and a 37% aqueous solution of HCHO (0.5 mL) were 
added to a solution of 33 (0.5 mmol), in MeOH (5 mL) and AcOH (to pH = 5).  The resulting mixture 
was stirred at room temperature for 1 h and then at 40 °C for 3 h. A 30% NaOH aqueous solution was 
added, and the aqueous phase was extracted with EtOAc.  After drying over Na2SO4, the combined 
organic layers were concentrated by distillation under reduced pressure to give a crude residue, which 
was purified by silica gel flash chromatography (cyclohexane−EtOAc 6:4 as eluent) and crystallization.  
White solid, mp 167−8 °C (EtOAc−petroleum ether); 72% yield.   
1H NMR (400 MHz, DMSO-d6): δ 7.76 (br t, 1H), 7.23−7.27 (m, 2H), 7.16−7.19 (m, 1H), 7.05 (ddd, 
1H, J1 = 1.5, J2 = 7.5, J3 = 8.0 Hz), 6.98−7.00 (m, 2H), 6.78 (dd, 1H, J1 = 1.5, J2 = 7.5 Hz), 6.70 (d, 1H, 
J = 8.0 Hz), 6.47 (ddd, 1H, J1 = 1.0, J2 =J3 = 7.5 Hz), 4.13 (dd, 1H, J1 = 1.0, J2 = 4.5 Hz), 3.10 (ddd, 
1H, J1 = 1.0, J2 = 4.0, J3 = 11.5 Hz), 2.96 (dd, 1H, J1 = 5 Hz, J2 = n.c.), 2.95 (s, 3H), 2.93 (dd, 1H, J1 = 
J2 = 11.5 Hz), 2.52 (dd, 1H, J1 = 9.0 Hz, J2 = n.c.), 2.28 (ddddd, 1H, J1 = 4.0, J2 = 4.5, J3 = 5.0, J4 = 9.0, 
J5 = 11.5 Hz), 2.09 (q, 2H, J = 8.0 Hz), 0.99 (t, 3H, J = 8.0 Hz).  13C NMR (100 MHz, MeOD): δ 175.7 
(CO), 145.9 (C9), 142.5 (C10), 129.54 (C5), 129.47, 127.5, 127.4 (C7), 126.0, 124.5, 116.0 (C6), 110.6 
(C8), 49.4 (C11), 46.2 (C4), 40.5 (C2), 37.8 (NCH3), 36.7 (C3), 28.7 (CH2CH3), 9.1 (CH2CH3). ESI MS 
(m/z): 309 (M + H)+.  HR MS (ESI): m/z calculated for C20H24N2O, [M + H]+: 309.1967, found: 
309.1967. 
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N-(Quinolin-3-yl)propionamide (35) 
 
 A solution of 3-aminoquinoline (1 g, 7 mmol), Et3N (1.53 mL, 11 mmol) and propionic anhydride (0.9 
mL, 7 mmol) in THF (30 mL) was heated at reflux for 3 h.  After removing the solvent by distillation 
under reduced pressure, the residue was taken up in CH2Cl2, washed twice with 2N NaOH, once with 
brine and dried (Na2SO4).  The solvent was removed under reduced pressure and the crude residue was 
purified by crystallization.  White solid, mp 167−8 °C (CH2Cl2-petroleum ether); 81% yield.   
1H NMR (200 MHz, DMSO-d6): δ 10.57 (s, 1H), 8.92 (s, 1H), 8.70 (s, 1H), 7.86−7.95 (m, 2H), 
7.50−7.65 (m, 2H), 2.43 (q, 2H, J = 7.5 Hz), 1.12 (t, 3H, J = 7.5 Hz).  EI MS (m/z): 200 (M+), 144 
(100).   
 
(±)-N-(1,2,3,4-Tetrahydroquinolin-3-yl)propionamide (36)33  
 
NaBH3CN (0.265 g, 4.2 mmol) was added portion wise during 5 min to a solution of N-(quinolin-3-
yl)propionamide 35 (0.2 g, 1 mmol) in AcOH (3 mL), and the resulting mixture was stirred at room 
temperature for 1 h, at 50 °C for 1 h, and finally at room temperature for 18 h.  The reaction mixture 
was quenched with water and adjusted to pH 11 by adding 30% NaOH, and the aqueous phase was 
extracted with CH2Cl2 (3×).  The combined organic layers were dried (Na2SO4) and concentrated under 
reduced pressure to afford a crude residue, which was purified by silica gel flash chromatography 
(CH2Cl2− EtOAc 6:4 as eluent) and crystallization.  White solid, mp 90−1 °C (diethyl ether−petroleum 
ether); 40% yield.   
1H NMR (200 MHz, CDCl3): δ 6.96−7.08, (m, 2H), 6.69 (ddd, 1H, J
1 = 1.0, J2 = J3 = 7.5 Hz), 6.55 (dd, 
1H, J1 = 1.0, J2 = 8.0 Hz), 5.95 (br s, 1H), 4.44−4.56 (m, 1H), 3.94 (br s, 1H), 3.39 (dd, 1H, J1 = 2.5, J2 
= 11.5 Hz), 3.22 (ddd, 1H, J1 = 2.0, J2 = 4.0, J3 = 11.5 Hz), 3.08 (dd, 1H, J1 = 5.0, J2 = 16.5 Hz), 2.74 
(ddd, 1H, J1 = 2.0, J2 = 3.5, J3 = 16.5 Hz), 2.17 (q, 2H, J = 7.5 Hz), 1.12 (t, 3H, J = 7.5 Hz).  EI MS 
(m/z): 204 (M+), 130 (100).   
  
44 
 
(±)-N-(1-Phenyl-1,2,3,4-tetrahydroquinolin-3-yl)propionamide (37a) 
 
A Schlenk flask was charged with Pd(OAc)2 (22 mg, 0.1 mmol), (±)-BINAP (60 mg, 0.1 mmol), t-
BuOK (0.26 g, 2.32 mmol), and 36 (0.204 g, 1 mmol) in dry toluene (2 mL) under nitrogen atmosphere.  
Bromobenzene (0.2 mL, 2 mmol) was added dropwise via syringe, and the resulting mixture was stirred 
at 100 °C for 6 h.  After cooling to room temperature, the reaction mixture was quenched with water 
and then extracted twice with CH2Cl2.  The combined organic phases were dried over Na2SO4 and 
concentrated by distillation under reduced pressure to yield a crude residue that was purified by silica 
gel flash chromatography (cyclohexane−EtOAc 3:7 as eluent) and crystallization.  Beige solid, mp 
163−4 °C (CH2Cl2−petroleum ether); 46% yield.   
1H NMR (200 MHz, CDCl3): δ 6.94−7.44 (m, 7H), 6.71−6.80 (m, 2H), 5.79 (br s, 1H), 4.53−4.63 (m, 
1H), 3.76 (dd, 1H, J1 = 2.5, J2 = 11.5 Hz), 3.59 (ddd, 1H, J1 = 2.0, J2 = 4.5, J3 = 11.5 Hz), 3.22 (dd, 1H, 
J1 = 5.5, J2 = 16.5 Hz), 2.83 (ddd, 1H, J1= 2.0, J2 = 3.5, J3 = 16.5 Hz), 2.14 (q, 2H, J = 7.5 Hz), 1.09 (t, 
3H, J = 7.5 Hz).  13C NMR (100 MHz, CDCl3): δ 173.3, 147.4, 143.9, 130.5, 129.7, 126.9, 125.2, 124.7, 
120.3, 118.9, 115.1, 54.0, 42.7, 33.4, 29.7, 9.7.  EI MS (m/z): 280 (M+), 206 (100).  HR MS (ESI): m/z 
calculated for C18H20N2O, [M + H]+: 281.1654, found: 281.1631.   
 
(±)-N-(1-Benzyl-1,2,3,4-tetrahydroquinolin-3-yl)propionamide (37b) 
 
A solution of 36 (0.204 g, 1 mmol), Et3N (0.8 mL, 5.7 mmol), and benzyl bromide (5 mmol) in dry 
toluene (6 mL) was heated for 1 h under reflux.  After cooling to room temperature, the reaction mixture 
was poured into water, extracted with EtOAc (4×), and the combined organic phases were washed with 
brine and dried (Na2SO4).  The solvent was removed by distillation in vacuo, and the residue was 
purified by silica gel flash chromatography (cyclohexane−EtOAc 3:7 as eluent) and crystallization.  
Beige solid, mp 132−3 °C (CH2Cl2− petroleum ether); yield 61%.   
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1H NMR (400 MHz, DMSO-d6): δ 7.77 (d, 1H, J = 7.5 Hz), 7.20−7.34 (m, 5H), 6.90− 6.95 (m, 2H), 
6.50−6.53 (m, 2H), 4.53 (d, 1H, J = 17.0 Hz), 4.43 (d, 1H, J = 17.0 Hz), 4.13 (dddd, 1H, J1 = 4.0, J2 = 
4.5, J3 = 8.5, J4 = 9.0 Hz), 3.40 (ddd, 1H, J1 = 1.5, J2 = 4.0, J3 = 11.0 Hz), 3.17 (dd, 1H, J1 = 8.5, J2 = 
11.0 Hz), 2.93 (ddd, 1H, J1 = 1.5, J2 = 4.5, J3 = 15.5 Hz), 2.69 (dd, 1H, J1 = 9.0, J2 = 15.5 Hz), 2.10 (q, 
2H, J = 7.5 Hz), 0.99 (t, 3H, J = 7.5 Hz).  13C NMR (100 MHz, CDCl3): δ 173.4 (CO), 144.6, 138.3, 
130.4, 128.7, 127.7, 127.1, 126.8, 118.6, 117.1, 111.5, 54.9 (C3), 53.2 (C2), 41.9 (CH2Ph), 33.5 (C4), 
29.7 (CH2CH3), 9.7 (CH2CH3).  EI MS (m/z): 294 (M+), 220 (100).  HRMS (ESI): m/z calculated for 
C19H22N2O, [M + H]+: 295.1810, found: 295.1810.   
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1.3 Dual-acting Melatoninergic Derivatives: 
Design, Synthesis and Pharmacological 
Investigations 
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1.3.1 Introduction and Aim of the Work 
 
Multitargeting compounds, able to simultaneously modulate more than a single biological 
target, have gained remarkable relevance in drug discovery owing to the complexity of multifactorial 
diseases such as cancer, inflammation, psychiatric and degenerative CNS disorders, or the metabolic 
syndrome.  Indeed, the high therapeutic success of many drugs in clinical use, such as acetyl salicylic 
acid, paracetamol, metformin or statins, is ascribed to their pleiotropic activities on multiple targets. 
The emerging field of systems or network biology, which considers the description of the complex 
interactions between the molecular constituents of a living cell, is further stimulating modern drug 
discovery to intentionally design small molecule drugs with defined multitarget activity.   
Multifunctional molecules may have a number of advantages over a “combination of single-
target drugs”, or a “single-pill drug combination”, including better distribution in the target tissue, 
decreased pharmacokinetic complexity, fewer drug-drug interactions, lower risk of toxicity, 
improved patient compliance and tolerance and lower risk of target-based drug resistance due to 
modulation of a few targets.  Furthermore, multitarget drug discovery also offers economic 
advantages because the clinical development of a single multitarget drug requires less clinical trials 
than multiple specific drugs, and can be also a base of drug repurposing.  However, it is not easy to 
design potent multitargeting compounds and problems arise starting from a proper target selection 
through affinity balancing to avoid affinity to related off-targets.   
Classical approaches to design multi-target agents involve three different ways of combination 
of two pharmacophores (Figure 15): linkage, fusion, and incorporation.   
 
Figure 15 (taken from ref 35) Multitarget agents can arise from linking pharmacophores with stable or biodegradable 
linkers, fusing of pharmacophores, or merging of pharmacophores for the biological targets of interest 
The simplest way to develop this kind of molecules is the pharmacophore connection of two 
(or more) distinct targets with a stable or biodegradable linker.  The length, regiochemistry (site of 
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attachment), and composition of linkers are crucial optimization tasks to ensure that the original 
scaffolds retain their activity.  For example, the linker cannot join a scaffold at a position that would 
prevent it from binding to its target.  The linker itself may also interact with the target; thus, its chemical 
properties need to be tailored in order to maximize interactions between the linker and the target.   
The fusion approach is basically an extension of the linkage approach with a linker length of zero, such 
that the two bioactive small molecules addressing two targets are directly joined to one another.   
The most elegant way of designing small multifunctional molecules is the incorporation approach, in 
which the key pharmacophore features required to interact with the targets of interest are combined in 
one merged pharmacophore.  To allow such pharmacophore merging, a certain overlap in the 
pharmacophores of the individual targets is required.  These types of molecules are most favorable in 
terms of drug-likeness but are the least likely to retain function.   
Interesting multifunctional molecules that bind to more than one biological target have recently 
been described also in the MLT field.  A good example is the recently marketed drug agomelatine 
(Valdoxan/ Thymanax), a potent agonist at melatonin receptors and an antagonist at 5-HT2C serotonin 
receptor, which elicited antidepressant activity with a relatively mild side-effect profile as well as 
positive effects on sleep.36  Recently, different series of dual-acting compounds, constituted by 
melatonin linked to another known neuroprotective agent have been reported as novel potential 
therapeutic agents for the treatment of neurodegenerative disorders such as Parkinson’s and 
Alzheimer’s diseases.  Examples of these compounds are shown in Figure 16, including melatonin-
tacrine hybrid with potent anticholinesterase and antioxidant activity,37 melatonin-N,N-dibenzyl(N-
methyl)amine hybrids and melatonin-curcumin dual-acting compound.38,39   
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Figure 16 Structures of previously reported melatonin dual-target compounds 
 
To further improve the therapeutic opportunities of MLT derivatives, during my PhD program, 
I also investigated the possibility to develop multi-target compounds.  In particular, we are interested 
to combine in a single multifunctional agent agonism at the MT1 melatonin receptor with the ability to 
enhance endocannabinoid neurotransmission, by inhibiting the activity of the Fatty acid amide 
hydrolase (FAAH), an integral membrane enzyme involved in the hydrolytic inactivation of the 
endocannabinoid anandamide (Figure 17).   
 
Figure 17 (taken from ref 40) 
Activation of MLT receptors and inhibition of FAAH have both shown potential benefits for 
the treatment of different diseases, such as depression, neurodegenerative CNS disorders, pain and 
glaucoma.41,42,43,44   
Glaucoma is a multifactorial disease characterized by progressive optic nerve injury and visual 
field defects.  Elevated intraocular pressure (IOP) is the most widely recognized risk factor for the onset 
and progression of glaucoma, and IOP-lowering medications represent the primary treatment strategy.  
Currently, the five most used pharmacologic classes of IOP-lowering drugs are α2-adrenergic receptor 
agonists (e.g. brimonidine), β‑adrenergic antagonists (e.g. timolol), carbonic anhydrase inhibitors (e.g. 
dorzolamide), cholinergic agonists (e.g. pilocarpine, carbachol) and prostaglandin analogs (e.g. 
latanoprost, travoprost, bimatoprost).   
Despite the availability of several active principles and their combinations, the search for new IOP 
lowering agents is highly active and aims at developing more potent compounds endowed with more 
persistent action and lower side effects compared to currently available drugs.  Currently, the focus of 
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new glaucoma medical treatments is on novel targets for increasing aqueous humor outflow and/or 
suppressing aqueous inflow.   
 
In the search of new compounds for the treatment of glaucoma, MLT has been tested as a natural 
compound with potential ocular hypotensive effects and interesting neuroprotective actions.9  As 
aforementioned, MLT is produced not only by the pineal gland, but also by several ocular structures, 
and its receptors have been identified in different areas, such as in the retina, ciliary body, cornea, lens, 
and sclera,45 justifying the hypothesis that MLT may be involved in the regulation of IOP.   Indeed, 
topical and systemic administration of melatonin has been shown to transiently reduce IOP in 
normotensive and hypertensive/glaucomatous animals, such as mice,46 rabbits,47 and monkeys,48 as well 
as in humans.49,50  MLT potentiates the IOP lowering effect exerted by the adrenergic system, as it 
increases expression of the α2- and reduces expression of the β2-adrenergic receptors that control the 
synthesis and drainage of aqueous humor in ciliary nonpigmented epithelium.51  Besides the natural 
ligand, synthetic MLT receptor agents such as agomelatine,46 5-MCA-NAT52 and IIK748 have shown 
IOP lowering effects.   
Reduction of IOP is also a well-known effect observed in cannabis users.53  The presence of a functional 
endocannabinoid system in the retina, which includes endogenous cannabinoids, enzymes involved in 
their synthesis and deactivation, and cannabinoid receptors, supports a role for cannabinoids in retinal 
circuitry and vision.54  More recently, reduction of IOP has been observed after administration of 
endogenous or exogenous cannabinoids, such as Δ9-tetrahydrocannabinol, the main active principle of 
cannabis, the synthetic cannabinoid CB1 and CB2 receptor agonist WIN55212-2, and the 
endocannabinoid anandamide (AEA) in studies performed in animals and humans.42 
Collectively, the findings outlined above suggest that both melatonin and endocannabinoid 
systems might contribute to the regulation of IOP through modulation of specific mechanisms.   
One of the main objectives of my PhD thesis was the design and development of novel dual-acting 
compounds that activate MLT receptors and inhibit FAAH potentially able to exert IOP lowering 
activity with mutual benefits.   
To design these compounds we started from previously developed chemical classes of FAAH 
inhibitors and MT1 ligands.  Among the previously reported MLT receptor ligands, the class of 
anilinoethylamides (Figure 18) has proved to be one of the most interesting and versatile.55  These 
compounds showed a generally good affinity for MLT receptors and, particularly, the possibility to be 
derivatized, giving predictable modulation of selectivity and intrinsic activity.  In particular, in this class 
an increase in the size of the substituent on the nitrogen atom shifts the activity from that of a 
nonselective full agonist (e.g., a methyl group: UCM 793) to an MT2-selective partial agonist for the 
phenyl derivative (UCM765), to a very selective MT2 antagonist in the case of the naphthyl derivative 
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(UCM800).55  Furthermore, the introduction of a bulky lipophilic group on the oxygen atom of the 
aniline scaffold provided a compound (UCM871) with modest selectivity for the MT1 receptor.23   
 
 
Figure 18 Anilinoethylamides 
To propose an explanation for the observed MT1 selectivity shown by UCM871, some years 
ago Rivara and coll. built a 3D homology model of the MT1 receptor based on the 3D structure of the 
active form of the adrenergic β2 receptor.24  In the proposed model, within the receptor binding site 
there is an accessory lipophilic pocket, mainly defined by the transmembrane helices TM3 and TM4, 
where the phenylbutyloxy group of compound UCM871, and in general a bulky lipophilic substituent, 
could be accommodated.  Selectivity for the MT1 receptor should come from the fact that the analogue 
MT2 binding site region has some bulkier amino acid residues, replacing Val, Leu and Gly in the MT1 
pocket, thus hampering the proper accommodation of the ligand.   
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Different classes of compounds are known to increase intracellular anandamide levels through 
FAAH inhibition, including carbamates56,57,58 and piperidine/ piperazine ureas59,60,61 that covalently bind 
to FAAH,62 and α- ketoheterocycle derivatives,63,64,65,66,67 which inhibit FAAH by reversible hemiketal 
formation with the catalytic serine of the enzyme.68  Among them, the N-alkyl-O-arylcarbamates 
URB59769 and URB69470 (Figure 19) have been extensively investigated.71,72,73,74  URB597 (IC50 = 4.6 
nM) was shown to inhibit FAAH in the nanomolar range and was devoid of activity in a panel of 
receptors (e.g., CB1/CB2, NOP1 receptor), ion channels (e.g., Na+, K+, and Ca2+ channels), transporters 
(e.g., AEA transporter), and enzymes (e.g., COX1/2 and MAGL) at 10 μM.75  It has been broadly used 
preclinically to explore the functions of FAAH, and has been advanced to clinical testing.   
 
 
Figure 19 N-alkyl-O-arylcarbamates 
FAAH is an integral membrane-bound enzyme belonging to the serine hydrolase family.76  
Crystal structures of FAAH show that the enzyme is a homodimer in solution, and its active site is 
characterized by an atypical catalytic triad, consisting of Ser241–Ser217–Lys142.  The binding site of 
FAAH comprises three functional channels: the membrane access channel (MAC), the acyl-chain 
binding channel (ACB), and the cytosolic port (CP) providing the accommodation of the acyl chain 
during catalysis, and removing the leaving group after hydrolysis, respectively.77   
Several studies, including computational modeling,78,79,80,81 supported by the resolution of the crystal 
structure of humanized rat FAAH in complex with URB597,82 indicate that O-arylcarbamates bind 
covalently to FAAH and cause its irreversible inhibition.  In particular, it has been seen that Ser241 
attacks the carbonyl group of these compounds, leading to the formation of carbamoylated, catalytically 
inactive FAAH and releasing the O-biphenyl moiety as the leaving group (Figure 20). 
 
Figure 20 FAAH inhibition mechanism operated by O-arylcarbamates  
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Docking studies performed using URB597 crystal structure and rat FAAH illustrated that the rotatable 
N-cyclohexyl ring occupied the ACB channel.  Adjacent to the cyclohexyl group, the carbamate group 
was confirmed to form a covalent bond with Ser241, while the hydroxybiphenyl moiety, which serves as 
a leaving group, was located in the cytoplasmic access channel and oriented to the other monomer. 
 
Fig. 21 Docking studies of rat FAAH bound to an irreversible inhibitor 
 
All the above cited observations suggest that both in the MT1 receptor and in the active site of 
FAAH there are zones of steric tolerance, allowing the inclusion of pharmacophore elements for both 
FAAH inhibition and melatonin receptor binding.  Therefore, we consider the possibility to join the 
pharmacophores of anilinoethylamide and N-alkyl-O-arylcarbamates through an appropriate linker.   
We devised therefore two new series of N-anilinoethylamide derivatives carrying on the aniline 
ring an alkoxy linker bound to a carbamoyl portion, intended to exert FAAH inhibition (Figure 22).  In 
one series, the N-cyclohexyl-O-phenylcarbamate portion was joined to the aniline O-alkyl side chain 
through a second bridging oxygen atom, while in the second one, the cyclohexyl substituent of URB597 
was replaced by the aniline O-alkyl chain, as known structure−activity relationships for O-aryl-N-alkyl 
carbamates had evidenced that a linear alkyl chain is tolerated without significantly affecting FAAH 
inhibitory potency.57  In an attempt to improve the potency and obtain compounds with similar activity 
on the two targets, we also evaluated the effects of the length of the spacer, of the introduction of smaller 
polar group at the 3’ position of the biphenyl nucleus or the replacement of the acetylamino group with 
a propionylamino one at the melatoninergic portion.  Indeed, increases in the FAAH inhibitory potency 
and melatonin binding affinity have been observed by introducing hydrophilic residues (e.g., carbamoyl 
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and hydroxyl groups) at the 3′-position of the biphenyl nucleus57 and increasing the length of the alkyl 
substituent attached to the amide carbonyl group from CH3 to C3H7,16 respectively.   
We also explored the possibility to replace the N-anilinoethylamide portion with the original 
indole structure of MLT.   
 
 
Figure 22 Dual-acting (MLT-FAAH) Designed compounds 
The design of these compounds, including the length and the site of attachment of the alkyl 
spacer, was supported by docking studies within both MT1 receptor model and the crystal structure of 
FAAH.  The binding pose into the MT1 receptor obtained for the putative dual-acting compound 55e is 
depicted in Figure 23 (left).  The melatoninergic fragment can undertake polar interactions with typical 
amino acids in the transmembrane helix 7 (in particular, a hydrogen bond between Tyr285 and the amide 
oxygen), and with Tyrosine 187 at the beginning of the transmembrane helix 5 (hydrogen bond with 
the alkoxy oxygen); instead the diphenyl carbamate alkyl portion could occupy the MT1 accessory 
lipophilic pocket and it is oriented toward the extracellular loop, where it could undertake polar 
interactions, provided that at least four-methylene long spacers were inserted.   
The same dual compound could be accommodated also in the FAAH binding site (Figure 23, right): 
like URB597, the carbamate is positioned in the catalytic site and the biphenyl substituent in the so-
called “cytoplasmic access.” channel.  The melatoninergic portion occupies the ACB channel and forms 
a hydrogen bond with Tyrosine 335.   
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Figure 23 Induced-fit docking solution obtained for compound 55e into the homology model of the MT1 receptor (left) and 
FAAH substrate binding site (right)  
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1.3.2 Results and Discussion 
1.3.2.1. Chemistry  
The first series of the designed dual-acting compounds (45-48) was prepared following the 
synthetic steps depicted in Scheme 5.  The key intermediates 40a−b were synthesized according to a 
well validated route to similar compounds,83 involving a reductive N-alkylation of 3-methoxy-N-
methylaniline with the suitable N-acylaminoacetaldehyde dimethylacetal 38a,b (prepared in turn by 
acylation of the commercially available 2,2-dimethoxy-ethylamine) in the presence of TFA/Et3SiH, 
followed by methyl ether cleavage of 39a−b using boron tribromide.  Target carbamates 47-48 were 
prepared by O-alkylation of 40a−b with the appropriate bromoalkylphenoxy derivative 41 or 42 
(previously prepared by O-alkylation of 3-(benzyloxy)phenol with the suitable dibromoalkane) in the 
presence of NaH, followed by O-debenzylation by hydrogenolysis (45−46) and subsequent O-
carbamoylation with c-hexylisocyanate in the presence of  triethylamine.   
 
 
Scheme 5 Synthesis of dual-acting compounds 45-48. Reagents and conditions: (a) Et3SiH, TFA, CH2Cl2, rt, 20 h, yield 
51−52%; (b) BBr3, CH2Cl2, 0°C to rt, 20 h, yield 68−76%; (c) K2CO3, acetone, 50 °C, 24 h, yield 68−82%; (d) NaH, DMF, 
−10 °C to rt, 16 h, yield 85−89%; (e) H2 (1 atm), 10% Pd−C, EtOH/EtOAc, rt, 16 h, yield 78−92%; (f) Et3N, EtOH/CH3CN, 
rt, 18 h, yield 65−95%. 
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The second series of multifunctional compounds 55a−e and 55g were prepared in a convergent 
fashion following the steps outlined in Scheme 6.  First, the aminoalkoxyphenyl intermediates 51a−d 
were synthesized by O-alkylation of the previously cited phenol derivatives 40a, b with the appropriate 
tert-butyl (ω-bromoalkyl)carbamate 49a−c in the presence of K2CO3/NaI and subsequent N-Boc-
deprotection (TFA).  The activated carbonates 54d−f were then prepared by reaction of 1,1-biphenyl-
3-ol derivatives (53d−f) [commercially available (53d) or prepared by a Suzuki coupling reaction of 3-
bromophenol with the suitable phenylboronic acid 52e−f] with p-nitrophenyl chloroformate in the 
presence of N,N-diisopropylethylamine (DIPEA).  Finally, carbamates 55a−f were obtained by 
coupling of the aminoalkoxyphenyl intermediates 51a−d with the appropriate 4-nitrophenyl carbonate 
(54d−f).  The final compound 55g was achieved by hydrogenolysis of the benzyloxy precursor 55f.  
 
 
Scheme 6 Synthesis of dual-acting compounds 55a-g. Reagents and conditions: (a) K2CO3, NaI, acetone, 60 °C, 24 h, yield 
20−44%; (b) TFA, CH2Cl2, rt, 16 h, yield 60−64%; (c) for 18e Pd(PPh3)4, Na2CO3, CH3CN, 90 °C, 1.5 h, yield 97%; (d) for 
18f Pd(OAc)2, Na2CO3, H2O, acetone, 35 °C, 40 min, yield 81%; (e) DIPEA, CH3CN, rt, 1 h, yield 47−74%; (f) Et3N, 
CH2Cl2, rt, 4 h, yield 38−90%; (g) H2 (1 atm), 10% Pd−C, EtOH/EtOAc, rt, 20 h, yield 76%. 
 
The dual acting-compounds (62-64), derived by bioisosteric replacement of the aniline moiety 
with the indole ring, were prepared according to the synthetic sequence outlined in Scheme 7 and 
including the condensation of 5-(aminoalkoxy)-N-acetyltryptamines 59−61 with the (4-
nitrophenyl)carbonate derivative 54d.  The intermediate amines 59−61 were prepared by O-alkylation 
of N-acetylserotonin with tert-butyl (6-bromohexyl)carbamate (49b) or tert-butyl (8-
bromooctyl)carbamate (49c) in the presence of K2CO3 and subsequent N-Boc deprotection with 
trimethylsilyl bromide.  The 2-bromoindole derivative 58 was obtained by bromination of 56 with 
trimethylphenylammonium tribromide in THF, before submitting it to N-Boc deprotection to give 61.   
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Scheme 7 Synthesis of dual-acting compounds 62-64. Reagents and conditions: (a) K2CO3, NaI, CH3CN, reflux, 20 h, yield 
47−59%; (b) (CH3)3N(Br3)C6H5, THF, rt, 30 min, yield 59%; (c) (CH3)3SiBr, CH3CN, rt, 1 h; (d) Et3N, CH2Cl2/DMF, rt, 3 
h, two steps (c, d) yield 83−95%. 
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1.3.2.2. In vitro Pharmacological Studies and SARs 
 
Newly synthesized compounds were evaluated for their binding affinity and intrinsic activity at 
hMT1 and hMT2 receptors (stably Expressed in NIH3T3 Cells) and for their ability to inhibit the 
hydrolysis of [3H]-anandamide operated by the enzyme FAAH (prepared from rat brain homogenates) 
and the results are reported in Table 9.   
The O-biphenylcarbamates hybrid compounds 55a-e, g showed moderate binding affinity for MLT 
receptors (about one hundred times lower than that of MLT), but not very different (10-nanomolar 
range) from that of the MLT receptor ligand UCM871.  Little differences in binding affinities were 
observed by modifying the length of the linker (i.e. 55a, 55c, 55d) or introducing hydrophilic residues 
(e.g., carbamoyl, and hydroxyl groups) at the 3′-position of the biphenyl nucleus (55e and 55g).  
Nevertheless, chain lengthening and/or introduction of polar substituents at C3′-position were correlated 
with an increase in intrinsic activity, with compounds 55c and 55g behaving as full agonists.  
Consistently with previously SAR profile of MLT ligands, a slight increase in binding affinity and 
intrinsic activity was observed by replacing the acetylamino group of 55c with a propionylamino one 
(55b).  We also synthesized and tested the aminoalkoxyphenyl derivatives 51a and 51d formally 
deriving from carbamate hydrolysis; these compounds do not display significant affinity for MLT 
receptors, and therefore the activity of O-biphenyl carbamates has to be ascribed to the whole hybrids, 
and not to metabolites deriving from FAAH hydrolysis.   
On the other hand, all these new bivalent ligands 55a-e, g are more potent than the reference  URB524 
or URB597 at inhibiting FAAH activity in vitro, with a subnanomolar IC50 value observed for 
compound 55c.  In general, increases in FAAH inhibitor potency were observed by lengthening the 
spacer from 4 to 8 carbon atoms (55a55d55c), and with the introduction of hydrophilic residues 
such as carbamoyl (55e) and hydroxyl (55g) groups at the 3′-position of the biphenyl nucleus. Inverting 
the arylcarbamate moiety (N-cyclohexylcarbamic acid O-phenyl esters 47 and 48) resulted in significant 
decreases in FAAH inhibitory potency, without altering the affinity for MLT receptors.   
The pharmacological results of the O-biphenylcarbamate derivatives 55a-e, g, demonstrated 
that it is possible to merge the structural features required for FAAH inhibition and for MLT receptor 
binding activation in the same molecule. Unfortunately, activity at the two targets resulted rather 
unbalanced, as FAAH inhibitory potency is about 10−100 times higher than binding affinity at 
melatonin receptors.   
In the attempt to improve MLT receptors binding affinity, the N-anilinoethyl fragment was 
replaced by the N-indolethyl portion of MLT.  This bioisosteric replacement allowed to increase MLT 
receptor binding affinity of about 1 order of magnitude (62-63), with maintenance of FAAH inhibitory 
potency in the nanomolar range.  Moreover, by the introduction of a bromine atom in position 2 of the 
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indole ring further increase in MLT receptor binding affinity were showed, consistent with previous 
SAR, leading to very potent dual-acting compound (64) with potencies in the low nanomolar 
concentration range for both molecular targets.   
Table 9 Binding affinity and intrinsic activity of new dual-acting compounds at human MT1 and MT2 and FAAH  receptors  
 
 
Cpd 
 
n 
 
R1 
 
R 
MLT receptors rFAAH 
hMT1 hMT2 
pKi ± SDa IAr ± SDb pKi ± SDa IAr ± SDb IC50 (nM) 
± SEMc 
MLT    9.69 ± 0.09 1.00 ± 0.01 9.54 ± 0.06 1.00 ± 0.03 ndd 
UCM871    8.93 ± 0.17 0.68 ± 0.09 7.19 ± 0.04 0.64 ± 0.05 ndd 
URB524    nd nd nd nd 25.6 ± 2.0e 
URB597    nd nd nd nd 4.6 ± 1.6e 
45 4   6.73 ± 0.08 0.27 ± 0.07 6.22 ± 0.07 0.18 ± 0.09 nd 
46 6   7.23 ± 0.11 0.62 ± 0.14 6.48 ± 0.04 0.57 ± 0.08 nd 
47 4   7.46 ± 0.10 0.07 ± 0.07 7.27 ± 0.01 0.05 ± 0.05 184 ± 3 
48 6   7.56 ± 0.09 0.71 ± 0.04 6.53 ± 0.06 071 ± 0.05 197 ± 6 
51a 4   5.51 ± 0.08 0.32 ± 0.09 4.89 ± 0.50 0.35 ± 0.04 nd 
51d 6   6.35 ± 0.03 0.34 ± 0.05 6.40 ± 0.04 0.08 ± 0.04 nd 
55a 4 H CH3 7.89 ± 0.03 0.64 ± 0.07 7.35 ± 0.03 0.39 ± 0.07 1.45 ± 0.01 
55b 6 H CH2 CH3 7.79 ± 0.04 0.77 ± 0.08 7.72 ± 0.02 0.88 ± 0.02 3.07 ± 0.08 
55c 8 H CH3 7.67 ± 0.01 0.70 ± 0.01 7.48 ± 0.02 0.75 ± 0.03 1.34 ± 0.03 
55d 6 H CH3 7.50 ± 0.01 0.85 ± 0.08 7.49 ± 0.02 0.96 ± 0.03 0.63 ± 0.04 
55e 6 CONH2 CH3 7.41 ± 0.03 0.79 ± 0.06 7.81 ± 0.05 1.01 ± 0.02 0.43 ± 0.01 
55g 6 OH CH3 7.53 ± 0.02 0.89 ± 0.08 7.57 ± 0.01 0.94 ± 0.02 0.36 ± 0.01 
62 6  H 8.22 ± 0.01 0.73 ± 0.08 8.34 ± 0.09 1.02 ± 0.02 2.38 ± 0.16 
63 8  H 8.31 ± 0.70 0.73 ± 0.08 8.20 ± 0.02 0.53 ± 0.02 4.00 ± 0.10 
64 6  Br 9.11 ± 0.10 0.73 ± 0.08 8.77 ± 0.03 0.97 ± 0.02 0.85 ± 0.01 
apKi values were calculated from IC50 values, obtained from competition curves by the method of Cheng and Prusoff,84 and are the mean of at 
least three determinations performed in duplicate. bThe relative intrinsic activity values were obtained by dividing the maximum analogue-
induced G protein activation by that of MLT. Measurements were performed in triplicate. cIC50 values are the mean of at least two 
determinations. dnd: not determined. eRef 57. 
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A representation of the docking solution obtained for the dual-acting compound 64 is provided in Figure 
24.   
Into the MT1 receptor binding site the carbamoyl portion of 64 protrudes out of the TM region 
giving hydrogen bond interactions with amino acids belonging to extracellular loop 2.  Into the active 
site of FAAH, the carbamate portion occupies the catalytic site, the biphenyl portion is accommodated 
in the cytoplasmic access channel and the bulky 2-bromoindole terminal portion has enough room to 
be properly accommodated in the ACB channel.   
 
  
Figure 24 Induced-fit docking solution obtained for compound 64 into the homology model of the MT1 receptor (left) and 
FAAH substrate binding site (right) 
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1.3.2.3. In vivo Intraocular Pressure (IOP) Lowering Effects  
 
As both the endocannabinoid system and the melatoninergic receptors are involved in the 
regulation of ocular homeostasis, some of the most interesting dual acting compounds (the aniline 
derivative 55e and the indole derivative 64) were evaluated in a normotensive glaucoma rabbit model 
for their intraocular pressure (IOP) lowering effects.  Their behaviour was compared with that of the 
parent mono-ligands MLT and URB597 and of dorzolamide (65), a drug usually prescribed for the 
treatment of glaucoma.  In these in vivo experiments, a transient ocular hypertension was induced by 
the injection of 0.1 mL of sterile hypertonic saline solution (5% distilled water) in the vitreous of New 
Zealand white rabbits, and then the tested compounds were topically administered (50 L of 1 mM 
solution).   
 
As seen from the data of Figure 25, MLT and the reference URB597, when given topically to 
the eye of the animals, induce a prompt IOP lowering effect, visible at 60 min, which was maintained 
also at 120 min, even if with lower efficacy.  Co-administration of compounds MLT and URB597 
produced the same effect as the administration of each single agent at 60 min.  However, the IOP 
reduction was maintained at 120 min, while single agents MLT and URB597 lost part of their efficacy 
at this time.  The carbonic anhydrase inhibitor dorzolamide had a prompt effect, similar to that of MLT 
and URB597 at 60 min, which is maintained at 120 min as well.  The N-anilinoethylamide derivative 
55e behaved similarly, showing limited effect after 60 min, which significantly increased at 120 min, 
exceeding those measured for the reference mono-ligands MLT and URB597.  The most potent in vitro 
compound, the N-indolylethylamide derivative 64, provided the highest IOP reduction at 120 min.  
Interestingly, the new hybrid compound 64 had a prolonged efficacy compared to the other tested 
compounds, showing efficacy even after 4 h post-administration, with an IOP drop of 3.5 mmHg.   
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Figure 25 Drop of intraocular pressure (ΔIOP, mm Hg) versus time (min) in hypertonic saline-induced ocular hypertension 
in New Zealand male albino rabbits measured after treatment with MLT, URB597, the combination of compounds MLT and 
URB597, the reference inhibitor dorzolamide, and dual-acting inhibitors 55e and 64, tested at 1 mM concentration 
(dorzolamide tested at 1% (w/v) concentration). 
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1.3.3 Conclusions 
 
Novel multifunctional compounds behaving as melatonin receptor agonists and as inhibitors of 
the enzyme fatty acid amide hydrolase were discovered.  Suitable combination of the structural features 
required for FAAH inhibition and for MLT receptor binding activation in the same molecule, led to 
compounds with remarkable and balanced activity at both targets.  Since both targets are involved in 
the control of intraocular pressure, two of the most interesting dual acting compounds (55e and 64) 
were tested for their potential IOP-lowering effects.  In an in vivo rabbit model of high IOP 55e and 64 
showed promising anti-glaucoma activity.  In particular, the IOP-lowering effects of compound 64 were 
significantly greater and long-lasting than those exerted by either melatonin or the FAAH-inhibitor 
URB597, and by dorzolamide, a currently used anti-glaucoma agent.   
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1.3.4 Experimental Section  
 
1.3.4.1 Materials and Methods 
 
Melting points were determined on a Buchi B-540 capillary melting point apparatus and are 
uncorrected.  1H NMR and 13C NMR spectra were recorded on a Bruker AVANCE 200 or 400 
instrument. Chemical shifts (δ scale) are reported in parts per million (ppm) relative to the central peak 
of the solvent. Coupling constants (J) are given in hertz (Hz).  1H and 13C signals were unambiguously 
assigned by COSY, NOESY, DEPT135, HMQC, and HMBC experiments. EI MS spectra (70 eV) were 
taken on a Fisons Trio 1000 instrument; only molecular ions (M+) and base peaks are given.  ESI MS 
spectra were taken on a Waters Micromass ZQ instrument; only molecular ions (M+1)+ or (M-1)- are 
given.  High-resolution mass spectroscopy was performed on a Micro mass Q-ToF Micromass 
spectrometer (Micromass, Manchester, UK) using an ESI source.  The purity of tested compounds, 
determined by high performance liquid chromatography (HPLC), was greater than 95%.  These 
analyses were performed on a Waters HPLC/UV/MS system (separation module Alliance HT2795, 
Photo Diode Array Detector 2996, mass detector Micromass ZQ; software: MassLynx 4.1).  Column 
chromatography purifications were performed under “flash” conditions using Merck 230−400 mesh 
silica gel.  Analytical thin-layer chromatography (TLC) was carried out on Merck silica gel 60 F254 
plates.  Chiral HPLC runs were conducted on a Jasco (Cremella, LC, Italy) HPLC system equipped 
with a Jasco AS-2055 plus autosampler, a PU2089 plus quaternary gradient pump, and an MD-2010 
plus multiwavelength detector.  Experimental data were acquired and processed by Jasco Borwin PDA 
and Borwin Chromatograph Software.  Solvents used for chiral chromatography were HPLC grade and 
supplied by Carlo Erba (Milan, Italy).  Optical rotation values were measured on a Jasco (Cremella, 
LC, Italy) photoelectric polarimeter DIP 1000 with a 0.2 dm cell at the sodium D line (λ = 589 nm); 
sample concentration values (c) are given in 10−2 g mL −1.  
 
1.3.4.2 Reagents 
 
Tert-butyl (4-bromobutyl)carbamate, tert-butyl (6-bromohexyl)carbamate, [1,1’-biphenyl]-3-
ol, (3-carbamoylphenyl)boronic acid, [3-(benzyloxy)phenyl]boronic acid, 3-(benzyloxy)phenol, 2,2-
dimethoxyethanamine and N-acetylserotonin  were purchased from commercial suppliers and used 
without further purification.   
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1.3.4.3 Synthesis and Physicochemical Characterization of Dual-acting 
Compounds 
 
General Procedure for the Synthesis of N-(2,2-Dimethoxyethyl)acylamines 38a, b 
 
Acetic or propionic anhydride (12 mmol) and Et3N (1.65 mL, 12 mmol) were added to a solution of 
2,2-dimethoxyethanamine (1.08 mL, 10 mmol) in dry CH2Cl2 (16 mL), and the resulting mixture was 
stirred at room temperature for 2 h.  The mixture was neutralized with a saturated solution of NaHCO3 
and extracted with CH2Cl2.  The combined organic phases were washed with brine, dried (Na2SO4), 
filtered, and concentrated in vacuo affording a crude residue that was purified by silica gel column 
chromatography.   
 
N-(2,2-Dimethoxyethyl)acetamide (38a) 
Flash chromatography (CH2Cl2−MeOH 98:2 as eluent). Oil; 90% yield.   
Chemical physical data were identical to those previously reported.85    
 
N-(2,2-Dimethoxyethyl)propionamide (38b) 
Flash chromatography (CH2Cl2−EtOAc 95:5 as eluent). Oil; 93% yield.   
1H NMR (400 MHz, CDCl3): δ 5.70 (br s, 1H), 4.38 (t, 1H, J = 5.0), 3.39−3.44 (m, 2H), 3.40 (s, 6H), 
2.23 (q, 2H, J = 7.5), 1.16 (t, 3H, J = 7.5).  ESI MS (m/z): 184 [M + Na]+.   
  
67 
 
General Procedure for the Synthesis of (Anilinoethyl)amido Derivatives 39a, b 
 
Trifluoroacetic acid (2.2 mL, 29 mmol) and triethylsilane (0.9 mL, 5.6 mmol) were added to a solution 
of 3-methoxy-N-methylaniline (0.3 mL, 2.3 mmol) and the suitable acetal 38a,b (3.1 mmol) in CH2Cl2 
(5 mL), and the resulting mixture was stirred at room temperature for 20 h under a nitrogen atmosphere.  
After cooling to 0 °C, the mixture was carefully neutralized with a saturated aqueous solution of 
NaHCO3, and the aqueous layer was extracted with CH2Cl2.  The combined organic phases were washed 
with brine, dried over Na2SO4, and concentrated under reduced pressure to give a crude residue that 
was purified by column chromatography.    
 
N-{2-[(3-Methoxyphenyl)methylamino]ethyl}acetamide (39a) 
Purification by silica gel flash chromatography (EtOAc as eluent) and crystallization.  White solid 
(diethyl ether/ petroleum ether), 51% yield.   
Chemical physical data were identical to those previously reported.23   
 
N-{2-[(3-Methoxyphenyl)methylamino]ethyl}propionamide (39b) 
Purification by silica gel chromatography (EtOAc−cyclohexane 7:3 as eluent).Oil, 52% yield.   
1H NMR (400 MHz, CDCl3): δ 7.16 (dd, 1H, J
1 = J2 = 8.5), 6.42 (dd, 1H, J1 = 2.0, J2 = 8.0 Hz), 6.31−6.33 
(m, 2H), 5.70 (br s, 1H), 3.80 (s, 3H), 3.46−3.47 (m, 4H), 2.95 (s, 3H), 2.16 (q, 2H, J = 7.5 Hz), 1.12 
(t, 3H, J = 7.5 Hz).  13C NMR (100 MHz, CDCl3): δ 174.0, 160.9, 150.6, 130.0, 105.8, 102.1, 99.3, 55.2, 
52.0, 38.6, 37.2, 29.6, 9.7.  ESI MS (m/z): 237 [M + H]+.   
 
General Procedure for the Synthesis of (3-Hydroxyanilino)ethylamido Derivatives 40a,b 
 
A 1 M solution of BBr3 in CH2Cl2 (2.5 mL, 2.5 mmol) diluted with dry CH2Cl2 (9mL) was added 
dropwise to an ice-cooled solution of the suitable amide 39a, b (1.23 mmol) in dry CH2Cl2 (9 mL), and 
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the resulting mixture was stirred at room temperature for 20 h.  After neutralization with a 2 N aqueous 
solution of Na2CO3, the mixture was extracted with CH2Cl2, and the combined organic phases were 
dried (Na2SO4) and concentrated under reduced pressure to give a crude residue that was purified by 
column chromatography.   
 
N-{2-[(3-Hydroxyphenyl)methylamino]ethyl}acetamide (40a)  
Purification by silica gel flash chromatography (CH2Cl2−MeOH 98:2 as eluent). Oil, 76% yield.   
Chemical physical data were identical to those previously reported.86   
 
N-{2-[(3-Hydroxyphenyl)methylamino]ethyl}propionamide (40b)  
Purification by silica gel chromatography (EtOAc−cyclohexane 7:3 as eluent).Oil, 68% yield.   
1H NMR (400 MHz, CDCl3): δ 7.09 (dd, 1H, J
1 = J2 = 8.0 Hz), 6.32−6.36 (m, 2H), 6.25 (d, 1H, J = 7.5 
Hz), 6.01 (br s,1H), 5.71(br s, 1H), 3.45−3.47 (m, 4H), 2.94 (s, 3H), 2.18 (q, 2H, J = 7.5 Hz), 1.13 (t, 
3H, J = 7.5 Hz).  ESI MS (m/z): 223 [M + H]+.   
 
General Procedure for the Synthesis of Bromoalkylphenoxy Derivatives 41 and 42  
 
K2CO3 (0.31 g, 2.25 mmol) and the suitable dibromoalkane (2.25 mmol) were added to a solution of 3-
(benzyloxy)phenol (0.3 g, 1.5 mmol) in dry acetone (4 mL), and the resulting mixture was stirred at 50 
°C for 24 h.  After addition of water, the mixture was extracted with EtOAc, and the combined organic 
phases were dried (Na2SO4).  After removing the solvent by distillation under reduced pressure, the 
crude residue was purified by silica gel column chromatography (cyclohexane−EtOAc 95:5 as eluent).   
 
1-(Benzyloxy)-3-(4-bromobutyloxy)benzene (41) 
Oil, 68% yield.   
Analytical data were in agreement with those previously reported.87   
 
1-(Benzyloxy)-3-(6-bromohexyloxy)benzene (42) 
Oil, 82% yield.   
1H NMR (400 MHz, CDCl3): δ 7.28−7.45 (m, 5H), 7.19 (dd, 1H, J
1 = J2 = 8.0 Hz), 6.58−6.62 (m, 3H), 
5.07 (s, 2H), 3.96 (t, 2H, J = 6.5 Hz), 3.45 (t, 2H, J = 6.5 Hz), 1.81−1.92 (m, 4H), 1.49−1.56 (m, 4H).  
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13C NMR (100 MHz, CDCl3): δ 160.3, 160.0, 137.0, 129.9, 128.6, 128.0, 127.5, 107.1, 106.9, 101.8, 
70.0, 67.7, 33.9, 32.7, 29.1, 27.9, 25.3.  ESI MS (m/z): 363−365 [M + H]+.   
 
General Procedure for the Synthesis of Derivatives 43 and 44 
 
NaH (60% in mineral oil, 0.026g, 0.65 mmol) was added to a solution of 40a (0.13 g, 0.63 mmol) in 
dry DMF (1 mL), and the resulting mixture was stirred at−10°C for 10 min under a nitrogen atmosphere.  
Then a solution of the suitable bromoalkylphenoxy derivative 41 or 42 (0.65 mmol) in dry DMF (1.5 
mL) was added, and the resulting mixture was stirred at room temperature for 16 h.  After addition of 
water, the mixture was extracted with EtOAc, the combined organic phases were dried (Na2SO4), 
filtered, and concentrated under reduced pressure to afford a crude product that was purified by silica 
gel column chromatography (EtOAc as eluent).   
 
N-[2-({3-[4-(3-Benzyloxy)phenoxy]butoxy}phenyl)methylaminoethyl]acetamide (43) 
Oil, 89% yield.   
1H NMR (400 MHz, CDCl3): δ 7.32−7.46 (m, 5H), 7.10−7.23 (m, 2H), 6.51−6.60 (m, 3H), 6.27−6.43 
(m, 3H), 5.61 (br s, 1H), 5.05 (s, 2H), 3.98−4.09 (m, 4H), 3.45−3.47 (m, 4H), 2.94 (s, 3H), 1.94−1.98 
(m, 4H), 1.94 (s, 3H).  ESI MS (m/z): 463 [M + H]+.   
 
N-{2-([3-[6-(3-Benzyloxy)phenoxy)hexyloxy]phenyl(methylamino)ethyl}acetamide (44) 
Oil, 85% yield.   
1H NMR (400 MHz, CDCl3): δ 7.32−7.46 (m, 5H), 7.10−7.22 (m, 2H), 6.50−6.59 (m, 3H), 6.26−6.40 
(m, 3H), 5.59 (br s, 1H), 5.05 (s, 2H), 3.92−4.00 (m, 4H), 3.44−3.49 (m, 4H), 2.93 (s, 3H), 1.94 (s, 3H), 
1.75−1.90 (m, 4H), 1.50−1.57 (m, 4H).  ESI MS (m/z): 491 [M + H]+.   
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General Procedure for the Synthesis of 3-Hydroxyphenoxy Derivatives 45 and 46 
 
A solution of the suitable benzyloxy derivative 43 or 44 (0.63 mmol) in EtOH (5 mL) and EtOAc (5 
mL) was hydrogenated (1 atm) at room temperature in the presence of 10% Pd− C (0.05 g) for 16 h.  
The catalyst was removed by filtration on Celite, and the filtrate was concentrated under reduced 
pressure to afford a crude residue that was purified by silica gel column chromatography (EtOAc as 
eluent) and crystallization.   
 
N-{2-((3-(4-(3-Hydroxyphenoxy)butoxy)phenyl)(methylamino)ethyl}acetamide (45) 
White solid, mp 113−4°C (EtOAc−petroleum ether), 92% yield.   
1H NMR (400 MHz, CDCl3): δ 7.09−7.18 (m, 2H), 7.00 (br s, 1H), 6.33−6.49 (m, 6H), 5.75 (br s, 1H), 
4.02−4.06 (m, 4H), 3.46−3.50 (m, 4H), 2.94 (s, 3H), 1.97 (m, 4H), 1.95 (s, 3H).  13C NMR (100 MHz, 
CDCl3): δ 171.1, 160.2, 157.5, 151.0, 130.0, 107.9, 106.7, 105.4, 102.5, 101.8, 99.7, 67.7, 51.8, 38.3, 
37.5, 29.7, 26.4, 26.1, 23.1.  ESI MS (m/z): 373 [M + H]+.  HR MS (ESI): m/z calculated for 
C21H29N2O4, [M + H]+: 373.2127, found: 373.2154.   
 
N-(2-((3-(6-(3-Hydroxyphenoxy)hexyloxy)phenyl)(methylamino)ethyl)acetamide (46) 
White solid, mp 108−9°C (EtOAc−petroleum ether), 78% yield.   
1H NMR (400 MHz, CDCl3): δ 7.07−7.19 (m, 2H), 6.72 (br s, 1H), 6.31−6.48 (m, 6H), 5.80 (br s, 1H), 
3.93−4.01 (m, 4H), 3.45−3.52 (m, 4H), 2.94 (s, 3H), 1.95 (s, 3H), 1.78−1.85 (m, 4H), 1.53−1.59 (m, 
4H).  13C NMR (100 MHz, CDCl3): δ 170.8, 160.4, 160.3, 157.2, 130.0, 107.8, 106.6, 105.5, 102.5, 
102.1, 99.9, 67.7, 67.6, 51.9, 38.1, 37.5, 29.1, 28.9, 25.8, 23.2.  ESI MS (m/z): 401 [M + H]+.  HR MS 
(ESI): m/z calculated for C23H33N2O4, [M + H]+: 401.2440, found: 401. 2417.   
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General Procedure for the Synthesis of Cyclohexyl Carbamates 47 and 48 
 
Cyclohexyl isocyanate (62 μL, 0.48 mmol) and Et3N (5 μL) were added to a solution of the appropriate 
phenol 45 or 46 (0.21 mmol) in absolute EtOH (0.6 mL) and dry CH3CN (0.6 mL), and the resulting 
mixture was stirred at room temperature for 18 h under a nitrogen atmosphere.  After removing the 
solvent by distillation under reduced pressure, the residue was purified by silica gel column 
chromatography (EtOAc−cyclohexane 7:3 as eluent) and crystallization.   
 
3-(4-{3-[(2-Acetamidoethyl)methylamino]phenoxy}butyloxy)phenylcyclohexylcarbamate (47)  
White solid, mp 115−6 °C (EtOAc−petroleum ether), 65% yield.   
1H NMR (400 MHz, CDCl3): δ 7.10−7.23 (m, 2H), 6.70−6.74 (m, 3H), 6.30−6.40 (m, 3H), 5.72 (br s, 
1H), 4.98 (br d, 1H), 4.00−4.06 (m, 4H), 3.54−3.58 (m, 1H), 3.44−3.47 (m, 4H), 2.94 (s, 3H), 1.92−2.05 
(m, 4H), 1.93 (s, 3H), 1.58−1.80 (m, 4H), 1.14− 1.50 (m, 6H).  13C NMR (100 MHz, CDCl3): δ 170.4, 
160.2, 159.8, 153.5, 152.0, 150.9, 130.0, 129.6, 113.7, 111.6, 108.1, 105.5, 102.3, 99.7, 67.6, 67.3, 51.7, 
50.1, 38.4, 37.3, 33.2, 26.0, 25.4, 24.7,23.2.  ESI MS (m/z): 498 [M+H]+.  HR MS (ESI): m/z calculated 
for C28H40N3O5, [M + H]+: 498.2968, found: 498.2961.   
 
3-(6-{3-[(2-Acetamidoethyl)methylamino]phenoxy}hexyloxy)phenylcyclohexylcarbamate (48) 
White solid, mp 99−101 °C (EtOAc−petroleum ether), 95% yield.   
1H NMR (400 MHz, CDCl3): δ 7.10−7.24 (m, 2H), 6.69−6.75 (m, 3H), 6.31−6.40 (m, 3H), 5.66 (br s, 
1H), 4.95 (br d, 1H), 3.92−4.01 (m, 4H), 3.54−3.59 (m, 1H), 3.45−3.47 (m, 4H), 2.94 (s, 3H), 1.94 (s, 
3H), 1.72−2.04 (m, 8H), 1.48−1.65 (m, 4H), 1.17− 1.46 (m, 6H).  13C NMR (100 MHz, CDCl3) δ: 170.4, 
160.4, 159.9, 153.5, 152.0, 150.9, 130.0, 129.5, 113.6, 111.6, 108.1, 105.4, 102.3, 99.8, 67.9, 67.7, 51.8, 
50.1, 38.4, 37.3, 33.2, 29.3, 29.1, 25.9, 25.8, 25.4, 24.7, 23.2.  ESI MS (m/z): 526 [M + H]+.  HR MS 
(ESI): m/z calculated for C30H44N3O5, [M + H]+: 526.3281, found: 526.3251.   
 
Procedure for the Synthesis of tert-Butyl (ω-Bromoalkyl)carbamates (49a−c) 
Tert-Butyl (8-bromooctyl)carbamate (49c) was prepared according to literature procedure, and 
chemical physical data were identical with those previously reported.88   
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Tert-Butyl (4-bromobutyl)carbamate (49a) and tert-butyl (6-bromohexyl)carbamate (49b) are 
commercially available.   
 
General Procedure for the Synthesis of N-Boc-aminoalkoxyphenyl Derivatives 50a−d 
 
The suitable tert-butyl (ω-bromoalkyl)carbamate 49a−c (1.50 mmol), K2CO3 (0.315 g, 2.25 mmol), and 
a catalytic amount of NaI were added to a solution of the appropriate (3-hydroxyanilino)ethylamido 
derivative 40a or 40b (1.50 mmol) in dry acetone (8 mL), and the resulting mixture was stirred at 60 
°C for 24 h under a nitrogen atmosphere.  After water addition the mixture was extracted with EtOAc, 
the combined organic phases were dried (Na2SO4), and the solvent was removed by distillation under 
reduced pressure to afford a crude residue that was purified by column chromatography.   
 
tert-Butyl {4-[3-((2-Acetamidoethyl)methylamino)phenoxy]butyl}carbamate (50a) 
This product was obtained following the above general procedure by reacting 40a with 49a.  Purification 
by silica gel chromatography (EtOAc as eluent).  Oil, 37% yield.   
1H NMR (400 MHz, CDCl3): δ 7.13 (dd, 1H, J
1 = J2 = 8.0 Hz), 6.28−6.38 (m, 3H), 5.71 (br s, 1H), 4.66 
(br s, 1H), 3.98 (t, 2H, J = 6.5 Hz), 3.44−3.48 (m, 4H), 3.17−3.21 (m, 2H), 2.94 (s, 3H), 1.94 (s, 3H), 
1.77−1.83 (m, 2H), 1.65−1.71 (m, 2H), 1.45 (s, 9H).  ESI MS (m/z): 380 [M + H]+.   
 
tert-Butyl {4-[3-((2-Propionamidoethyl)methylamino)phenoxy]butyl}carbamate (50b) 
This product was obtained following the above general procedure by reacting 40b with 49b.  
Purification by silica gel chromatography (EtOAc−cyclohexane 7:3 as eluent).  Oil, 20% yield.   
1H NMR (400 MHz, CDCl3): δ 7.13 (dd, 1H, J
1 = J2 = 8.0 Hz), 6.29−6.38 (m, 3H), 5.65 (br s, 1H), 
4.55(br s, 1H), 3.94 (t, 2H, J = 6.5 Hz), 3.45−3.49 (m, 4H), 3.10−3.15 (m, 2H), 2.94 (s, 3H), 2.16 (q, 
2H, J = 7.5 Hz), 1.74−1.81 (m, 2H), 1.38− 1.52 (m, 6H), 1.45 (s, 9H), 1.12 (t, 3H, J = 7.5 Hz).  13C 
NMR (100 MHz, CDCl3): δ 174.0, 160.3, 156.0, 130.0, 105.5, 102.2, 99.7, 67.6, 51.8, 40.5, 38.4, 37.2, 
30.0, 29.6, 29.2, 28.4, 26.5, 25.8, 9.7.  ESI MS (m/z): 422 [M + H]+.   
 
tert-Butyl {8-[3-((2-Acetamidoethyl)methylamino)phenoxy]octyl}carbamate (50c)  
This product was obtained following the above general procedure by reacting 40a with 49c. Purification 
by silica gel chromatography (EtOAc as eluent).  Oil, 37% yield.   
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1H NMR (400 MHz, CDCl3): δ 7.12 (dd, 1H, J
1 = J2 = 8.0), 6.27−6.37 (m, 3H), 5.69 (br s, 1H), 4.52 (br 
s, 1H), 3.93 (t, 2H, J = 6.5 Hz), 3.42−3.46 (m, 4H), 3.05−3.13 (m, 2H), 2.92 (s, 3H), 1.93 (s, 3H), 
1.70−1.77 (m, 2H), 1.39−1.48 (m, 4H), 1.43 (s, 9H), 1.22−1.37 (m, 6H).  ESI MS (m/z): 436 [M + H]+.   
 
tert-Butyl {6-[3-((2-Acetamidoethyl)methylamino)phenoxy]hexyl}carbamate (50d) 
This product was obtained following the above general procedure by reacting 40a with 49b. Purification 
by silica gel chromatography (EtOAc as eluent).  Oil, 44% yield.   
1H NMR (400 MHz, CDCl3): δ 7.14 (dd, 1H, J
1 = J2= 8.0 Hz), 6.27−6.40 (m, 3H), 5.67 (br s, 1H), 4.55 
(br s, 1H), 3.95 (t, 2H, J = 6.5 Hz), 3.44−3.46 (m, 4H), 3.08−3.16 (m, 2H), 2.94 (s, 3H), 1.95 (s, 3H), 
1.73−1.82 (m, 2H), 1.45 (s, 9H), 1.36−1.55 (m, 6H).  ESI MS (m/z): 408 [M + H]+.   
 
General Procedure for N-Boc Deprotection: Synthesis of Aminoalkoxyphenyl Derivatives 51a−d 
 
Trifluoroacetic acid (0.8 mL, 10 mmol) was added to an ice-cooled solution of the suitable N-Boc 
derivative 50a−d (0.3 mmol) in dry CH2Cl2 (3.5 mL), and the resulting mixture was stirred at room 
temperature for 16 h under a nitrogen atmosphere. The reaction mixture was basified by dropwise 
addition of a 2 N aqueous solution of Na2CO3 and extracted with CH2Cl2.  The combined organic phases 
were washed with brine, dried (Na2SO4), and the solvent removed by distillation under reduced pressure 
to give the desired crude amines that were used without further purification or purified by filtration 
through a pad of silica gel.   
 
N-{2-[(3-(4-Aminobutoxy)phenyl)methylamino]ethyl}acetamide (51a) 
Purification by filtration on silica gel (EtOAc−MeOH−conc. NH3 9:1:1 as eluent). Oil, 60% yield.   
1H NMR (400 MHz, CDCl3): δ 7.12 (dd, 1H, J
1 = J2 = 8.0 Hz), 6.35−6.37 (m, 1H), 6.26− 6.31 (m, 2H), 
5.95 (br s, 1H), 3.97 (t, 2H, J = 6.0 Hz), 3.42−3.44 (m, 4H), 2.93 (s, 3H), 2.81 (t, 2H, J = 7.0 Hz), 1.93 
(s, 3H), 1.77−1.85 (m, 2H), 1.64−1.71 (m, 2H).  13C NMR (100 MHz, CDCl3): δ 170.7, 160.5, 150.4, 
130.1, 105.8, 102.5, 99.5, 67.9, 51.7, 42.0, 38.5, 37.1, 29.6, 26.7, 23.3.  ESI MS (m/z): 280 [M + H]+.  
HR MS (ESI): m/z calculated for C15H26N3O2, [M + H]+: 280.2020, found: 280.2031.   
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N-{2-[(3-(6-Aminohexyloxy)phenyl)methylamino]ethyl}propionamide (51b)  
This intermediate was used for the next step without any further purification.   
ESI MS (m/z): 322 [M + H]+.   
 
N-{2-[(3-(8-Aminooctyloxy)phenyl)methylamino]ethyl}acetamide (51c) 
This intermediate was used for the next step without any further purification.   
ESI MS (m/z): 336 [M + H]+.   
 
N-{2-[(3-(6-Aminohexyloxy)phenyl)methylamino]ethyl}acetamide (51d)  
Purification by filtration on silica gel (EtOAc− MeOH−conc. NH3 9:1:1 as eluent). Oil, 64% yield.   
1H NMR (400 MHz, CDCl3): δ 7.11 (dd, 1H, J
1 = J2= 8.0 Hz), 6.33−6.36 (m, 1H), 6.23−6.28 (m, 2H), 
5.90 (br s, 1H), 3.92 (t, 2H, J = 6.5 Hz), 3.41−3.44 (m, 4H), 2.91 (s, 3H), 2.69 (t, 2H, J = 7.0 Hz), 1.91(s, 
3H), 1.72−1.79(m, 2H), 1.35−1.51 (m, 6H).  13C NMR (100 MHz, CDCl3) δ: 170.6, 160.3, 150.8, 129.9, 
105.4, 102.2, 99.5, 67.6, 51.7, 41.7, 38.4, 37.2, 29.7, 29.2, 26.5, 25.9, 23.1.  ESI MS (m/ z): 308 [M+H]+.  
HR MS (ESI): m/z calculated for C17H30N3O2, [M+ H]+: 308.2338, found: 308.2321.   
 
3′-Hydroxy-(1,1′-biphenyl)-3-carboxamide (53e) 
 
3-Bromophenol (0.25 g, 1.44 mmol) and a 0.4 M aqueous solution of Na2CO3 (7.5 mL) were added to 
a solution of 3-carbamoylphenylboronic acid (52e) (0.25 g, 1.5 mmol) in CH3CN (7.5 mL); the reaction 
mixture was degassed by bubbling N2 for 10 min and then added Pd(PPh3)4 (10 mg).  After stirring at 
90 °C for 1.5 h, the reaction mixture was filtered on Celite, and the filtrate was poured in H2O and 
extracted with EtOAc.  The combined organic phases were dried over Na2SO4, filtered, and concentrated 
in vacuo to yield a crude residue that was purified by silica gel column chromatography 
(EtOAc−cyclohexane 8:2 as eluent).  White solid, 97% yield.   
Chemical physical data were identical to those previously reported.89   
  
75 
 
3′-(Benzyloxy)-[1,1′-biphenyl]-3-ol (53f) 
 
Na2CO3 (0.11 g, 2 mmol), Pd(OAc)2 (0.001 g), and a solution of 3-bromophenol (0.17, 1 mmol) in H2O 
(0.7 mL) were added to a solution of 3-(benzyloxy)phenylboronic acid 52f (0.336 g, 2 mmol) in acetone 
(3 mL), and the resulting mixture was stirred at 35 °C for 40 min.  The mixture was extracted with 
EtOAc, the combined organic phases were dried (Na2SO4), and the solvent removed by distillation 
under reduced pressure to yield a crude residue that was purified by silica gel column chromatography 
(cyclohexane−EtOAc 9:1 as eluent).  Oil, 81% yield.   
1H NMR (400 MHz, CDCl3): δ 7.30−7.50 (m, 7H), 7.16−7.23 (m, 3H), 7.06−7.07 (m, 1H), 7.00 (ddd, 
1H, J1 = 1.0, J2 =2.5, J3 = 8.0 Hz), 6.84 (ddd, 1H, J1 = 1.0, J2 =2.5, J3 = 8.0 Hz), 5.43 (br s, 1H), 5.14 
(s, 2H).  ESI MS (m/z): 275 [M − H]−.   
 
General Procedure for the Synthesis of Carbonates 54d−f 
 
DIPEA (0.15 mL, 0.8 mmol) and a solution of 4-nitrophenyl chloroformate (0.16 g, 0.8 mmol) in dry 
CH3CN (4 mL) were added dropwise to a solution of the suitable phenol 53d−f (0.8 mmol) in dry 
CH3CN (2.5 mL), and the resulting mixture was stirred at room temperature for 1 h under a nitrogen 
atmosphere.  Upon completion, the mixture was poured into water and filtered to separate the desired 
solid precipitate (for 54e) or extracted with EtOAc (for cpds 54d and 54f).  The combined organic 
phases were washed with brine, dried (Na2SO4), and the solvent removed by distillation under reduced 
pressure to give a crude residue that was purified by silica gel column chromatography 
(cyclohexane−EtOAc 9:1 as eluent) and crystallization.   
 
[1,1′-Biphenyl]-3-yl-(4-nitrophenyl)carbonate (54d)  
White solid, mp 84−5°C (EtOAc−petroleum ether); 47% yield.   
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1H NMR (400 MHz, CDCl3): δ 8.34 (d, 2H, J = 9.0 Hz), 7.51 (d, 2H, J = 9.0 Hz), 7.37−7.67 (m, 8H), 
7.28−7.29 (m, 1H).   
 
3′-Carbamoyl-[1,1′-biphenyl]-3-yl-(4-nitrophenyl)carbonate (54e) 
Amorphous solid, 74% yield.   
 1H NMR (DMSO-d6): δ 8.38 (d, 2H, J = 9.0 Hz), 8.21 (br s, 1H), 8.12 (br s, 1H), 7.83−7.92 (m, 3H), 
7.74(d, 2H, J =9.0 Hz), 7.73−7.76 (m, 1H), 7.57−7.64 (m, 2H), 7.45−7.47 (m, 2H).  ESI MS (m/z): 379 
[M + H]+.   
 
3′-(Benzyloxy)-[1,1′-biphenyl]-3-yl (4-nitrophenyl)carbonate (54f)  
Amorphous solid, 50% yield.   
1H NMR (400 MHz, CDCl3): δ 8.34 (d, 2H, J = 9.0 Hz), 7.48 (d, 2H, J = 9.0 Hz), 7.36−7.53 (m, 9H), 
7.20−7.29 (m, 3H), 7.01(dd, 1H, J1 =2.5, J2 = 8.0 Hz), 5.14 (s, 2H).   
 
General Procedure for the Synthesis of O-Biphenyl Carbamate Derivatives 55a−f 
 
A solution of the appropriate amine 51a−d (0.23 mmol) in dry CH2Cl2 (2 mL, dry DMF for 55e) and 
Et3N (0.14 mL, 1.05 mmol) was added to an ice-cooled solution (room temperature for 55e) of the 
suitable (4-nitrophenyl)carbonate 54d−f (0.11 g, 0.33 mmol) in dry CH2Cl2 (2 mL) under a nitrogen 
atmosphere, and the resulting mixture was stirred for 4 h at room temperature.  Upon completion of the 
reaction, a saturated solution of NaHCO3 was added, and the aqueous phase was extracted with CH2Cl2 
(EtOAc for 55e).  The combined organic phases were washed with brine, dried (Na2SO4), and the 
solvent removed by distillation under reduced pressure to afford a crude residue that was purified by 
silica gel column chromatography (EtOAc−cyclohexane 8:2 as eluent or EtOAc−MeOH 95:5 for 55e).   
 
[1,1′-Biphenyl]-3-yl{4-[3-((2-acetamidoethyl)methylamino)phenoxy]butyl}carbamate (55a)  
This product was obtained starting from amine 51a and carbonate 54d.  Amorphous solid, 75% yield.   
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1H NMR(400 MHz, CDCl3): δ 7.55− 7.57 (m, 2H), 7.34−7.44 (m, 6H), 7.11−7.16 (m, 2H), 6.29−6.38 
(m, 3H), 5.71 (br s, 1H), 5.38 (br s, 1H), 4.04 (t, 2H, J = 6.0 Hz), 3.36− 3.43 (m, 6H), 2.93 (s, 3H), 1.87 
(s, 3H), 1.64−1.94 (m, 4H).  13C NMR (100 MHz, CDCl3): δ 170.5, 160.1, 154.7, 151.4, 142.6, 140.3, 
130.1, 129.5, 128.7, 128.0, 127.6, 127.1, 127.0, 124.0, 120.4, 105.6, 102.2, 99.6, 67.4, 51.7, 40.9, 38.4, 
37.0, 26.7, 26.4, 23.1.  ESI MS (m/z): 476 [M + H]+.  HR MS (ESI): m/z calculated for C28H34N3O4, 
[M + H]+: 476.2549, found: 476. 2557.   
 
[1,1′-Biphenyl]-3-yl{6-[3-(methyl(2-propionamidoethyl)amino)phenoxy]hexyl}carbamate (55b)  
This product was obtained starting from amine 51b and carbonate 54d.  Oil, 79% yield.   
1H NMR (400 MHz, CDCl3): δ 7.54− 7.59 (m, 2H), 7.35−7.45 (m, 6H), 7.11−7.13 (m, 2H), 6.28−6.38 
(m, 3H), 5.64 (br s, 1H), 5.14 (br s, 1H), 3.97 (t, 2H, J = 6.5 Hz), 3.44−3.47 (m, 4H), 3.28−3.34 (m, 
2H), 2.94 (s, 3H), 2.11−2.18 (m, 2H) 1.79− 1.83 (m, 2H), 1.61−1.66 (m, 2H), 1.47−1.54 (m, 4H), 1.11 
(t, 3H, J = 7.5 Hz).  13C NMR (100 MHz, CDCl3): δ 174.1, 160.3, 154.6, 151.4, 150.8, 142.6, 140.3, 
130.0, 129.5, 128.7, 127.5, 127.2, 124.0, 120.4, 105.4, 102.1, 99.6, 67.6, 51.7, 41.2, 38.4, 37.2, 29.7, 
29.6, 29.2, 26.4, 25.8, 9.7.  ESI MS (m/z): 518 [M + H]+.  HR MS (ESI): m/z calculated for C31H40N3O4, 
[M + H]+: 518.3019, found: 518.3015.   
 
[1,1′-Biphenyl]-3-yl{8-[3-((2-acetamidoethyl)methylamino)phenoxy]octyl}carbamate (55c)  
This product was obtained starting from amine 51c and carbonate 54d.  Amorphous solid, 90% yield.   
1H NMR (400 MHz, CDCl3): δ 7.55−7.61 (m, 2H), 7.32−7.47 (m, 6H), 7.09−7.17 (m, 2H), 6.27−6.41 
(m, 3H), 5.63 (br s, 1H), 5.10 (br s, 1H), 3.95 (t, 2H, J = 6.5 Hz), 3.44−3.46 (m, 4H), 3.25−3.31 (m, 
2H), 1.48−1.52 (m, 2H), 1.34−1.47 (m, 6H).  13C NMR (100 MHz, CDCl3): δ 170.4, 160.4, 154.6, 151.4, 
150.9, 142.6, 140.3, 130.0, 129.5, 128.7, 127.5, 127.2, 124.0, 120.4, 105.5, 102.3, 99.7, 67.7, 51.8, 41.3, 
38.4, 37.4, 29.8, 29.3, 29.2, 29.1, 26.6, 26.0, 23.2.  ESI MS (m/z): 532 [M + H]+.  HR MS (ESI): m/z 
calculated for C32H42N3O4, [M + H]+: 532.3175, found: 532.3183.  
 
[1,1′-Biphenyl]-3-yl{6-[3-((2-acetamidoethyl)methylamino)phenoxy]hexyl}carbamate (55d)  
This product was obtained starting from amine 51d and carbonate 54d.  Oil, 85% yield.   
1H NMR (400 MHz, CDCl3): δ 7.56−7.61 (m, 2H), 7.28− 7.47 (m, 6H), 7.11−7.18 (m, 2H), 6.26−6.49 
(m, 3H), 5.70 (br s, 1H), 5.18(br s, 1H), 3.98 (t, 2H, J = 6.0 Hz), 3.44−3.46 (m, 4H), 3.26−3.37 (m, 2H), 
2.95 (s, 3H), 1.93 (s, 3H), 1.71−1.89 (m, 2H), 1.58−1.65 (m, 6H).  13C NMR (100 MHz, CDCl3): δ 
170.5,160.1, 154.7, 151.4, 142.6, 140.3, 130.1, 129.5, 128.7, 128.0, 127.6, 127.1, 127.0, 124.0, 120.4, 
105.6, 102.2, 99.6, 67.5, 51.7, 41.2, 38.5, 37.1, 29.7, 29.3, 26.4, 25.7, 23.1.  ESI MS (m/z): 504 [M+H]+.  
HR MS (ESI): m/z calculated for C30H38N3O4, [M + H]+: 504.2862, found: 504.2856   
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3′-Carbamoyl-[1,1′-biphenyl]-3-yl{6-[3-((2-acetamidoethyl) methylamino) phenoxy] hexyl} 
carbamate (55e) 
This product was obtained starting from amine 51a and carbonate 54e. Purification by silica gel 
chromatography (EtOAc−MeOH 95:5 as eluent).  Amorphous solid, 38% yield.   
1H NMR (400 MHz, CDCl3): δ 7.99−8.01 (m, 1H), 7.81 (d, 1H, J = 8.0 Hz), 7.37 (d, 1H, J = 8.0 Hz), 
7.36−7.54 (m, 4H), 7.11−7.15 (m, 2H), 6.46 (br s, 1H), 6.28−6.35 (m, 3H), 5.84 (br s, 1H), 5.73(br s, 
1H), 5.27(br s, 1H), 3.97 (t, 2H, J = 6.5 Hz), 3.39−3.41 (m, 4H), 3.29−3.38 (m, 2H), 2.91 (s, 3H), 1.88 
(s, 3H), 1.77−1.84 (m, 2H), 1.60−1.67 (m, 2H), 1.47−1.54 (m, 4H).  13C NMR (100 MHz, CDCl3): δ 
170.6, 169.3, 160.3, 154.7, 153.9, 151.5, 141.6, 140.8, 134.0, 130.6, 130.0, 129.7, 129.1, 126.5, 126.2, 
124.1, 121.0, 120.6, 105.5, 102.2, 99.6, 67.6, 51.7, 41.1, 38.4, 37.2, 29.6, 29.1, 26.3, 25.7, 23.2.  ESI 
MS (m/z): 547 [M + H]+.  HR MS (ESI): m/z calculated for C31H39N4O5, [M + H]+: 547.2920, found: 
547.2940.   
 
3′-(Benzyloxy)-[1,1′-biphenyl]-3-yl {6-[3-((2-acetamidoethyl) methylamino) phenoxy]hexyl} 
carbamate (55f) 
This product was obtained starting from amine 51a and carbonate 54f.  Oil, 57% yield.   
1H NMR (400 MHz, CDCl3): δ 7.32−7.48 (m, 9H), 7.10−7.22 (m, 4H), 6.97 (dd, 1H, J
1 = 2.0, J1 = 8.0 
Hz), 6.29−6.41 (m, 3H), 5.66 (br s, 1H), 5.13 (br s, 1H), 5.12 (s, 2H), 3.97 (t, 2H, J = 6.5 Hz), 3.43−3.45 
(m, 4H), 3.29−3.34 (m, 2H), 2.93 (s, 3H), 1.92 (s, 3H), 1.77−1.83 (m, 2H), 1.47−1.66 (m, 6H).  ESI MS 
(m/z): 610 [M + H]+.   
 
3′-Hydroxy-[1,1′-biphenyl]-3-yl {6-[3-((2-acetamidoethyl) methylamino) phenoxy] hexyl} 
carbamate (55g)  
 
A solution of the benzyloxy derivative 55f (0.13 g, 0.21 mmol) in EtOH (0.5 mL) and EtOAc (2.5 mL) 
was hydrogenated (1 atm) at room temperature in the presence of 10% Pd−C (0.03 g) for 20 h.  The 
catalyst was removed by filtration on Celite and the filtrate concentrated under reduced pressure to 
afford a crude product, which was purified by silica gel chromatography (EtOAc as eluent).  Amorphous 
solid, 76% yield.   
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1H NMR (400 MHz, CDCl3): δ 7.38−7.40 (m, 2H), 7.30−7.32 (m, 1H), 7.25−7.29 (m, 2H), 7.07−7.18 
(m, 3H), 7.02−7.04 (m, 1H), 6.84 (dd, 1H, J1 = 2.0, J2 = 8.0 Hz), 6.32−6.37 (m, 3H), 5.81 (br s, 1H), 
5.18 (br s, 1H), 3.98 (t, 2H, J = 6.5 Hz), 3.42−3.44 (m, 4H), 3.28−3.33 (m, 2H), 2.91 (s, 3H), 1.93 (s, 
3H), 1.76−1.83 (m, 2H), 1.58−1.66 (m, 2H), 1.44−1.57 (m, 4H).  13C NMR (100 MHz, CDCl3): δ 170.1, 
160.3, 156.7, 154.9 151.3, 142.5, 141.7, 130.1, 129.9, 129.5, 124.0, 120.4, 120.3, 119.0, 114.8, 114.2, 
105.6, 102.7, 99.9, 67.8, 51.9, 41.1, 38.5, 37.2, 29.6, 29.0, 26.3, 25.7, 23.1.  ESI MS (m/z): 520 [M + 
H]+.  HR MS (ESI): m/z calculated for C30H38N3O5, [M + H]+: 520.2811, found: 520.2798.   
 
General Procedure for the Synthesis of 5-(N-Boc-aminoalkoxy)-N-acetyltryptamines 56−57 
 
K2CO3 (0.19 g, 1.4 mmol) was added to a solution of N-acetylserotonin (0.10 g, 0.46 mmol) in dry 
CH3CN (3 mL), and the resulting mixture was stirred under reflux for 1 h under a nitrogen atmosphere.  
Then a solution of the suitable N-Boc derivative 49b or 49c (0.46 mmol) in dry CH3CN (2 mL) and a 
catalytic amount of NaI were added, and the resulting mixture was refluxed for 20 h.  Water was added 
to quench the reaction, and the aqueous phase was extracted with EtOAc.  The combined organic phases 
were dried (Na2SO4) and concentrated under reduced pressure to give a crude residue that was purified 
by silica gel column chromatography (EtOAc as eluent).   
 
tert-Butyl (6-{[3-(2-Acetamidoethyl)-1H-indol-5-yl]oxy}hexyl)carbamate (56) 
Amorphous solid; 59% yield.   
1H NMR (400 MHz, CDCl3): δ 7.97 (br s, 1H), 7.26 (d, 1H, J = 8.5 Hz), 7.03−7.05 (m, 2H), 6.87 (dd, 
1H, J2 = 2.0, J2 = 8.5 Hz), 5.75 (br s, 1H), 4.55 (br s, 1H), 4.00 (t, 2H, J = 6.5 Hz), 3.59−3.61 (m, 2H), 
3.13−3.15 (m, 2H), 2.95 (t, 2H, J = 6.5 Hz) 1.96 (s, 3H), 1.78−1.85 (m, 4H), 1.48 (s, 9H), 1.38−1.56 
(m, 4H).   
ESI MS (m/z): 418 [M + H]+.  ESI MS (m/z): 416 [M − H]−.   
 
tert-Butyl (8-{[3-(2-Acetamidoethyl)-1H-indol-5-yl]oxy}octyl)carbamate (57)  
White solid, mp 75−6 °C; (EtOAc petroleum ether), 47% yield.   
1H NMR (400 MHz, CDCl3): δ 8.01 (br s, 1H), 7.27 (d, 1H, J = 8.5 Hz), 7.02−7.04 (m, 2H), 6.88 (dd, 
1H, J1 = 2.0, J2 8.5 Hz), 5.75 (br s, 1H), 4.52 (br s, 1H), 4.00 (t, 2H, J = 6.5 Hz), 3.58−3.61 (m, 2H), 
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3.08−3.11 (m, 2H), 2.95 (t, 2H, J = 6.5 Hz), 1.95 (s, 3H), 1.78−1.82 (m, 2H), 1.45 (s, 9H), 1.42−1.54 
(m, 4H), 1.29−1.41 (m, 6H).   
ESI MS (m/z): 446 [M + H]+.  ESI MS (m/z): 444 [M − H]−.   
 
tert-Butyl (6-{[3-(2-Acetamidoethyl)-2-bromo-1H-indol-5-yl]oxy}hexyl)carbamate (58)  
 
Trimethylphenyl ammonium tribromide (0.050 g, 0.132 mmol) was added to a solution of 56 (0.055 g, 
0.132 mmol) in dry THF (2.5 mL), and the resulting mixture was stirred at room temperature for 30 
min under a nitrogen atmosphere.  After removing the solvent by distillation under reduced pressure, 
the residue was partitioned between water and EtOAc.  The combined organic phases were dried 
(Na2SO4) and concentrated under reduced pressure to afford a crude residue that was purified by silica 
gel column chromatography (EtOAc−cyclohexane 6:4 as eluent).  Oil, 59% yield.   
1H NMR (400 MHz, CDCl3): δ 8.71 (br s, 1H), 7.19 (d, 1H, J = 8.5 Hz), 6.94−6.96 (m, 1H), 6.81 (dd, 
1H, J1 = 2.0, J2 = 8.5 Hz), 5.72 (br s, 1H), 4.63 (br s, 1H), 3.96 (t, 2H, J = 6.5 Hz), 3.51−3.54 (m, 2H), 
3.11−3.15 (m, 2H), 2.90 (t, 2H, J = 6.5 Hz), 1.94 (s, 3H), 1.76−1.80 (m, 2H), 1.45 (s, 9H), 1.34−1.52 
(m, 6H).  ESI MS (m/z): 496 [M + H]+.   
 
General Procedure for the Synthesis of Indole Target Compounds 62−64 
 
(CH3)3SiBr (48 μL, 0.36 mmol) was added to a solution of the suitable N-Boc-derivative 56−58 (0.12 
mmol) in dry CH3CN (1.2 mL), and the resulting mixture was stirred at room temperature for1 h under 
a nitrogen atmosphere.  Upon completion of the reaction, MeOH was added, and the resulting mixture 
was concentrated in vacuo to give the corresponding crude amine that was used for the next step without 
any further purification. Et3N (0.075 mL, 0.53 mmol) and a solution of the suitable above crude amine 
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(59−61) in dry CH2Cl2 (2 mL) and DMF (0.2 mL) were added to an ice-cooled solution of carbonate 
54d (0.06 g, 0.17 mmol) in dry CH2Cl2 (1 mL) under a nitrogen atmosphere, and the resulting mixture 
was stirred at room temperature for 3 h.  The reaction mixture was neutralized by addition of an aqueous 
saturated solution of NaHCO3 and extracted with CH2Cl2.  The combined organic phases were dried 
(Na2SO4) and concentrated under reduced pressure to afford a crude residue that was purified by column 
chromatography.   
 
[1,1′-Biphenyl]-3-yl(6-((3-(2-aminoethyl)-1H-indol-5-yl)oxy)hexyl)carbamate (62) 
Purification by silica gel chromatography (EtOAc as eluent) and crystallization.  White solid, mp 100−1 
°C (EtOAc−petroleum ether); 83% yield.   
1H NMR (400 MHz, CDCl3): δ 8.02 (br s, 1H), 7.55−7.59 (m, 2H), 7.41−7.45 (m, 4H), 7.33−7.37 (m, 
2H), 7.24−7.26 (m, 1H), 7.10−7.13 (m, 1H), 7.05 (d, 1H, J = 2.0 Hz), 6.99−7.02 (m, 1H), 6.89 (dd, 1H, 
J1 = 2.0, J2 =8.5 Hz), 5.70 (br s, 1H), 5.20 (br s, 1H), 4.03 (t, 2H, J =6.5 Hz), 3.57−3.60 (m, 2H), 
3.31−3.34 (m, 2H), 2.93 (t, 2H, J = 6.5 Hz), 1.93 (s, 3H), 1.81−1.88 (m, 2H), 1.43−1.70 (m, 6H).  13C 
NMR (100 MHz, CDCl3): δ 170.8, 154.6, 153.5, 151.4, 142.6, 140.3, 131.5, 129.5, 128.7, 127.8, 127.5, 
127.2, 127.1, 124.0, 122.7, 120.4, 113.0, 112.7, 111.9, 101.8, 68.7, 41.2, 39.8, 29.8, 29.3, 26.5, 25.8, 
25.3, 23.3.  ESI MS (m/z): 514 [M + H]+.  HR MS (ESI): m/z calculated for C31H36N3O4, [M + H]+: 
514.2706, found: 514.2700.   
 
[1,1′-Biphenyl]-3-yl(8-((3-(2-aminoethyl)-1H-indol-5-yl)oxy)octyl)carbamate (63) 
Purification by silica gel chromatography (EtOAc as eluent) and crystallization.  White solid, mp 108−9 
°C (EtOAc−petroleum ether); 95% yield.   
1H NMR (400 MHz, CDCl3): δ 7.96 (br s, 1H), 7.57−7.60 (m, 2H), 7.41−7.46 (m, 4H), 7.35−7.38 (m, 
2H), 7.25−7.29 (m, 1H), 7.10−7.14 (m, 1H), 7.04−7.05 (d, 1H, J = 2.0 Hz), 7.01−7.03 (m, 1H), 6.88 
(dd, 1H, J1 = 2.0, J2 8.5), 5.68 (br s, 1H), 5.10(br s, 1H), 4.01(t, 2H, J = 6.5 Hz), 3.57−3.62 (m, 2H), 
3.27− 3.32 (m, 2H), 2.94 (t, 2H, J = 6.5 Hz), 1.93 (s, 3H), 1.80−1.85 (m, 2H), 1.26−1.67 (m, 10H).  13C 
NMR(100 MHz, CDCl3)δ:170.8, 154.6, 153.5, 151.4, 142.6, 140.3, 131.5, 129.5, 128.7, 127.8, 127.5, 
127.2, 124.0, 122.7, 120.4, 113.0, 112.7, 111.9, 101.7, 68.8, 41.3, 39.8, 29.8, 29.4, 29.2, 29.1, 26.6, 
26.0, 25.2, 23.3.  ESI MS (m/z): 542 [M + H]+.  HR MS (ESI): m/z calculated for C33H40N3O4, [M + 
H]+: 542.3019, found: 542.3044.   
 
[1,1′-Biphenil]-3-yl(6-((3-(2-aminoethyl)-2-bromo-1H-indol-5yl)oxy)hexyl)-carbamate (64):  
Purification by silica gel chromatography (cyclohexane−EtOAc 7:3 as eluent).  Amorphous solid; 83% 
yield.  1H NMR (400 MHz, CDCl3): δ 8.18 (br s, 1H), 7.54−7.57 (m, 2H), 7.40−7.43 (m, 4H), 7.37−7.39 
(m, 2H), 7.13 (d, 1H, J = 8.5 Hz), 7.11−7.15 (m, 1H), 6.97−6.99 (m, 1H), 6.83 (dd, 1H, J1 =2.0, J1 = 
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8.5 Hz), 6.18 (br s, 1H), 5.27 (br s, 1H), 4.01 (t, 2H, J = 6.5 Hz), 3.48−3.52 (m, 2H), 3.30−3.31 (m, 
2H), 2.89 (t, 2H, J = 6.5 Hz), 1.94 (s, 3H), 1.80−1.84 (m, 2H), 1.62−1.67 (m, 2H), 1.44−1.57 (m, 4H).  
13C NMR (100 MHz, CDCl3): δ 171.0, 154.8, 153.8, 151.4, 142.6, 140.3, 131.3, 129.6, 128.7, 128.1, 
127.6, 127.2, 124.0, 120.4, 120.4, 112.8, 111.9, 111.5, 108.9, 101.2, 68.7, 41.2, 39.6, 29.7, 29.2, 26.5, 
25.8, 24.7, 22.9.  ESI MS (m/z): 592 [M+H]+.  HR MS (ESI): m/z calculated for C31H35N3O4Br, [M + 
H]+: 592.1811, found: 592.1844.   
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Section II: C8-Substituted Temozolomide Derivatives:   
SAR Studies and Effects on Stability 
 
 
 
 
 
 
 
 
 
 
 
 
The following work has been conducted during my period of visiting spent abroad at the University of Illinois at 
Urbana-Champaign under the guidance of Professor Paul Hergenrother 
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2.1 Introduction and Aim of the Work 
 
2.1.1 General Introduction 
Gliomas are the most common adult primary 
tumors affecting the central nervous system (CNS) 
with an annual incidence in the USA of 5–8/ 100,000 
population.90  Gliomas are neuroepithelial tumors 
currently subclassified by the World Health 
Organization (WHO) according to the morphological 
appearance into astrocytic, oligodendroglial, 
ependymal, and choroid plexus tumors, ranging from 
low (grade I) to high (grade IV) based on histological 
tumor aberrations hallmarks such as nuclear atypia, 
mitotic activity, endothelial hyperplasia, and 
necrosis.91  About half of all newly diagnosed gliomas 
are neoplastic astrocytes and are classified as 
Glioblastoma (GBM, Astrocytomas grade IV, Figure 26).  GBM are the most infiltrative and lethal 
types of brain cancers and manifest three or four morphological abnormalities.  Standard treatment of 
GBM consists of maximal surgical resection, radiotherapy, and concomitant and adjuvant 
chemotherapy with temozolomide (TMZ, 66, Figure 27).  Despite surgical resection and genotoxic 
treatment, median reported survival does not exceed 1 year, highlighting the need for better treatment 
strategies.92,93  
TMZ is a small molecule DNA alkylating agent developed for the first time at Aston University, 
in Great Britain, in 1984 as one of the second-generation imidazotetrazine series.94  The most active 
compound of this series was the N3-β-chloroethyl derivative mitozolomide (67, Figure 27).  However, 
mitozolomide development was discontinued during Phase I-II clinical trials after it was found to cause 
severe and irreversible thrombocytopenia, due to its high DNA-cross-linking ability.95  Replacement of 
N3-β-chloroethyl group by methyl led to the less toxic analogue, with comparable antitumor activity, 
temozolomide that was approved in 1999, by the US Food and Drug Administration (FDA), for the 
treatment of anaplastic astrocytoma patients who were refractory to both nitrosourea drug (BCNU or 
CCNU) and procarbazine.  In 2005, FDA and the European Agency approved temozolomide 
(Temodar® and Temodal® respectively) also for newly diagnosed GBM patients.   
Figure 26 Gliobastoma (astrocytoma) WHO grade IV - 
MRI coronal view, post contrast. 15 year old boy. 
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Figure 27 Imidazotetrazine drugs 
Among the beneficial properties contributing to TMZ commercial and clinical success is the 
benefit of the drug to be administered orally in an outpatients setting.  It is well established that TMZ 
acts as a prodrug, stable at acidic pH values, a property which permits oral administration, but labile 
above pH 7, with a plasma half-life of 1.8 hours at pH 7.4.  Thus, TMZ is rapidly absorbed intact by 
the digestive system, and once in the bloodstream, easily crosses the BBB due to its lipophilic 
characteristics.  Once TMZ reaches alkaline pH (in tissue such as cerebrospinal fluid and brain), it is 
spontaneously hydrolyzed in a ring-opening reaction to the open chain triazene active metabolite 5-(3-
methyltriazen-1-yl) imidazole-4-carboxamide (MTIC) through a pH dependent hydrolytic attack at C4.  
MTIC, which is also unstable, breaks down into two parts: 5-aminoimidazole-4-carboxamide (AIC) 
excreted by kidneys, and the highly reactive methyldiazonium cation, the real active species (Scheme 
8).96    
 
 
 
Scheme 8 Mechanism of TMZ activation 
 
The methyldiazonium ion reacts with nucleophilic groups on DNA, resulting in DNA 
methylation, preferentially at N7 positions of guanine (N7-MG; 70%), but also at the N3 position of 
adenine (N3-MA; 9%) and at the O6 position of guanine (O6-MG; 6%) (Figure 28).   
Products of N-methylation are readily repaired by the base-excision repair pathway (BER) and are not 
major contributors to cytotoxicity.  In contrast, the least frequent, methylation of guanine at O6 (O6-
MG) is critical for temozolomide cytotoxicity.   
There is a narrow pH window close to physiological pH at which the whole process of TMZ 
prodrug activation to methyldiazonium can occur.  Brain tumours possess a more alkaline pH compared 
with surrounding healthy tissue, a situation that favours prodrug activation preferentially within tumour 
tissue.97,98,99,100  Thus TMZ is used to treat (but not exclusively) brain tumours, imparting significant 
therapeutic benefit to GBM patients.101   
86 
 
 
 
Figure 28 Methyl diazonium-alkylating sites 
 
In normal cells, O6-methylguanine (O6-MG) lesions are reversed by the suicide enzyme methylguanine 
DNA methyltransferase (MGMT), which removes the methyl adduct and restores the guanine (Figure 
29).  Specifically, a cysteine residue in MGMT active site removes the alkyl group through a SN2 
mechanism, protecting cells from carcinogens.   
Unrepaired O6-MG alerts DNA mismatch repair (MMR) that recognizes this mispairing in the DNA 
daughter strands and excises it.  Therefore, after many cycles of thymine re-insertion and removal, the 
replication fork collapse, inducing cell cycle arrest and apoptosis.102,103,104,105 
 
 
Figure 29 Repair of O6-methylguanine adducts by MGMT 
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However, this suicide enzyme is also able to protect cancer cells from chemotherapeutic drugs 
such as TMZ and a strong positive correlation exists between MGMT activity and alkylating agent 
resistance.  In gliomas, high MGMT expression has been detected in 45% - 70% of cases.106,107   
 
2.1.2 Summary of Known SAR on Imidazotetrazines Derivatives 
SAR expansion of this class of compounds was limited both by the high sensibility to protic 
solvents and basic reagents, and by the fact that the usually exploited synthetic procedures require the 
use of isocyanate, a poisonous gas, or reagents such as N-succinimidyl, N-methylcarbamate or N-
methylcarbamic chloride108 that drastically reduce the cyclization yield.  Furthermore, a broad 
exploration of the link between imidazotetrazine structure and biological activity was precluded by the 
fact that most of these SAR studies refer to non CNS cancer models,109 making their translation to GBM 
tumor models difficult.   
The N3 substituent seems to be very important for imidazotetrazines antitumor activity.  
Compounds such as mitozolomide, bearing a N3 β-chloroethyl substituent, result the most potent ones.   
Replacement of chloroethyl group by methyl group leads to analogues with retained activity, although 
slightly lower, whereas substitution by ethyl, bromoethyl, methoxyethyl, chloropropyl, allyl, and other 
alkyl groups gives compounds without good antitumor activity.110  The N3 substituent also plays a 
pivotal role in MGMT mediated resistance.  In fact, while TMZ shows low potency across MGMT 
positive tumors, N3-methyl replacement by groups such as an alkyne or a 2-
(trimethylsilyl)ethoxymethyl (SEM), leads to interesting analogues with in vitro growth-inhibitory 
potency higher than that of TMZ in both MGMT deficient and positive cell lines.  Nitrogen shifts from 
position 7 to 6 is tolerated and leads to pyrazolotriazines series, but these compounds showed lower 
cytotoxicity than the corresponding imidazotetrazines and are more difficult to synthesize.111,112  C6 
position tolerates hydrogen or small straight-chain alkyl groups, but not branched alkyl substituents.113  
 
 
Figure 30 Current SARs of Imidazotetrazines  
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The TMZ C8 position has never been fully explored.  It has been previously suggested that the 
C8-amide is essential for anticancer activity.  Such claims were supported by NMR studies outlining 
the importance of a C8 hydrogen bond donator to enable TMZ ring-opening in solution.114,115  However, 
more recent studies have shown that other functionalities, such as amides and esters, can be tolerated at 
this position. 116,117,118   
The C8-amide requirement is probably an artifact related to the synthetic approach originally 
used to prepare imidazotetrazines, involving the reaction of 5-diazoimidazole-4-carboxamide (69), 
prepared by nitrosation of AIC, and an isocyanate (Scheme 9).119,120  The remarkable stability of diazo 
69 that rapidly precipitates out of solution as pure compound, in spite of other soluble diazonium, 
favored its use in imidazotetrazines synthesis.121,122  
 
 
Scheme 9 TMZ original synthesis 
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2.1.3 Aim of the Work 
 
Despite enormous sums of money and vast efforts to identify alternative treatments, even in the 
era of personalized medicine temozolomide remains the front line drug for treatment of glioblastoma, 
in patients whose tumors do not express O6-methylguanine DNA methyltransferase.123  However, due 
to inherent and acquired resistance conferred by multiple mechanisms,124 TMZ does not increase 
median survival to over one year, highlighting the need for better treatment strategies.   
The principal aspect governing the anticancer activity of imidazotetrazines is the hydrolytic 
activation of the prodrug.  The half-life of TMZ is ∼2 hours in vivo and in aqueous solution in vitro, 
enabling a discrete TMZ accumulation within the central nervous system before methyldiazonium 
release (cerebral spinal fluid: blood ratio of 17:83 in human cancer patients).125,126   
Despite the fact that TMZ has been FDA approved for two decades, the relationship between 
TMZ half-life and anticancer activity has never been clarified.  Indeed, there is lack of information 
about compound optimal half-life and it is still unclear if these two hours are suitable to maximize its 
antitumor effect or if longer or shorter half-lives improve the prodrug efficacy.   
To understand the relationship between its structure, hydrolytic stability, and anticancer 
activity, we synthetized new imidazotetrazine derivatives bearing new previously unexplored 
functionality at the C8 position (such as aliphatic, ketone, halogen, and aryl groups).  Specifically, we 
hypothesized that electronics at C8 may directly translate through imidazotetrazine ring to the C4, and 
strategic substitutions at this position could be used to tune the hydrolytic stability of imidazotetrazines.   
Additionally, C8-substitution could also affect the CNS penetrance, with consequences on brain 
accumulation and the systemic toxicity profile (since myelosuppresion limits TMZ dosage).127,128,129 
 
 
Figure 31 TMZ BBB penetrance and hydrolytic stability 
Groups with different electronic characters were inserted at C8, after developing new synthetic 
approaches.  To enhance BBB penetrance, the C8 substituents were also chosen by using calculated 
cLogBB values130 (based on compound’s cLogP and total polar surface area)i and CNS multiparameter 
optimization (MPO) tool131,132 (which score is based on six physicochemical properties and spans from 
                                                          
i Brain-to-plasma ratio: cLogBB = Log P – (N + O); (N + O) is the number of nitrogen and oxygen atoms). 
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0 to 6.0) (Figure 32).  These types of in silico metrics are a well-established measure of compounds 
hydrophilicity and have been used reliably on several occasions to predict relative changes in biological 
phenomena, among which the blood-brain barrier penetrance.133,134,135   
 
Figure 32 TMZ C8-derivatives with interesting cLogBB values, missing from the literature 
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2.2 Result and Discussions 
 
To widen the relationship between the structure, hydrolytic stability, and anticancer activity of 
imidazotetrazines we studied the effects deriving from strategic substitutions at the C8 position.   
We began our C8 exploration by alkylation of TMZ amide in order to improve the lipophilicity 
of the resulting compounds.  Derivatives (73-78), were synthetized employing established synthetic 
procedures depicted in Scheme 10a.136  TMZ amide was converted to the corresponding carboxylic acid 
derivative 71 in good yield, by using specific acid conditions (a water solution of sodium nitrite and 
Sulfuric acid).137  The carboxylic acid 71 was transformed to the corresponding acid chloride (72) and 
then converted to the desired amide (73-76), ester (77) or thioester (78) derivatives by treatment with 
the appropriate nucleophile.  To provide access to cyano derivative 70, a previously reported procedure 
of dehydration was employed (thionyl chloride in DMF at 60° C; Scheme 10a).138   
While certain derivatives (e.g. amides and esters) can be obtained directly from TMZ using 
validated routes developed for mitozolomide, other derivatives of interest, such as the ketone derivative 
and those eliminating the carbonyl (aliphatic, halogen and aryl groups), cannot be synthesized using 
known methods.  To have access to these previously unexplored functionality new synthetic methods 
have been developed.   
The synthetic route adopted for the preparation of C8-methyl derivative 81 is outlined in 
Scheme 10b, and involves the diazotization of commercially available 5-amino-4-methylimidazole, 
followed by cyclization with the methyl isocyanate surrogate N-methylcarboyl chloride.   
Considering the imidazotetrazine ring instability to Grignard and alkyl lithium reagents, the ketone 
derivative 85 was prepared starting from 5-amino-4-methylimidazole 83 that was converted to the 
intermediate 84 by treatment with N-succinimidyl N-methylcarbamate, followed by diazotization in the 
presence of LiCl and spontaneous compound cyclization.  The ketone intermediate 83 was prepared 
according to a previous reported strategy, starting from 6-methylpurine N-oxide 82 by oxidation and 
subsequently hydrolytic degradation (Scheme 10c).139   
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Scheme 10 Synthesis of new C8- derivatives of temozolomide  
 
To introduce an aryl group to the C8 position, two synthetic routes seemed to be feasible (Figure 
33).  Firstly, a modular intermediate, such as one containing a reactive cross-coupling partner (or a 
group primed for displacement) can be developed (Figure 33a).  This first strategy could give access to 
a small library of unique derivatives appended directly to the C8 carbon, as the last step of the synthetic 
sequence.   
 
 
Figure 33 Modular synthetic routes 
A classic method to generate carbon–carbon bonds is the palladium‑catalysed Suzuki–Miyaura 
cross‑coupling reaction of organoboronic acids with aryl halides.140  To prepare the C8-bromo key 
intermediate (79), TMZ amide was hydrolyzed to the carboxylic acid derivative (71) 141 that was then 
submitted to several decarboxylative bromination strategies.  Classical brominating agents, such as NBS 
or Ag(II)/Br2, were not useful.  Conversely, hypervalent iodine reagents, such as Dess-Martin 
periodinane (DMP) and 2-iodoxybenzoic acid (IBX), in combination with tetraethylammonium 
bromide (TEAB) allowed getting the desired bromine derivative (79), even if in traces (Table 10, entry 
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b and d).  To improve the product yield, a HPLC screening of the reaction condition have been 
performed (Table 10), enhancing isolated yield to 58% (Table 10, entry r and Scheme 11).  The value 
of this new strategy, which has never been applied to imidazole rings, is largely due to the employment 
of mild conditions to successfully convert carboxylic acid compounds in bromine derivatives.    
Table 10 Decarboxylative halogenation; Condition screening (HPLC conversion) 
Entry Solvent Conditions Temperature 
(°C) 
Time 
(h) 
  
Isolated 
yield 79 
(%) 
a CH2Cl2 IBX : TEAB 
2 : 2 
rt 1 trace 3.3 nd 
b CH2Cl2 IBX : TEAB 
2 : 2 
rt 4 trace 8.3 trace 
c CH2Cl2 DMP : TEAB 
1 : 1 
rt 1 72.9 13.3 nd 
d CH2Cl2 DMP : TEAB 
1 : 1 
rt 4 63.4 16.3 trace 
e CH2Cl2 DMP : TEAB 
1 : 1 
rt 20 53.8 8 nd 
f CH2Cl2 DMP : TEAB 
2 : 2 
rt 1 82 16.1 nd 
g CH2Cl2 DMP : TEAB 
2 : 2 
rt 2 46.6 36.5 nd 
h CH2Cl2 DMP : TEAB 
2 : 2 
rt 6 40.6 48 23 
i CH2Cl2 DMP : TEAB 
2 : 2 
rt 20 40 23.4 nd 
l CH2Cl2 DMP : TEAB 
3 : 3 
rt 2 40 31 nd 
m CH3CN DMP : TEAB 
1 : 1 
50 2 52.5 31.1 nd 
n CH3CN DMP : TEAB 
1 : 1 
50 4 52 30.3 nd 
o CH3CN DMP : TEAB 
1 : 1 
80 1 52 39.4 nd 
p CH3CN DMP : TEAB 
1 : 1 
80 2 51 28.7 nd 
q CH2Cl2 DMP : TEAB 
2 : 2 
50 2 trace 45.6 nd 
r CH3CN DMP : TEAB 
2 : 2 
50 2 trace 62.9 58 
s CH2Cl2 DMP : TEAB 
3 : 3 
rt 2 40 31 nd 
nd = not determined  
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We also explored the possibility to apply this new methodology to synthesize other halo-
derivatives by using different tetraalkylammonium salts.  While this method worked properly for the 
chlorine derivative (80) (using tetramethylammonium chloride), both iodo and fluorine derivatives 
cannot be obtained according to this method (Scheme 11).   
 
 
Scheme 11 Synthesis of C8-halogenated derivatives of temozolomide 
In order to obtain the C8-phenyl-imidazotetrazine 89a, several cross coupling reaction were 
tested starting from the bromo derivative 79.  However, all coupling attempts were unsuccessful (Table 
11), probably due to imidazotetrazine sensitivity to protic solvent and basic reagents.   
 
Table 11 Coupling attempts (*Reaction performed using PhSn(Bu)3; **Reaction preformed on carboxylic acid 71 
 Catalyst Additive or Base Solvent Temperature °C 
a Pd(PPh3)4 TEBAC / CsF toluene/ H2O rt; 50; 70 
b* Pd(PPh3)2 CsF toluene rt; 50; 70 
c Pd(PPh3)4 Na2CO3 DME/ H2O rt; 110 
d PdCl2 Bu2NH DMF rt; 60; 100 
e XPhos PdG2 Na2CO3 DME/ H2O rt; 90 
f** BrettPhos PdG1 Cu(OAc)2 / LiCl CH3CN rt; 50 
g XPhos PdG2 K3PO4 Dioxane/ H2O rt; 110 
h BrettPhos PdG1 K3PO4 Dioxane/ H2O rt; 110 
 
A second alternative method involves imidazole scaffold functionalization, followed by 
imidazole-derivative cyclization (Figure 33b). This second route, even if longer, appears to be more 
feasible.  Briefly, 5-nitro-4-bromoimidazole (86) was submitted to Suzuki coupling reaction with the 
suitable phenylboronic acids in the presence of a different palladium catalyst.  While classic catalyst 
(e.g. PdCl2(PPh3)2, Pd(dba)2) did not prove useful, XPhos Palladacycle enabled the preparation of the 
desired compound 87a-h, which were subsequently reduced to corresponding 88a-h by Pd-catalyzed 
hydrogenation.  The obtained amines 88 were then cyclized to the final aryl-substituted imidazotetrazine 
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(89a-h) by diazotization and subsequently treatment with N-methylcarbamic chloride in EtOAc 
(Scheme 12a).   
Finally, to further explore C8-SAR, heterocyclic compounds 91 and 93 were built on TMZ 
amide.  Specifically, using Lawesson reagent, TMZ amide was converted to corresponding thioamide 
(90) which, upon cyclization with α-bromoacetone, led to the target 4-methylthiazole 91.  The target 
compound 93 was prepared according to a well-validated route for similar compounds,118 involving 
TMZ amide activation to the corresponding acid chloride 72, followed by nucleophilic substitution with 
the suitable amide and final cyclization with POCl3 (Scheme 12b).   
 
Scheme 12 Synthesis of C8-aryl and -heteroaryl derivatives of temozolomide 
Anticancer activity of new C8-substituted imidazotetrazines was evaluated against a series of 
human GBM cell lines (Table 12).  Cell lines both expressing and lacking MGMT were included and 
cytotoxicity of each compound was compared to that of TMZ.  Consistently with the literature, MGMT 
deficient cell lines were sensitive to TMZ (IC50 ≤ 51 M), whereas those MGMT positive were resistant 
(IC50 ≥ 322 M).  Cyano derivative 70 and carboxylic acid derivative 71, similarly to mitozolomide 
analogues, were inactive.  Conversely, amide, ester and thioester derivatives proved to be as active as 
TMZ in the absence of MGMT and more potent in cell lines expressing the enzyme.  The retention of 
activity for these compounds supports our hypothesis concerning the C8-hydrogen bond donating non-
necessity.  Likewise, imidazotetrazines lacking the carbonyl group (e.g. halogenated, aryl and 
heteroaryl derivatives) proved to be as or more effective against U87 and D54 cell lines, and 
significantly more potent in those expressing MGMT (U118MG, T98G and U3054MG).  In particular, 
insertion of methyl or phenyl substituent at C8 position afforded to the most active compounds across 
all cell lines.    
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Table 12 C8 substituted imidazotetrazines-IC50 value (µM) in multiple GBM cell lines  
 
 
 
 
 
 
MGMT(-) 
 
 
 
MGMT(-) 
 
 
 
MGMT(+) 
 
 
 
MGMT(+) 
 
 
 
MGMT(+) 
Compound R U87 D54 U118MG T98G U3054MG 
66 (TMZ) CONH2 51 ± 8 12 ± 1 322 ± 7 660 ± 10 370 ± 40 
70 CN 500 ± 60 91 ± 6 670 ± 20 >1000 870 ± 60 
71 COOH 320 ± 7 130 ± 8 370 ± 20 321 ± 8 nd 
73 CONHMe 49 ± 7 11 ± 1 280 ± 20 580 ± 20 229 ± 20 
74 CONMe2 40 ± 20 12 ± 5 130 ± 30 250 ± 60 132 ± 6 
75 CONEt2 80 ± 30 13 ± 2 80 ± 10 160 ± 40 nd 
76 CON(n-Bu)2 27 ± 6 11 ± 2 62 ± 2 140 ± 20 nd 
77 COOEt 66 ± 3 7 ± 1 180 ± 20 236 ± 10 nd 
78 COSEt 64 ± 21 8 ± 1 165 ± 4 327 ± 4 nd 
79 Br 26 ± 7 20 ± 1 84 ± 17 55 ± 14 nd 
80 Cl 15 ± 4 21 ± 4 60 ± 20 60 ± 10 87 ± 4 
81 Me 3 ± 1 6 ± 3 7 ± 1 6 ± 1 nd 
85 COMe 44 ± 6 18 ± 1 115 ± 9 240 ± 20 125 ± 4 
89a Ph 9 ± 1 7 ± 1 3 ± 1 14 ± 1 18 ± 1 
89c pCF3-Ph 16 ± 1 nd nd >100 nd 
91 4-Me-Thiaz 9 ± 1 8 ± 1 12 ± 2 31 ± 4 nd 
93 5Me-Ox 27 ± 4 9 ± 1 70 ± 20 100 ± 20 123 ± 6 
 
Panel of C8-substituted imidazotetrazines and associated IC50 values (µM) in multiple GBM cell lines. Cell lines were incubated with 
compound for 7 days then viability was assessed using the Alamar Blue assay. Error is SEM, n≥3.  
 
As already mentioned, despite being known since 1984, FDA approved since 1999, and 
reaching $1 billion in sales in 2009, the relationship between TMZ hydrolytic stability and anticancer 
activity is unknown and specifically, there is a scarce information on the compound optimal half-life.  
Towards this end, effects of compounds with C8 substituents were evaluated in buffered saline, using 
PBS, which mimics in vivo conditions.  A HPLC assay was developed to quantify the fraction of prodrug 
in solution remained intact after 2 hours at pH 7.4, 37°C.  In this condition, TMZ showed a half-life of 
119 minutes.  The results of this experiment confirmed that the electronic effects of the substituent 
hanging at C8 dramatically influenced prodrug stability, leading to 2 h-stabilities ranging from 0% to 
97% (Figure 34).   
Since the electronic character of the group at C8 has a clear effect on the hydrolysis rate of the 
prodrug, substituents Hammett constants (σp)142 were mapped against the percentage remaining after 
two hours.  This value, derived by Hammett in 1937 from the ionization constants of benzoic acids para 
substituted, is based on substituent inductive and mesomeric effects.  As shown in Figure 34, rendering 
C8 positions more electron-rich increases the prodrug stability (e.g. 81; σp = -0.17, half-life 40 h), while 
replacing the amide with more electron withdrawing functionality decreases the stability (e.g. 70; σp = 
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0.66, half-life 0.5 h).  Additionally, compound stability seems strictly related to in vitro anticancer 
activity.  While compounds displaying lower anticancer activities against cell lines are mainly 
characterized by very short hydrolytic half-lives, those with remarkable stability and very long half-
lives showed the greatest potency in vitro.  Indeed, a very short half-life probably give rise to hydrolysis 
too quickly, which will release methyl diazonium before accumulating in the DNA microenvironment.  
Conversely, long half-life, enable compound distribution to the nucleus before its activation, thus 
leading to a high anticancer potency.  Compounds possessing substituents with electronic sigma values 
ranging from 0.23 ≤ σp ≤ 0.50, then close to TMZ ones (σp = 0.36, half-life ∼2 h) showed similar 
stability and potency in culture.   
 
 
Cpd R t1/2 (h) 
70 CN 0.57 ± 0.03 
85 COMe 1.20 ± 0.10 
66 (TMZ) CONH2 1.98 ± 0.01 
73 CONHMe 2.70 ± 0.10 
74 CONMe2 2.80 ± 0.20 
89c pCF3-Ph 2.90 ± 0.30 
93 5Me-Ox 3.00 ± 0.10 
80 Cl 3.10 ± 0.10 
89e pF-Ph 8.7 ± 0.8 
89a Ph 27 ± 3 
81 Me 40 ± 1 
 
Figure 34 Hydrolytic stability of C8-substituted imidazotetrazines. (left) The percentage of compound remaining after 2 
hours plotted against the Hammett constant of its C8 substituent.  Compounds with hydrolytic stability similar to TMZ are 
enclosed in the oval. (right) Half-lives of select C8 derivatives in PBS (pH 7.4, 37°C). 
 
Among beneficial pharmacokinetic properties of TMZ is its ability to avoid primary 
metabolism.  To determine if the C8 modifications lead to significant metabolic liability, the stabilities 
of select compounds were tested in the presence of mouse liver microsomes and compared to control 
runs without microsomes.  As shown in Table 13, TMZ is insensitive to metabolic perturbation.  Amide-
alkylation (73-75) enhances microsomes susceptibility and particularly, alkylation with larger 
substituents, as shown for compound 76, proved to be detrimental for compounds metabolic stability.  
The ketone (85) and the chlorine (80) have revealed compounds with interesting microsomes stability, 
suggesting that for these compounds hydrolysis could drive the in vivo pharmacokinetics as for TMZ.   
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Table 13 C8-Metabolic stability and cLogBB and CNS MPO values for relevant C8 analogs 
 
Compound Stability 
2h, Microsomes 
Stability 
2h, No Microsomes 
cLogBB CNS MPO 
Propranol 68 ± 2 102 ± 3 nd nd 
66, TMZ 87 ± 6 86 ± 4 -1.58 4.9 
73 86 ± 1 93 ± 1 -1.34 5.7 
74 81 ± 2 92 ± 3 -1.18 6.0 
75 81 ± 1 95 ± 2 -1.07 6.0 
76 1 ± 1 98 ± 3 -0.78 5.6 
80 91 ± 3 91 ± 1 -0.72 6.0 
85 70 ± 1 77 ± 3 -1.08 6.0 
89a 44 ± 2 103 ± 5 -0.56 5.7 
93 71 ± 1 95 ± 4 -1.19 5.9 
 
The metabolic stability was assessed in mouse liver microsomes. Compounds were incubated in microsomes for 2 h, then the residual substrate 
was quantified relative to t0. Experiments assessing stability in the absence of microsomes were identical but replacing liver microsomes with 
PBS. Error is SEM, n≥2. Internal standard = N3-propyl TMZ. Blood 
 
To verify if replacing the amide at C8 could be a viable strategy to increase BBB penetrance 
and to reach enhanced brain concentrations, selected compounds showing great antitumor activity, 
appropriate hydrolytic and metabolic stability, and optimal cLogBB and CNS MPO values, have been 
assessed in vivo for their brain penetrance.   
First, the BBB penetrance of top compounds was evaluated head-to-head with TMZ.  In an 
initial experiment, the mono- (73) and di- (74) methylated compounds were tested (Figure 35b).  
Unfortunately, due to their fast metabolisms, 73 and 74, even if showed enhanced brain concentration 
after five minutes, displayed brain-blood ratio equivalent to TMZ ones.   
To verify if compounds with higher predicted BBB penetrance could reach an increased brain 
permeability, in a second experiment the oxazole 93 and the ketone 85 were assessed with TMZ and 
the dimethyl derivative 74.  While TMZ had an absolute brain-blood ratio of 8:92, 93 and 85 boasted 
this ratio of 55:45 and 69:31, respectively, confirming our hypothesis (Figure 35e).   
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Figure 35 Blood-brain barrier permeability of imidazotetrazines. (a) Structures of lead C8-substituted compounds. (b) 
Relevant brain:serum ratios of TMZ, Me-TMZ, and DiMe-TMZ (25 mg/kg) were measured 5 minutes after IV injection into 
mice. Values are the fold change of brain:serum ratio relative to TMZ. In a second experiment, brain (c) and serum (d) 
concentrations of TMZ and C8 analogs (25 mg/kg) were quantitated 5 minutes after IV injection into mice. (e) Brain:serum 
ratios were calculated based on (c) and (d) assuming a mouse blood volume of 58.5 mL/kg. Error is SEM, number of mice per 
cohort = 3. Statistical significance was determined by using a two-sample Student’s t-test (two-tailed test, assuming equal 
variance).   
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The elevated brain concentration of compounds 93 and 85 might decreases in vivo 
hematological toxicity of imidazotetrazines.  Since myelosuppresion, which occurs in ~20% of TMZ-
treated patients, is the major dose-limiting TMZ toxicity,143 in order to prove our hypothesis an in vivo 
study have been assessed.  Specifically, mice were treated with a single dose of 125 mg/kg TMZ, 93 or 
85 intravenously and, after 7 days, their blood was collected and analyzed.  In this experiment, while 
TMZ produced severe myelosuppresion by white blood cell (WBC) depletion and both lymphocyte and 
neutrophil concentration decrease, treatment with 93 or 85 did not gives rise to hematological toxicity 
(Figure 36 and 37). 
 
Figure 36  Assessment of the hematological toxicity of imidazotetrazines in vivo. Mice were administered a single IV dose of 
125 mg/kg imidazotetrazine. After 7 days, whole blood was collected and a complete blood count was obtained for each 
individual mouse. (a) Total WBC count. Control vs. Ox-TMZ: P = 0.7, Control vs. K-TMZ: P = 0.9. (b) Lymphocyte 
concentrations. Control vs. Ox-TMZ: P = 0.5, Control vs. K-TMZ: P = 0.9. Error is SEM, number of mice per cohort = 4. 
Statistical significance was determined by using a two-sample Student’s t-test (two-tailed test, assuming equal variance).  
 
 
Figure 37 Assessment of the hematological toxicity of imidazotetrazines in vivo.  Mice were treated with a single IV dose of 
125 mg/kg imidazotetrazine and a complete blood count was obtained for each mouse after 7 days. (a) Neutrophil 
concentrations (b) RBC concentrations (c) Platelet concentrations (d) Cohort weights of mice prior to treatment and at the 
time of blood collection 7 days post-treatment. Error is SEM, number of mice per cohort = 4.    
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Finally, in vivo anticancer activity of most interesting imidazotetrazines was evaluated.  Mice 
were implanted intracranial with GBM oncosphere Br23c cells, which accurately recapitulate the 
genetic and histopathological features of human GBM.144  In the first experiment, five days post 
implantation, mice were orally treated with 15 mg/kg TMZ or equimolar equivalent of Me-TMZ (73) 
or DiMe-TMZ (74).  Compounds 73 and 74 outperformed TMZ by increasing median survival by 24% 
and 46%, respectively, suggesting that increasing the BBB permeability of imidazotetrazine prodrugs 
is a viable strategy to improve anticancer efficacy (Figure 38a).  For this reason, in a second experiment 
mice were orally treated with TMZ or DiMe-TMZ (74) or ketone 85.  This study (Figure 38b) supported 
our hypothesis, since mice treated with 85 achieved an extended median survival over 50 days past 
TMZ-treated mice.   
 
Figure 38 Evaluation of imidazotetrazines in intracranial mouse models of GBM. GBM Br23c oncospheres were 
intracranially implanted into female athymic nude mice. Treatment was started 5 days post implantation. (a) Mice were 
administered 15 mg/kg TMZ or an equimolar dose of Me-TMZ (16.1 mg/kg) or DiMe-TMZ (17.2 mg/kg) orally once per-day, 
5x/week for 7 weeks. Control vs. TMZ: P = 0.0014, TMZ vs. DiMe-TMZ: P = 0.061, TMZ vs. Me-TMZ: P = 0.016. (b) Mice 
were administered 15 mg/kg TMZ or an equimolar dose of DiMe-TMZ (17.2 mg/kg) or K-TMZ (14.9 mg/kg) orally once-per-
day for 5 total doses. Control vs. TMZ: P = 0.0007, DiMe-TMZ vs. TMZ: P = 0.7, K-TMZ vs. TMZ: P = 0.055. Compounds 
were formulated in 10% PEG in PBS immediately prior to each treatment. Number of mice per treatment cohort ≥5. Survival 
curves were compared using log-rank test.    
 
Importantly, the methyl derivative 81, which displays the highest efficacy in cell culture and an 
extended half-life in aqueous solution (around 40 hours), had no effect in this in vivo model (Figure 39), 
suggesting that dramatically elongated half-lives are less likely in vivo, as compounds clearance occurs 
before activation following alternative pathways.   
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Figure 39 GBM oncosphere Br23c cells were intracranially implanted into female athymic nude mice. Treatment was 
started 5 days post implantation. Mice were administered compound 81 (12.8 mg/kg, equimolar to 15 mg/kg TMZ) orally 
once-per-day for 5 doses. Compound was formulated in 10% PEG in PBS. n≥5. 
    
103 
 
2.3 Conclusions 
New synthetic methods enabling the construction of novel C8-substituted imidazotetrazines 
have been developed.  These challenging approaches allowed us to construct a panel of compounds that 
were previously inaccessible.  Evaluation of these novel imidazotetrazines against a set of human GBM 
cell lines and in in vivo assays led us to definitively conclude that the C8 amide is not required for 
anticancer activity.   
The principal aspect governing the anticancer activity of imidazotetrazines is the hydrolytic 
activation of the prodrug.  We demonstrated that the electronic properties of the C8-substituent 
(Hammett constant σp value) affect the in vitro hydrolytic stability of the novel imidazotetrazines, as 
well as the cytotoxic activity in multiple GBM cell lines.  However, the in vivo anticancer activity of 
TMZ derivatives seems to be depend on additional factors.  Our analysis suggested the in vivo existence 
of a critical threshold of aqueous stability (∼1 hour), below which hydrolysis occurs too quickly to 
methylate target DNA.  Based on these studies, it appears that compounds with C8-substituents having 
electronic properties close to those of TMZ, ranging from 0.23 ≤ σp ≤ 0.50, are favorites in vivo.   
The C8-substitution seems also to influence the BBB-penetrance of imidazotetrazines.  
Compounds such as the oxazole 93 and the ketone 85 displayed higher brain: serum rate compared to 
TMZ ones.  These compounds demonstrated lower in vivo toxicity profile and enhanced efficacy in vivo 
intracranial models of glioblastoma.  As such, the novel imidazotetrazines synthetized could hold 
considerable promise for treatment of GBM and other cancers.  Indeed, the C8-ketone derivative 85 is 
the first imidazotetrazine – ever – to provide a notable survival benefit relative to TMZ in animal 
models.   
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2.4 Experimental Section  
 
2.4.1 Materials and Methods 
 
1H and 13C NMR spectra were recorded on Bruker 500 (500 MHz, 1H; 125 MHz, 13C) or Varian 
Unity Inova 500 (500 MHz, 1H) MHz spectrometers.  Chemical shifts (δ scale) are reported in parts per 
million (ppm) relative to the central peak of the solvent. Coupling constants (J) are given in hertz (Hz).  
Multiplicities are indicated by s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), and br 
(broad).  High resolution mass spectrometry (HR MS) was performed on a Waters Q-Tof Ultima or 
Waters Synapt G2-Si instrument with electrospray ionization (ESI) or electron impact ionization (EI).  
The purity of tested compounds, determined by high performance liquid chromatography (HPLC), was 
greater than 95%.  Chemical reagents were purchased from commercial sources and used without 
further purification.  Column chromatography purifications were performed under “flash” conditions 
using 230−400 mesh silica gel.  Anhydrous solvents were dried after being passed through columns 
packed with activated alumina under positive pressure of nitrogen.  Unless otherwise noted, all reactions 
were carried out in oven-dried glassware with magnetic stirring under nitrogen atmosphere.   
 
2.4.2 Synthesis and Physicochemical Characterization of C8-Temozolomide 
Derivatives 
 
Procedure for Preparation of 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-
carbonitrile (70): 
 
Synthetic procedures and experimental data for the compound have been published.145   
  
General Scheme for Preparation of Amide, Ester, and Thioester Derivatives 73–78: 
 
Synthetic procedures and experimental data for compounds 71,146 72,108 and 77147 have been previously 
reported.   
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In an oven-dried 25 mL round bottom flask, acyl chloride 72 (148.6 mg, 0.70 mmol) was dissolved in 
anhydrous THF (2.8 mL).  The appropriate amine, alcohol or thiol (0.73 mmol) was then added and the 
reaction was stirred for 3 h at room temperature.  When complete, the reaction was stopped and the 
solvent was evaporated.  The crude solid was purified by flash silica gel chromatography (100% EtOAc) 
to yield desired compound as pure solid.   
 
N,3-dimethyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide (73): 
68% yield as a white solid.   
1H NMR (500 MHz, DMSO-d6): δ 8.84 (s, 1H), 8.45 (d, 1H, J = 4.9 Hz), 3.86 (s, 3H), 2.81 (d, 3H, J = 
4.8 Hz).  13C NMR (125 MHz, DMSO-d6): δ 160.1, 139.2, 134.3, 130.6, 128.4, 36.1, 25.8.  HR MS 
(ESI) calc. for C7H8N6O2Na, [M+Na]+: 231.0606, found: 231.0608.   
 
N,N,3-trimethyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide (74): 
76% yield as a white solid.   
1H NMR (500 MHz, DMSO-d6): δ 8.81 (s, 1H), 3.85 (s, 3H), 3.06 (s, 6H).  13C NMR (125 MHz, DMSO-
d6): δ 161.8, 139.2, 133.6, 132.0, 128.6, 38.1, 36.0, 34.8.  HR MS (ESI) calc. for C8H11N6O2, [M+H] +: 
223.0938, found: 223.0943.   
 
N,N-diethyl-3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide (75): 
91% yield as a white solid.   
1H NMR (500 MHz, DMSO-d6): δ 8.81 (s, 1H), 3.84 (s, 3H), 3.49 (q, 2H, J = 7.1 Hz,), 3.38 (q, 2H, J = 
7.0 Hz), 1.18 (t, 3H, J = 7.1 Hz), 1.11 (t, 3H, J = 7.0 Hz).  13C NMR (125 MHz, DMSO-d6): δ 161.3, 
139.2, 133.5, 132.7, 128.4, 42.5, 36.0, 14.4, 12.8.  HR MS (ESI) calc. for C10H15N6O2, [M+H]+: 
251.1256, found: 251.1250.   
 
N,N-dibutyl-3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide (76): 
85% yield as a white solid.   
1H NMR (500 MHz, DMSO-d6): δ 8.80 (s, 1H), 3.84 (s, 3H), 3.45 (m, 2H), 3.34 (m, 2H), 1.59 (m, 2H), 
1.49 (m, 2H), 1.35 (h, 2H, J = 7.4 Hz), 1.11 (h, 2H, J = 7.4 Hz), 0.94 (t, 3H, J = 7.4 Hz), 0.76 (t, 3H, J 
= 7.4 Hz).  13C NMR (125 MHz, DMSO-d6): δ 161.7, 139.2, 133.3, 132.8, 128.4, 47.7, 44.4, 36.0, 30.5, 
29.2, 19.6, 19.2, 13.8, 13.5.  HR MS (ESI) calc. for C14H23N6O2, [M+H]+: 307.1882, found: 307.1881.   
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S-ethyl 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carbothioate (78):  
92% yield as a white solid.   
1H NMR (500 MHz, DMSO-d6): δ 8.86 (s, 1H), 3.89 (s, 3H), 3.02 (q, 2H, J = 7.4 Hz), 1.28 (t, 3H, J = 
7.4 Hz).  13C NMR (125 MHz, DMSO-d6): δ 184.6, 139.0, 133.8, 131.5, 129.2, 36.5, 22.1, 14.7.  HR 
MS (ESI) calc. for C8H10N5O2S, [M+H]+: 240.0555, found: 240.0551.   
 
Procedure for Preparation of 8-bromo-3-methylimidazo[5,1-d][1,2,3,5]tetrazin-4(3H)-one (79): 
 
 
To a stirred suspension of Dess-Martin periodinane (477 mg, 1.12 mmol) in anhydrous CH3CN (2.6 
mL), tetraethylammonium bromide (240 mg, 1.12 mmol) was added.  Reaction was stirred 5 min at 
room temperature before 71 (100 mg, 0.51 mmol) was added.  The resultant reaction mixture was heated 
at 50°C for 2 h.  Upon completion, the solvent was concentrated under reduced pressure to give the 
crude product that was purified by flash silica gel chromatography (9:1 hexane:EtOAc) to afford 73 mg 
(58%) of 79 as a white solid.   
1H NMR (500 MHz, CDCl3): δ 8.37 (s, 1H), 3.98 (s, 3H).  13C NMR (125 MHz, CDCl3): δ 138.7, 133.3, 
128.6, 117.2, 36.4.  HR MS (ESI) calc. for C5H5N5OBr, [M+H]+: 229.9677, found: 229.9684.   
 
Procedure for Preparation of 8-chloro-3-methylimidazo[5,1-d][1,2,3,5]tetrazin-4(3H)-one (80): 
 
 
To a stirred suspension of Dess-Martin periodinane (477 mg, 1,12 mmol) in anhydrous CH3CN (2.6 
mL), tetramethylammonium chloride (123 mg, 1.12 mmol) was added.  The reaction was stirred 5 min 
at room temperature before 71 (100 mg, 0.51 mmol) was added.  The resultant reaction mixture was 
heated at 50°C for 2 hours.  Upon completion, the solvent was concentrated under reduced pressure to 
give the crude product that was purified by flash silica chromatography (9:1 hexane:EtOAc) to afford 
43 mg (45%) of 80 as a white solid.   
1H NMR (500 MHz, CDCl3): δ 8.33 (s, 1H), 3.98 (s, 3H).  13C NMR (125 MHz, CDCl3): δ 138.7, 130.8, 
129.8, 127.2, 36.4.  HR MS (ESI) calc. for C5H5N5OCl, [M+H]+: 186.0183, found: 186.0186.   
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Procedure for Preparation of 3,8-dimethylimidazo[5,1-d][1,2,3,5]tetrazin-4(3H)-one (81): 
 
 
To a 15 mL round bottom flask, 4-methyl-1H-imidazol-5-amine dihydrochloride (44.2 mg, 0.3 mmol) 
was added and dissolved in 1M HCl (0.4 mL) before NaNO2 (26.2 mg, 0.4 mmol) in water (0.4 mL) 
was added at 0ºC in the dark.  The solution was stirred 30 minutes then concentrated and azeotroped 
twice with toluene to afford crude 4-diazo-5-methyl-4H-imidazole.  To the crude diazo suspended in 
ethyl acetate (1.3 mL), anhydrous triethylamine (0.08 mL, 0.6 mmol) and methylcarbamic chloride (79 
mg, 0.8 mmol) were added in the dark.  The reaction was stirred overnight before being purified via 
flash silica gel chromatography (4:1 hexane:EtOAc) to afford 2.4 mg (6%) 81 as a pale yellow solid.   
Note: To minimize decomposition of the crude diazo species, concentration was done (without heating) 
in the dark as quickly as possible.   
1H NMR (500 MHz, CDCl3): δ 8.35 (s, 1H), 3.94 (s, 3H), 2.66 (s, 3H). 13C NMR (125 MHz, CDCl3): δ 
139.7, 139.6, 132.5, 127.9, 35.8, 12.5. HR MS (EI) calc. for C6H7N5O, [M+H ]+: 165.0651, found: 
165.0654.   
 
Procedure for Preparation of 8-acetyl-3-methylimidazo[5,1-d][1,2,3,5]tetrazin-4(3H)-one (85): 
 
 
Synthetic procedures and experimental data for compounds 94,148 82,149 and 83150 have been published.  
 
4-acetyl-5-amino-N-methyl-1H-imidazole-1-carboxamide (84): 
To an oven-dried 25 mL round bottom flask, 83 (186 mg, 0.89 mmol) and N-succinimidyl N-
methylcarbamate (321 mg, 1.86 mmol) were added and suspended in anhydrous acetonitrile (1.5 mL).  
Next, under nitrogen, dry triethylamine (0.34 mL, 2.4 mmol) was slowly added and the solution was 
stirred overnight at room temperature.  Upon completion, the mixture was concentrated and purified by 
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silica gel flash chromatography (100% CH2Cl2 to 4:1 CH2Cl2:methanol) to afford 106 mg (66%) of 
intermediate 84 as a gold solid.   
1H NMR (500 MHz, DMSO-d6): δ 8.17 (br s, 1H), 7.97 (s, 1H), 7.56 (s, 2H), 3.36 (d, 3H, J = 4.5 Hz), 
2.73 (s, 3H).   
 
8-acetyl-3-methylimidazo[5,1-d][1,2,3,5]tetrazin-4(3H)-one (85): 
In a 15 mL round bottom flask, LiCl (802 mg, 19 mmol) was dissolved in distilled water (1.3 mL) and 
AcOH (0.10 mL) and stirred for 30 minutes until the exotherm dissipated.  Intermediate 84 (96.3 mg, 
0.53 mmol) was added in one portion and stirred for 30 minutes.  The suspension was then cooled to 
0°C in an ice bath before a solution of NaNO2 (57 mg, 0.8 mmol) in a minimal amount of distilled water 
was added dropwise.  The resultant mixture was stirred at 0°C for 30 minutes, then warmed to room 
temperature and stirred an additional 5 hours.  Upon completion, the reaction mixture was diluted with 
CH2Cl2 and the organic layer was separated.  The aqueous layer was extracted with CH2Cl2 (x6) and 
the combined organic layers were dried over Na2SO4 and concentrated to yield crude solid which was 
purified by flash silica chromatography (1:1 hexane:EtOAc) to afford 36 mg (35%) of 85 as a white 
solid.   
1H NMR (500 MHz, DMSO-d6): δ 8.86 (s, 1H), 3.90 (s, 3H), 2.68 (s, 3H).  13C NMR (125 MHz, DMSO-
d6): δ 191.5, 139.0, 135.6, 133.3, 129.1, 36.4, 28.3.  HR MS (ESI) calc. for C7H8N5O2, [M+H]+: 
194.0678, found: 194.0683.   
 
General Scheme for Preparation of Aryl Derivatives 89a-g: 
 
General Procedure for Suzuki Coupling Reaction (87a-g):  
A mixture of 4-bromo-5-nitro-1H-imidazole 86 (400 mg, 2.08 mmol), phenylboronic acid (507 mg, 
4.17 mmol), XPhos PdG2 (164 mg, 0.2 mmol) and K3PO4 (1.32 g, 6.24 mmol) under nitrogen was 
suspended in degassed 1:1 H2O:dioxane (16 mL).  The resulting mixture was stirred at 110°C for 16 h.  
The reaction was cooled to room temperature and H2O was added.  The aqueous layer was extracted x3 
with EtOAc and the combined organic layers were dried over Na2SO4 and concentrated.  The residue 
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obtained was purified by flash silica gel chromatography (100% EtOAc) to afford desired compounds, 
which were used for next step as crude without further purification.   
 
5-nitro-4-phenyl-1H-imidazole (87a): 
Compound was obtain using the procedure above as a dark solid, ∼55% yield.   
1H NMR (500 MHz, DMSO-d6): δ 13.50 (br s, 1H), 7.92 (s, 1H), 7.66-7.65 (m, 2H), 7.53-7.51 (m, 3H).  
13C NMR (125 MHz, DMSO-d6): δ 143.1, 135.1, 131.7, 130.1, 130.0, 128.8, 128.2.  HPLC-MS ESI = 
190.06 [M+H]+.   
 
4-(4-chlorophenyl)-5-nitro-1H-imidazole (87b): 
Compound was obtain using the procedure above as a dark solid, ∼19% yield.   
1H NMR (500 MHz, DMSO-d6): δ 13.56 (br s, 1H), 7.94 (s, 1H), 7.69 (d, 2H, J = 8.5 Hz), 7.60 (d, 2H, 
J = 8.5 Hz).  HPLC-MS ESI = 224.02 [M+H]+.   
 
5-nitro-4-(4-(trifluoromethyl)phenyl)-1H-imidazole (87c): 
Compound was obtain using procedure above as a brown solid, ∼49% yield.   
1H NMR (500 MHz, DMSO-d6):  13.69 (s, 1H), 8.00 (s, 1H), 7.89 (br s, 4H).  13C NMR (125 MHz, 
DMSO-d6): δ 143.6, 135.6, 132.3, 130.9, 130.2, 129.9, 125.6 (q, J = 3.7 Hz, 1C), 123.39.  HPLC-MS 
ESI = 208.05 [M+H]+.   
 
4-(4-methoxyphenyl)-5-nitro-1H-imidazole (87d): 
Product was obtain using procedure above as a dark solid, ∼17% yield.   
1H NMR (500 MHz, DMSO-d6): δ 13.37 (s, 1H), 7.87 (s, 1H), 7.61 (dt, 2H, J
1 = 8.8, J2 = 2.9 Hz,), 7.07 
(dt, 2H, J1 = 8.8, J2 = 2.9 Hz,), 3.83 (s, 3H).  HPLC-MS ESI = 220.07 [M+H]+.   
 
4-(4-fluorophenyl)-5-nitro-1H-imidazole (87e) 
Compound was obtain using procedure above as a dark solid, ∼35% yield.   
HPLC-MS ESI = 208.05 [M+H]+.   
 
4-(5-nitro-1H-imidazol-4-yl)benzonitrile (87f): 
Compound was obtain using procedure above as a dark solid, ∼69% yield.   
1H NMR (500 MHz, DMSO-d6): δ 13.72 (br s, 1H), 8.41 (s, 1H), 8.00-7.98 (m, 1H), 7.94-7.78 (m, 1H).  
HPLC-MS ESI = 115.06 [M+H]+.   
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1-(4-(5-nitro-1H-imidazol-4-yl)phenyl)ethan-1-one (87g): 
Product was obtain using procedure above as a dark solid, ∼31% yield.   
1H NMR (500 MHz, DMSO-d6): δ 13.69 (br s, 1H), 8.07 (dt, 2H, J
1 = 8.5, J2 = 1.8 Hz), 8.00 (s, 1H), 
7.81 (dt, 2H, J1 = 8.5, J2 = 1.8 Hz), 2.64 (s, 3H).  13C NMR (125 MHz, DMSO-d6): δ 198.1, 137.6, 
135.6, 134.7, 132.5, 130.5, 130.3, 128.5, 27.4.  HPLC-MS ESI = 232.07 [M+H]+.   
 
General Procedure for Nitro Reduction (88a-g):  
Compounds 87a-g was dissolved in dry MeOH (10 mL) containing 10% Pd/C before H2 (1 atm) was 
introduced.  The reaction was stirred for 16 h at room temperature before the catalyst was filtered over 
Celite.  The filtrate was concentrated under reduced pressure and purified by flash silica gel 
chromatography (95:5 CH2Cl2:MeOH) providing the desired compounds 88a-g, which were used for 
next step as crude without further purification.   
 
4-phenyl-1H-imidazol-5-amine (88a): 
Compound was obtain using procedure above as a purple solid, ∼54% yield.   
1H NMR (500 MHz, DMSO-d6): δ 11.77 (br s, 1H), 7.53 (br s, 2H), 7.32 (t, 2H, J = 7.5 Hz), 7.03 (t, 
1H, J = 7.5 Hz), 4.51(br s, 2H).  13C NMR (125 MHz, DMSO-d6): δ 143.1, 135.1, 131.7, 130.1, 130.0, 
128.8, 128.2.  HPLC-MS ESI = 160.09 [M+H]+.   
 
4-(4-chlorophenyl)-1H-imidazol-5-amine (88b): 
Compound was obtain using procedure above as a purple solid, ∼56% yield.   
1H NMR (500 MHz, DMSO-d6): δ 11.78 (br s, 1H), 7.56 (br d, 2H, J = 7.0 Hz), 7.33 (d, 2H, J = 8.5 
Hz), 7.28 (br s, 1H), 4.68 (br s, 2H).  HPLC-MS ESI = 194.05 [M+H]+.   
 
4-(4-(trifluoromethyl)phenyl)-1H-imidazol-5-amine (88c): 
Compound was obtain using procedure above as a brown solid, ∼55% yield.   
1H NMR (500 MHz, DMSO-d6): δ 7.75 (d, 2H, J = 8.32 Hz), 7.63 (d, 2H, J = 8.3 Hz), 7.41 (br s, 1H), 
5.04 (br s, 2H).  HPLC-MS ESI = 178.08 [M+H]+.   
 
4-(4-methoxyphenyl)-1H-imidazol-5-amine (88d): 
Compound was obtain using procedure above as a dark green solid, ∼35% yield.   
1H NMR (500 MHz, DMSO-d6): δ  11.73 (s, 1H), 7.54 7.61 (d, 2H, J = 8.6 Hz), 7.28 (s, 1H), 6.98 (d, 
2H, J = 8.6 Hz), 4.42 (br s, 2H), 3.81 (s, 3H).  HPLC-MS ESI = 190.10 [M+H]+.   
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4-(4-fluorophenyl)-1H-imidazol-5-amine (88e): 
Compound was obtain using procedure above as a brown solid, ∼39% yield.   
1H NMR (500 MHz, DMSO-d6): δ 11.76 (br s, 1H), 7.58 (br s, 2H), 7.26 (br s, 1H), 7.15 (t, 2H, J = 8.8 
Hz), 4.54 (br s, 2H).  HPLC-MS ESI = 178.08 [M+H]+.   
 
4-(5-amino-1H-imidazol-4-yl)benzonitrile (88f): 
Compound was obtain using procedure above as a dark solid, ∼28% yield.   
HPLC-MS ESI+ = 185.08 [M+H]+.   
 
1-(4-(5-amino-1H-imidazol-4-yl)phenyl)ethan-1-one (88g) 
Compound was obtain using procedure above as a dark solid, ∼43% yield.   
HPLC-MS ESI = 202.10 [M+H]+.   
 
General Procedure for Cyclization (89a-g):  
To a suspension of intermediate 88a-g in 1 M HCl (2.9 mL) at 0°C was added a pre-formed solution of 
NaNO2 (186 mg, 2.7 mmol) in H2O (2.9 mL) dropwise.  The resultant mixture was stirred at 0°C in the 
dark for 30 min.  Upon completion, the solvent was evaporated and the crude diazo compound was 
dissolved in EtOAc (9.6 mL, 0.2 M) before triethylamine (544 µL, 4.6 mmol) and methylcarbamic 
chloride (1010 mg, 10.8 mmol) were added.  The reaction mixture was stirred at room temperature for 
16 h protected from light. Upon reaction completion, the solvent was concentrated under reduced 
pressure and the residue was purified by flash silica gel chromatography (9:1 hexane:EtOAc) to afford 
89a-g as pure solids.  
Note: To minimize decomposition of the crude diazo species, concentration was done (without heating) 
in the dark as quickly as possible.   
 
3-methyl-8-phenylimidazo[5,1-d][1,2,3,5]tetrazin-4(3H)-one (89a):  
White solid, 6% yield (3 steps).   
1H NMR (500 MHz, DMSO-d6): δ 8.84 (s, 1H), 8.31-8.29 (m, 2H), 7.57-7.53 (m, 2H), 7.44 (tt, 1H, J
1 
= 7.4, J2 = 1.3 Hz,), 3.85 (s, 3H).  13C NMR (125 MHz, CDCl3): δ 140.0, 137.0, 132.3, 131.9, 129.9, 
129.5, 129.4, 127.1, 36.3.  HR MS (ESI) calc. for C11H10N5O, [M+H]+: 228.0885, found: 228.0878.   
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8-(4-chlorophenyl)-3-methylimidazo[5,1-d][1,2,3,5]tetrazin-4(3H)-one (89b): 
Yellow solid, 1.2% yield (3 steps).   
1H NMR (500 MHz, DMSO-d6): δ 8.86 (s, 1H), 8.30 (dt, 2H, J
1 = 9.25, J2 = 2.5 Hz), 7.62 (dt, 2H, J1 = 
9.25, J2 = 2.5 Hz), 3.86 (s, 3H).  13C NMR (125 MHz, d-DMSO): δ 139.9, 135.7, 133.97, 132.4, 130.7, 
130.0, 129.6, 128.6, 36.4.  HR MS (ESI) calc. for C11H9N5OCl, [M+H]+: 262.0496, found: 262.0489.   
 
3-methyl-8-(4-(trifluoromethyl)phenyl)imidazo[5,1-d][1,2,3,5]tetrazin-4(3H)-one (89c):  
Yellow solid, 5% yield (3 steps).   
1H NMR (500 MHz, CDCl3): δ 8.52 (d, 2H, J = 8.2 Hz), 8.48 (s, 1H), 7.75 (d, 2H, J = 8.2 Hz), 4.02 (s, 
3H).  13C NMR (125 MHz, CDCl3): δ 139.3, 137.9, 134.3, 131.9, 131.0 (q, 1C, J = 32.3 Hz), 128.8, 
127.6, 125.8 (q, 1C, J = 3.8 Hz), 123.0, 36.1.  HR MS (ESI) calc. for C12H9N5OF3, [M+H]+: 296.0759, 
found: 296.0754.   
 
8-(4-methoxyphenyl)-3-methylimidazo[5,1-d][1,2,3,5]tetrazin-4(3H)-one (89d): 
Yellow solid, 0.7% yield (3 steps).   
1H NMR (500 MHz, CDCl3): δ 8.42 (s, 1H), 8.34 (dt, 2H, J = 9.7, 2.9 Hz), 7.03 (dt, 2H, J
1 = 9.7, J2 = 
2.9 Hz,), 3.97 (s, 3H), 3.88 (s, 3H).  13C NMR (125 MHz, CDCl3): δ 160.8, 139.9, 139.8, 130.5, 129.0, 
128.5, 123.7, 114.4, 55.4, 35.9.  HR MS (ESI) calc. for C12H12N5O2, [M+H]+: 258.0991, found: 
258.0998.   
 
8-(4-fluorophenyl)-3-methylimidazo[5,1-d][1,2,3,5]tetrazin-4(3H)-one (89e): 
Yellow solid, 3% yield (3 steps).   
1H NMR (500 MHz, CDCl3): δ 8.46 (s, 1H), 8.44-8.40 (m, 2H), 7.24-7.19 (m, 2H), 4.01 (s, 3H).  13C 
NMR (125 MHz, CDCl3): δ 164.6, 162.6, 139.2 (d, 1C, J = 86.4 Hz), 131.0, 129.4 (d, 1C, J = 8.3 Hz), 
128.6, 127.3 (d, 1C, J = 3.3 Hz), 116.0 (d, 1C, J = 21.6 Hz), 36.0.  HR MS (ESI) calc. for C11H9FN5O, 
[M+H]+: 246.0791, found: 246.0788.   
 
8-(4-acetylphenyl)-3-methylimidazo[5,1-d][1,2,3,5]tetrazin-4(3H)-one (89f): 
White solid, 1.3% yield (3 steps).   
1H NMR (500 MHz, CDCl3): δ 8.92 (s, 1H), 8.44 (dt, 2H, J
1 = 8.5, J2 = 1.8 Hz), 8.14 (dt, 2H, J1 = 8.5, 
J2 = 1.8 Hz), 3.87 (s, 3H), 2.63 (s, 3H).  13C NMR (125 MHz, CDCl3): δ 197.9, 139.9, 136.9, 136.1, 
135.4, 133.2, 130.2, 129.5, 127.0, 36.5, 27.3.  HR MS (ESI) calc. for C13H12N5O2, [M+H]+: 270.0991, 
found: 270.0993.   
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4-(3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazin-8-yl)benzonitrile (89g): 
White solid, 4.4% yield (3 steps).   
1H NMR (500 MHz, CDCl3): δ 8.53 (d, 2H, J
1 = 8.4, J2 = 1.8 Hz), 8.49 (s, 1H), 7.79 (d, 2H, J1 = 8.4, J2 
= 1.8 Hz), 4.03 (s, 3H).  HR MS (ESI) calc. for C12H9N6O, [M+H]+: 296.0838, found: 253.0835.   
Note: Compound 89g results extremely unstable, it decomposes during 13C-NMR times.   
 
Procedure for Preparation of 3-methyl-8-(4-methylthiazol-2-yl)imidazo[5,1-d][1,2,3,5]tetrazin-
4(3H)-one (91): 
 
 
The route to 4-substituted thiazol-2-yls at the C8 position of imidazotetrazines is known,118 however, 
the synthesis of compound 91 had never been reported.   
 
3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carbothioamide (90): 
Compound was synthetized following a different route from that used in the literature.   
A mixture of temozolomide (500 mg, 2.6 mmol) and Lawesson reagent (1146 mg, 2.83 mmol) was 
refluxed in CH2Cl2 (13.5 mL) for 18h.  Reaction was quenched with water and the precipitate was 
filtered and washed with water and diethyl ether.  Solid was purified by flash chromatography over 
silica gel (EtOAc) to afford 433 mg (80%) of pure 24 as yellow solid.   
The experimental data are conform to literature.118   
1H NMR (500 MHz, DMSO-d6): δ 9.92 (br s, 1H), 9.44 (br s, 1H), 8.81 (s, 1H), 3.87 (s, 3H).  13C NMR 
(125 MHz, DMSO-d6): δ 188.3, 139.6, 135.0, 134.4, 128.2, 36.6.  HPLC-MS ESI = 211.04 [M+H]+.   
 
3-methyl-8-(4-methylthiazol-2-yl)imidazo[5,1-d][1,2,3,5]tetrazin-4(3H)-one (91): 
To a solution of 90 (550 mg, 2.6 mmol) in acetonitrile (40 mL) was added α-bromo acetone (220 µL, 
2.6 mmol) and the solution was stirred at room temperature for 18 h.  Upon completion, the reaction 
was stopped, and the precipitate was filtered and purified by flash silica gel chromatography (4:6 
hexane:EtOAc) to afford 167 mg (26%) of the desired product 91 as a yellow solid.   
 1H NMR (500 MHz, DMSO-d6): δ 8.87 (s, 1H), 7.46 (d, 1H, J = 0.9 Hz), 3.86 (s, 3H), 2.48 (d, 3H, J = 
0.9 Hz).  13C NMR (125 MHz, DMSO-d6): δ 158.6, 154.6, 139.7, 131.9, 131.8, 130.2, 116.6, 36.5, 17.4.  
HR MS (ESI) calc. for C9H9N6OS, [M+H]+: 249.0559, found: 249.0559.   
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Procedure for Preparation of 3-methyl-8-(5-methyloxazol-2-yl)imidazo[5,1-d][1,2,3,5]tetrazin-
4(3H)-one (93): 
 
 
The route to 4-substituted oxazol-2-yls at the C8 position of imidazotetrazines is known,118 however, 
the synthesis of compound 93 via intermediate 92 had never been reported.   
 
3-methyl-4-oxo-N-(2-oxopropyl)-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8carboxamide (92): 
To 72 (447 mg, 2.09 mmol) and 2-aminoacetophenone hydrochloride (229 mg, 2.09 mmol) were added 
DMF (4.4 mL) and pyridine (0.9 mL).  The reaction mixture was stirred for 16 h at room temperature. 
Water was added and the aqueous layer was extracted x5 with EtOAc.  The combined organic layers 
were dried over Na2SO4 and concentrated.  The residue obtained was purified by flash silica gel 
chromatography (100% EtOAc) to afford 266 mg (51%) of 92 as an orange solid.   
1H NMR (500 MHz, DMSO-d6): δ 8.87 (s, 1H), 8.59 (t, 1H, J = 5.7 Hz), 4.17 (d, 2H, J = 5.7 Hz), 3.88 
(s, 3H), 2.15 (s, 3H).  13C NMR (125 MHz, DMSO-d6): δ 204.5, 160.1, 139.6, 135.1, 130.2, 129.1, 49.6, 
36.7, 27.5.  LC-MS (ESI) calc. for C9H11N6O3 [M+H]+: 251.0893, found: 251.09.  
 
3-methyl-8-(5-methyloxazol-2-yl)imidazo[5,1-d][1,2,3,5]tetrazin-4(3H)-one (93): 
Intermediate 92 (266 mg, 1.06 mmol) was added to phosphoryl chloride (6.5 mL) and the stirred mixture 
was heated at 110°C for 3 h.  Upon completion, ice water was added and the aqueous layer was extracted 
x4 with EtOAc.  The combined organic layers were dried over Na2SO4 and concentrated.  The residue 
obtained was purified by flash silica gel chromatography (100% EtOAc) to afford 80 mg (32%) of the 
product 93 as a yellow solid.   
1H NMR (500 MHz, DMSO-d6): δ 8.89 (s, 1H), 7.13 (br d, 1H, J = 1.2 Hz), 3.87 (s, 3H), 2.44 (d, 3H, 
J = 1.2 Hz).  13C NMR (125 MHz, DMSO-d6): δ 154.1, 150.5, 139.6, 133.6, 130.4, 126.1, 125.4, 36.6, 
11.2.  HR MS (ESI) calc. for C9H9N6O2, [M+H]+: 233.0782, found: 233.0787.   
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List of Abbreviations 
4-P-PDOT = 4-Phenyl-2-propionamidotetralin 
Ac = Acetyl 
ACB = Acyl chain binding 
AIC = 5-aminoimidazole-4-carboxamide 
BBB = Blood brain barrier 
BCNU = Carmustine or bis-chloroethylnitrosourea 
BER = DNA base excision repair 
BINAP = (1,1′-Binaphthalene-2,2′-diyl)bis(diphenylphosphine), (R)-(+)-2,2′-Bis(diphenylphosphino)-
1,1′-binaphthalene 
Bn = Benzyl 
BrettPhos PdG1 = Chloro[2-(dicyclohexylphosphino)-3,6-dimethoxy-2′,4′, 6′-triisopropyl-1,1′-
biphenyl][2-(2-aminoethyl)phenyl]palladium(II) 
Bu = Butyl 
CA = Cytoplasmic access 
CB = Cannabinoid receptor  
CCNU = Lomustine 
CNS = Central nervous system 
COSY = Correlation spectroscopy 
CP = Cytosolic port 
Cpd = Compound 
CSF = Cerebrospinal fluid 
DIPEA = N,N-diisopropylethylamine 
DMF = N,N-dimethylformamide 
DMP = Dess-Martin periodinane  
DMSO = Dimethyl sulfoxide 
EDG = Electron donating groups 
Et = Ethyl 
EWG = Electron withdrawing groups 
FAAH = Fatty acid amide hydrolase 
FDA = US Food and Drug Administration 
GBM = Glioblastoma Multiforme 
GPCR = G protein-coupled receptors 
HPLC = High Performance Liquid Chromatography 
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IBX = 2-iodoxybenzoic acid 
IOP = Intraocular pressure 
MAC = Membrane access channel 
Me = Methyl 
MGMT = O6-methylguanine DNA methyl transferase 
MLT = Melatonin 
MMR = DNA mismatch repair 
MPO = CNS multiparameter optimization 
MT = Melatonin receptor 
MTIC = 5-(3methyl)1-triazen1yl)imidazole-4-carboxamide 
N3MA = N3-methyladenine 
N7MG = N3-methylguanine 
NBS = N-Bromosuccinimide 
nc = Not computable 
nd = Not determined 
NOE = Nuclear overhauser effect 
NOESY = Nuclear overhauser effect spectroscopy 
NMDA = N-methyl-D-aspartate receptor 
NMR = Nuclear magnetic resonance 
Nrf2 = Nuclear factor (erythroid-derived 2)-like 2 
O6MG = O6-methylguanine  
Ox = Oxazole 
PBS = Phosphate-buffered saline 
Pd(dba)2 = Palladium(0) bis(dibenzylideneacetone) 
Ph = Phenyl 
PK = Pharmacokinetics 
Py = Pyridine 
QSAR = Quantitative structure-activity relationship  
RGC = Retinal ganglion cells 
SAR = Structure-activity relationship 
SCN = Suprachiasmatic nucleus  
SEM = 2-(trimethylsilyl)ethoxymethyl 
SNMC = N-succinimydil N-methylcarbamate  
TEA = Triethylamine 
TEAB = Tetraethylammonium bromide 
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TEBAC = Benzyltriethylammonium chloride  
TFA = Trifluoroacetic acid 
THF = Tetrahydrofuran 
Thiaz = Thiazole 
THQ = Tetrahydroquinoline 
TM = Transmembrane 
TMZ = Temozolomide 
WBC = White blood cell 
WHO = World Health Organization 
XPhos PdG2 = Chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-
biphenyl)]palladium(II 
σp = Hammett constants  
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